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Summary 
 
 
The tumour suppressor, p53, is a vital DNA damage response protein and its means of 
transcriptional regulation are vast. hnRNPUL-1 is a multifunctional protein and previous 
studies have implicated it in the modulation of p53 transcriptional activity, although this has 
been rather poorly understood. Results presented here demonstrate that hnRNPUL-1 represses 
p53 transcriptional activity and negatively regulates p21 levels. This is consistent with the 
depletion of hnRNPUL-1 leading to an increase in cells arrested in G1/S. Together these 
results confirm that hnRNPUL-1 acts as a p53 co-repressor with specific cellular targets.  
Mutations in p53 and other DNA damage response proteins not only often contribute to the 
onset of tumourigenesis but can also be the cause of drug resistance during treatment.  The 
development of a novel chemotherapeutic agent, Alchemix (ALX), was based on the 
requirement for effective treatment in the face of resistance mechanisms. Little has been 
known about the mechanism of action of ALX up to now. Findings here demonstrate that 
ALX treatment primarily induces an ATR-dependent DNA damage response that occurs 
specifically in cycling cells and culminates in cell death via mitotic catastrophe. Results also 
show that the response elicited by ALX requires TOP2α and TOP2β, as well as its alkylating 
ability, but does not involve ATM, p53, or components of the MMR and FA pathway. 
Therefore, ALX has the potential to treat tumours that have developed resistance to 
conventional chemotherapeutic drugs.  
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CHAPTER 1 INTRODUCTION 
1.1 HALLMARKS OF CANCER 
The development of cancer is a multi-step process characterised by distinct events that drive 
the progression of normal cells into malignant ones. These hallmarks include: an evasion of 
apoptosis, sustained angiogenesis, tissue invasion and metastasis, self-sufficiency in 
proliferation, insensitivity to growth-inhibitory factors and a limitless replication potential 
(Hanahan and Weinberg, 2000). Recently, further traits that contribute to the process of 
tumourigenesis have emerged. These include the evasion of immune destruction and the 
ability to modify cellular metabolism (Hanahan and Weinberg, 2011). These hallmarks are 
essentially alterations within the cell that enable tumour cells to survive and proliferate. The 
ability of cancer cells to acquire these capabilities depends on the genomic instability of that 
cell. Chromosomal instability (CIN) is the most common form of genomic instability present 
in cancer cells and this can lead to mass chromosomal lesions (Negrini et al., 2010). 
Microsatellite instability (MSI) has also been described as a form of genomic instability and 
this is characterised by the disruption of oligonucleotides present in repetitive DNA sequences 
known as microsatellites (Thibodeau et al., 1993). Both types of genomic instability can 
generate mutations that lead to the acquisition of the hallmarks listed above.  
The integrity of the genome is constantly under threat of damage from both exogenous and 
endogenous agents that induce DNA lesions. These are recognised by components of the 
DDR pathway, which trigger the activation of cellular responses that can, in turn, lead to the 
maintenance of genomic integrity through cell cycle arrest and repair of the DNA lesion or 
apoptosis if the damage to the DNA is too great. Very often, genomic instability is 
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attributable to mutations in genes that would otherwise recognise and detect these lesions; 
these are known as the “caretakers” of the genome (Kinzler and Vogelstein, 1997). Known 
caretaker genes involved in the DDR whose mutations lead to genomic instability include 
BRCA1, BRCA2, ATM and genes involved in repair pathways. 
1.2 THE DNA DAMAGE RESPONSE  
Key regulators of the DDR include members of the phosphatidylinositol 3-kinase-like protein 
kinase (PIKK family) – ATM (ataxia-telangiectasia mutated), ATR (ATM- and Rad3-related) 
and DNA-PK (DNA-dependent protein kinase). Other members of the PIKK family include 
SMG1 (suppressor with morphological effect on genitalia family), mTOR (mammalian target 
of rapamycin) and TRAPP (transformation/transcription domain-associated protein). 
Although ATM, ATR and DNA-PK are the main PIKKs that regulate the DDR, there is 
evidence that SMG1 is implicated in the response to genotoxic stress (Brumbaugh et al., 
2004).  
Of the PIKKs that are involved in the DDR, ATM and DNA-PK are primarily activated in 
response to double strand breaks (DSBs), which are the most deleterious of DNA lesions 
since failure to properly detect and repair them leads to chromosomal instability and 
consequently to tumourigenesis (Jeggo and Lobrich, 2007). In contrast, ATR responds mainly 
to RPA-coated single-stranded DNA (ssDNA) regions that are generated at stalled replication 
forks and DSBs  (Cimprich and Cortez, 2008). This is of particular importance during DNA 
replication when replication forks are under threat from both exogenous and endogenous 
agents. If not dealt with correctly, a stalled replication fork is detrimental to the cell since it 
can develop into unstable structures that can, in turn, lead to genomic instability (Paulsen and 
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Cimprich, 2007). DNA-PKcs (DNA-dependent kinase catalytic subunit) plays a major role in 
the DSB repair pathway of non-homologous end-joining (NHEJ) where it is recruited to sites 
of damage and coordinates the signalling cascade that results in the repair process. In this 
way, DNA-PK differs from ATM and ATR in that it is involved primarily in DNA repair 
mechanisms themselves rather than the signalling of the break and subsequent responses such 
as the induction of cell cycle checkpoints. 
1.2.1 ATM-mediated DNA damage response 
The recruitment of ATM to sites of DSBs is dependent on the MRE11-RAD50-NBS1 (MRN) 
mediator complex, which senses DSBs and binds to DNA through two DNA binding sites 
located in MRE11 whilst a conserved region at the C-terminus of NBS1 is responsible for the 
binding of ATM (Falck et al., 2005, van den Bosch et al., 2003). In this way, the MRN 
complex facilitates the recruitment and activation of ATM at sites of DNA damage and is 
therefore a prerequisite for ATM-dependent signalling. In unstressed cells, ATM exists as an 
inactive dimer that allows the protein to remain stable but unable to phosphorylate its 
downstream targets  (Bakkenist and Kastan, 2003).  Evidence shows that the activation of 
ATM upon DNA damage requires its autophosphorylation on serine residues S1981, S367 
and S1893 (Bakkenist and Kastan, 2003, Kozlov et al., 2006). These phosphorylation events 
result in the dissociation of ATM dimers into catalytically-active monomers. Activated ATM 
is able to phosphorylate histone H2AX on serine residue 139 (referred to as γH2AX),  which 
is an early event in the response to DSBs and initiates chromatin rearrangement in the 
immediate vicinity of the DSB to allow the accumulation of repair or damage-signalling 
components to sites of damage (Xu and Price, 2011). This establishes phosphorylation as
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Figure 1.1 ATM-mediated DDR 
DSBs that are generated from IR treatment or collapsed replication forks are sensed by the 
MRN complex, which binds to DNA and recruits ATM. This facilitates ATM kinase 
activation through its autophosphorylation and Tip-60-mediated acetylation. Activated ATM 
phosphorylates H2AX, which triggers MDC1 localisation. phosphorylation by ATM results in 
its association with RNF8, which then ubiquitinates H2A-type histones. RNF168 binds to 
these ubiquitylated histones and catalyses their poly-ubiquitylation, promoting a more open 
chromatin conformation. This consequently leads to the recruitment of further DDR proteins, 
53BP1 and BRCA1 (adapted from Ciccia and Elledge, 2010). 
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critical to the activation of an ATM-mediated DDR. However, acetylation by the histone 
acetyltransferase, Tip60 has also proven to be indispensible since autophosphorylation of 
ATM at S1981 only occurs if ATM has been previously acetylated by Tip60 (Sun et al., 
2005). In addition, Tip60 is also required for the acetylation of histones that leads to the 
generation of open, relaxed chromatin, which is crucial for the processing and repair of the 
DSB (Xu and Price, 2011). 
One of the proteins that is recruited to sites of DSBs after H2AX phosphorylation is the 
mediator of DNA damage checkpoint protein 1 (MDC1), which binds to γH2AX through the 
BRCA1 C-terminal repeat (BRCT) domains (Figure 1.1)  (Stewart et al., 2003, Stucki et al., 
2005). MDC1 is constitutively phosphorylated by casein kinase 2 (CK2) within SDT repeats 
in its N-terminus and these sites have been shown to bind to the FHA domain of NBS1, 
therefore tethering the MRN complex to sites of damaged chromatin  (Melander et al., 2008, 
Spycher et al., 2008). The binding of MDC1 to γH2AX also facilitates the recruitment of 
phosphorylated ATM to the damaged chromatin; therefore the accumulation of both ATM 
and the MRN complex through MDC1 amplifies the ATM-dependent DDR via the spreading 
of phosphorylated H2AX to the extended chromosomal regions surrounding DSBs (measured 
in megabases) (Lou et al., 2006).  
In addition, MDC1 provides a docking site whereby other protein complexes can accumulate 
at the area surrounding the DSB. ATM-mediated phosphorylated sites of MDC1 have been 
found to interact with the E3 ubiquitin ligase, RNF8, which, in concert with another E3 ligase, 
HERC2 and the E2-conjugating enzyme, UBC13, ubiquitylates H2A-type histones that 
surround the DNA lesion (Figure 1.1) (Bekker-Jenson et al., 2010, Huen et al., 2007, Kolas et 
al., 2007). Ubiquitylated histones are recognised by another E3 ubiquitin ligase, RNF168, 
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which, together with UBC13, ubiquitylates H2A-type histones and, therefore, further 
amplifies the ubiquitin signal (Stewart et al., 2009).This leads to the coordinated assembly of 
BRCA1 and 53BP1 at sites of DNA damage and the consequent activation of cell cycle 
checkpoints and DNA repair pathways. 53BP1 is recruited to sites of damage via the 
interaction between its tudor domain and Lys79-methylated histone H3 and Lys20-methylated 
histone H4, which are unmasked by histone ubiquitylation (Botuyan et al., 2006, Huyen et al., 
2004). The recruitment of BRCA1 to DNA breaks is mediated through the interaction 
between poly-ubiquitylated histones and RAP80, which tethers the BRCA1-binding protein, 
Abraxas, and therefore recruits the BRCA1 complex (Kim et al., 2007, Sobhian et al., 2007). 
1.2.2 ATR-mediated DNA damage response 
ATR primarily responds to ssDNA structures, which rapidly become coated by replication 
protein A (RPA), which is required to protect ssDNA (Fanning et al., 2006). The recognition 
of these ssDNA structures is one way in which ATR is able to respond to a range of DNA 
lesions or replication fork blockages. The localisation of ATR to RPA-coated ssDNA sites 
depends on the interaction between ATR and ATR-interacting protein (ATRIP), the latter 
being able to indirectly recognise ssDNA through its interaction with the large RPA (70K) 
subunit (Ball et al., 2007, Ball et al., 2005, Cortez et al., 2001). Once the ATR-ATRIP 
complex is localised to RPA-ssDNA, RPA recruits a DNA damage-specific clamp loader, 
RAD17-replication factor C (RFC), which consequently loads a RAD9-RAD1-HUS1 (9-1-1) 
checkpoint clamp onto 5’ends adjacent to the area of RPA-ssDNA (Figure 1.2) (Zou et al., 
2003). This checkpoint clamp is needed for the recruitment of the ATR activator protein, 
topoisomerase-binding protein-1 (TOPBP1). TOPBP1 is brought to the vicinity of ATR-
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ATRIP through the interaction between the two BRCT domains on TOPBP1 and a 
phosphorylated C-terminal tail of RAD9 – a component of the 9-1-1 complex (Lee et al., 
2007). The binding of TOPBP1 with ATR-ATRIP utilises the activation domain of TOPBP1 
and a region on ATRIP. This results in the activation of ATR kinase, enabling it to 
phosphorylate numerous downstream targets, including its effector kinase, the S/T kinase 
checkpoint kinase-1 (Chk1). The activation of Chk1 requires its phosphorylation by ATR on 
two serine residues, S317 and S345 (Zhao and Piwnica-Worms, 2001). Two protein 
complexes found at replication forks mediate the activation of Chk1 by ATR; Claspin and a 
complex composed of Timeless (Tim) and Tim-interacting protein (Tipin) (Figure 1.2) (Liu et 
al., 2006, Unsal-Kacmaz et al., 2007). Upon its phosphorylation, Chk1 targets and 
phosphorylates the CDC25 phosphatases to inhibit their activity and as a result, prevent CDK 
activation. This culminates in cell cycle arrest. 
The activities of ATR extend to the maintenance of replication fork integrity by promoting 
replication fork stability and mediating the recovery of stalled forks. Downstream targets of 
ATR such as components of the MCM2-7 replicative helicase, MCM2 and MCM3, promote 
replication fork stabilisation and to allow the completion of replication (Cimprich and Cortez, 
2008, Cortez et al., 2004). Once these MCM proteins are activated, they recruit Polo-like 
kinase-1 (PLK1), which facilitates the completion of replication at sites near the stalled fork 
(Trenz et al., 2008). 
1.2.3 ATM and ATR cross-talk 
Evidence suggests that a degree of cross-talk exists between the ATM- and ATR-mediated 
signalling pathways despite the different DNA structures to which each kinase responds. This  
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Figure 1.2 ATR-mediated DDR 
The generation of ssDNA after UV damage or replication stress leads to the accumulation of 
RPA. RPA-caoted ssDNA recruits the ATR/ATRIP complex, followed by the loading of the 
9-1-1 complex in an RCF-dependent manner. TOPBP1 recruitment to 9-1-1 activates ATR 
kinase activity. ATR phosphorylates Claspin, which, together with another mediator protein, 
Tipin, mediates the phosphorylation and activation of Chk2 by ATR. Once activated, Chk1 is 
able to phosphorylate key targets and consequently leads to cell cycle arrest (adapted from 
Cimprich and Cortez, 2008). 
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phenomenon is partly explained by the fact that these structures are partially interchangeable 
during different forms of DNA repair  (Cimprich and Cortez, 2008).  DNA-end resection is 
one example since it is initially ATM-dependent but eventually leads to ATR activation via 
the generation of ssDNA (1.3.1.5) (Jazayeri et al., 2006). In addition, stalled replication forks 
can collapse in the absence of ATR and DSBs often form at these sites, which results in the 
activation of ATM (Brown and Baltimore, 2003). However, the role of ATM at sites of 
collapsed forks where no DSBs are generated has yet to be elucidated. There is also the 
observation that a subset of substrates, such as p53 and BRCA1, can be phosphorylated by 
both kinases, which again suggests interplay between ATM and ATR signalling pathways 
(Cortez et al., 1999, Tibbetts et al., 1999, Tibbetts et al., 2000) 
There is evidence to suggest that ATR is able to phosphorylate ATM after replication fork 
stalling or after treatment with UV; this results in the activation of ATM, indicating that ATR 
can function upstream of ATM in certain signalling pathways (Stiff et al., 2006). Furthermore 
it has also been shown that ATR and ATM can both phosphorylate another member of the 
PIKK family, DNA-PK (Chen et al., 2007, Yajima et al., 2006). Therefore it is clear that an 
interdependent relationship exists between members of the PIKK family throughout the 
network of interacting pathways that together execute the DDR.  
1.2.4 Cell cycle checkpoints 
One of the most fundamental outcomes of the DDR is the activation of cell cycle checkpoints. 
These function to delay or arrest cell cycle progression to allow the cell time to repair the 
damage or if the damage is too severe, to initiate apoptosis. The components of the DDR can 
mediate checkpoints at different phases of the cell cycle: gap 1 (G1), DNA replication (S) or 
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gap 2 (G2). The predominant mechanism for control of cell cycle progression is through the 
regulation of cyclin-dependent kinases (CDKs) and their regulatory subunits, cyclins (Elledge 
and Harper, 1994). These exist in complexes and are activated by phosphatases that remove 
the inhibitory phosphorylation on CDKs, which allows the cell to progress through the cell 
cycle. This process is mediated by the CDC25 family of phosphatases, which consist of three 
mammalian isoforms: CDC25A, -B and -C and specifically regulate the activities of CDK1 
and CDK2 (Boutros et al., 2007). Effector kinases phosphorylate the CDC25 phosphatases in 
response to DNA damage and inhibit their activity thereby preventing CDK activation and 
consequently cell cycle progression (Figure 1.3).  
1.2.4.1 The G1 phase checkpoint 
Damage encountered in G1 results in the activation of the G1/S checkpoint, which prevents 
cells with DNA damage from undergoing DNA replication in S phase. The ATM/Chk2 and 
ATR/Chk1 pathways primarily mediate cell cycle arrest in G1 and the kinases within these 
pathways mainly target CDC25A and p53 during this phase. ATM can directly phosphorylate 
p53 within its N-terminal region serine 15 (S15) residue and together with the ATM-
dependent Chk2 phosphorylation of p53 on serine 20 (S20) and threonine 18 (T18) this results 
in the stabilisation of the p53 transcription factor (Banin et al., 1998, Canman et al., 1998, 
Shieh et al., 2000). Phosphorylation of these amino acids inhibits the p53-MDM2 interaction 
and disrupts the MDM2-induced nuclear export and degradation of p53 (Dumaz and Meek, 
1999, Schon et al., 2002). There is evidence that ATR can directly phosphorylate p53 on S15 
as well, although ATM appears to be the dominant PIKK that mediates G1 arrest (Tibbetts et 
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al., 1999). The increased stabilisation of p53 through its phosphorylation not only results in 
its accumulation after DNA damage; its activity as a transcription factor is enhanced as well.  
One of the main transcription targets of p53 is the cyclin-dependent kinase inhibitor (CKI), 
p21, which inhibits CDK4/cyclinD1 and CDK2/cyclin E (Figure 1.3) (He et al., 2005a). The 
activation of p21 inhibits the phosphorylation of pRB (Retinoblastoma protein), which leads 
to the stabilisation of the Rb/E2F complex and therefore, inactivation of E2F-dependent 
transcription of pro-proliferation genes that are normally required for progression through 
G1(Delavaine and La Thangue, 1999, Dimri et al., 1996). In late G1, the expression of ATR 
and Chk1 increases and, in response to DNA damage, Chk1 is activated by ATR-mediated 
phosphorylation. A key target of Chk1 is CDC25A, the phosphorylation of which leads to the 
inhibition of the CDK2/cyclin E complex (Figure 1.3) (Zhao et al., 2002). 
1.2.4.2 The S phase checkpoint 
The S phase checkpoint is the term used to describe the cell cycle arrest that occurs during 
DNA replication in response to genotoxic stress. The integrity of the genome is most 
vulnerable during S phase since spontaneous lesions can occur during the process of 
replication as well as from DNA damaging agents (Bartek et al., 2004). Therefore three S 
phase checkpoints exist: the replication-independent intra-S phase checkpoint (intra-S phase 
checkpoint), the replication-dependent intra-S phase checkpoint (replication checkpoint) and 
the S/M checkpoint (Bartek et al., 2004). The latter two checkpoints respond to stresses 
during DNA replication whereas the intra-S phase checkpoint does not require replicating 
DNA and is activated by DSBs. The replication checkpoint functions through the ATR-
mediated damage response pathways in response to a stalled replication fork as described  
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Figure 1.3 Cell cycle checkpoints 
Regulation of cell-cycle progression is primarily mediated through CDK and cyclin 
complexes, which are in turn regulated by CDC25 phosphatases. Progression through G1/S is 
medated by CDK4/cyclin D and CDK2/cyclin E. p21 inhibitis both of these complexes. Chk1 
phosphorylates CDC25A, inhibiting its activity and preventing its activation of CDK2. 
Similarly, CDC25A is inhibited in S phase, disrupting its dephosphorylation and activation of 
CDK2. All 3 CDC25s function in G2/M to activate CDK1/cyclin A and CDK1/cyclin B. All 
CDC25s are inhibited by DNA damage-inducible kinases in this phase. 
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previously in 1.2.2; this ATR-dependent pathway is the primary regulator of the progression 
from S to M phase when replication forks stall. The S/M checkpoint is an ATR-independent 
pathway that ensures that replication has accurately completed before cells divide and 
involves the inhibition of CDK1/cyclin B although the mechanism is not fully understood 
(Brown, 2003). 
The intra-S phase checkpoint responds to DSBs during S phase and is mediated through the 
ATM/Chk2 pathway as described previously, the outcome in this phase of the cell cycle being 
the S phase-dependent degradation of CDC25A. There is evidence to suggest that this process 
does depend on the underlying activity of the ATR/Chk1 pathway that also phosphorylates 
CDC25A but the exposure to DSBs enhances the proteolysis of this phosphatase during S 
phase (Falck et al., 2001, Zhao and Piwnica-Worms, 2001). Therefore both Chk1 and Chk2 
phosphorylate CDC25A leading to the consequent inhibition of CDK2/cyclin A activity 
(Figure 1.3). This blocks the loading of the CDC45 initiation factor onto chromatin, which 
would otherwise mediate the recruitment of DNA polymerase α (Pol α) to pre-replication 
complexes (Kastan and Bartek, 2004). The inhibition of CDK2 therefore prevents the firing of 
new replication origins.  
Another branch of the intra-S phase checkpoint is the ATM-dependent phosphorylation of 
SMC1 (structural maintenance of chromosomes-1) and NBS1, although the significance of 
the phosphorylation of these ATM targets in relation to the intra-S phase checkpoint is 
currently unknown (Kim et al., 2002, Yazdi et al., 2002).  
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1.2.4.3 The G2/M phase checkpoint 
The G2/M checkpoint is activated when damage occurs in the G2 phase of the cell cycle or if 
cells progress into G2 phase with unrepaired damage from G1 or S phase; this halts 
progression into mitosis and inhibits segregation of damaged chromosomes (Kastan and 
Bartek, 2004). The mode of regulation within this checkpoint is predominantly by the 
inactivation of CDK1/cyclin B1 through phosphorylation of CDC25s. CDC25C can be 
phosphorylated by Chk1 and Chk2, which allows the binding of 14-3-3 proteins to this 
phosphatase and renders it inactive and/or sequesters it to the cytoplasm (Abraham, 2001). 
Another mechanism involved in the G2/M checkpoint utilises the p38 mitogen-activated 
protein kinase (MAPK) pathway that has been shown to target all three CDC25s (Bulavin et 
al., 2001, Reinhardt et al., 2007). In addition, the Polo-like kinase, Plk3, has been found to 
play a role in this checkpoint via inhibitory phosphorylation of CDC25C (Figure 1.3) (Bahassi 
et al., 2004). The p53-dependent transcription of cell cycle inhibitors such as p21, 14-3-3 
sigma proteins and GADD45a (growth arrest and DNA damage-inducible 45 alpha) also 
maintains the G2 checkpoint. Other checkpoint mediators include BRCA1 and 53BP1 (Wang 
et al., 2002, Xu et al., 2001). 
1.3 DNA DAMAGE REPAIR  
1.3.1 Repair of double strand breaks 
Double strand breaks (DSBs) are the most deleterious of DNA lesions and can be repaired by 
a network of DNA repair pathways. Failure to repair such lesions would be disastrous for the 
cell, leading to death (Jeggo and Lobrich, 2007). The inappropriate repair of DSBs can result 
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in chromosomal alterations that can subsequently lead to the onset of tumourigenesis. The 
repair of DSBs is conducted by at least four pathways: homologous recombination (HR), non-
homologous end-joining (NHEJ), alternative non-homologous end-joining (alt-NHEJ) and 
single strand annealing (SSA).  
1.3.1.1 Homologous Recombination   
Homologous recombination (HR) repair is an important repair pathway of DSBs and utilises 
homologous sequences to repair damaged DNA. Because of this, HR repair primarily 
functions in late S and G2 phases of the cell cycle and is regarded as being an error-free repair 
pathway. The substrate for the initiation of HR repair is the ssDNA that arises from the 
processing of a DSB as in 1.3.1.5. HR is catalysed by the recombinase family of enzymes, 
namely Rad51, which polymerises on ssDNA to form a nucleoprotein filmament and, 
consequently, the presynaptic filament. Rad51 possesses a lower affinity for ssDNA than 
RPA; therefore different proteins act to mediate the displacement of RPA by Rad51 
(Hartlerode and Scully, 2009). Rad52 is one example, as is BRCA2, which interacts directly 
with Rad51, recruits it to ssDNA and catalyses the nucleation of Rad51 (Sugiyama and 
Kowalczykowski, 2002, Yang et al., 2005). Rad51 is also modified by Chk1, which mediates 
the phosphorylation of Rad51 and is required for its recruitment to sites of damage (Sørensen 
et al., 2005). 
The Rad51 nucleoprotein filament binds duplex DNA and, in concert with the accessory 
protein Rad54, invades an undamaged dsDNA template to locate homologous regions of 
DNA (Figure 1.4) (Mazin et al., 2000). In the process of strand invasion, one strand becomes 
displaced and a displacement (D)-loop structure is formed  (Jackson, 2002). Strand invasion is  
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Figure 1.4 Homologous Recombination 
ssDNA generated from DNA end-resection is initially bound by RPA. BRCA2 and Rad52 aid 
the formation of the Rad51 nucleoprotein filament. Together with Rad54, the Rad51 filament 
interacts with an undamaged DNA duplex, displacing one strand to form a D-loop. The 
second resected end is captured in a Rad52-dependent manner, after which DNA synthesis 
occurs to fill in both sides of resected DNA. Branch migration leads to the formation of a 
double Holliday junction. Crossover and non-crossover products are generated after 
resolution of the double Holliday junction (adapted from Ciccia and Elledge, 2010, Jackson, 
2002). 
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followed by DNA synthesis, which is conducted by DNA polymerases such as Pol δ that use 
the homologous DNA as a template to replace the sequence of DNA that was previously on 
the damaged strand (Maloisel et al., 2008). At this point the reaction can proceed through the 
synthesis-dependent strand annealing pathway (SDSA) where the newly synthesised strand is 
displaced by the RTEL helicase and anneals with the ssDNA on the other side of the break.   
The SDSA pathway of HR explains the fact that crossover events in mitotic DSBR are rare 
and also that meiotic DSBR events do not result in crossovers (Allers and Lichten, 2001, 
Ferguson and Holloman, 1996).  Alternatively, the reaction can occur via the DSBR pathway 
where the invading strand captures the second resected DNA break in a process known as 
second end capture, which is facilitated by Rad52 (Nimonkar et al., 2009). DNA synthesis at 
either side of the structure follows, along with branch migration, and results in an 
intermediate known as a double Holliday junction (HJ). 
 These intermediates must then be resolved to separate the covalently-bound sister 
chromatids. Resolution of HJs is dependent on the activities of the Mus81/Eme1 and 
SLX1/SLX4 endonuclease complexes as well as the HJ resolvase, GEN1 (Ciccia et al., 2003, 
Constantinou et al., 2002, Fekairi et al., 2009, Ip et al., 2008). The generation of non-
crossover events prevent the loss of heterozygosity and genomic rearrangement and occur if 
there is no exchange of DNA sequences between the sister chromatids. Conversely, crossover 
events occur if DNA is exchanged between the two chromosomes. Double HJs can also be 
processed through dissolution and this is reliant on the Bloom syndrome protein (BLM) 
helicases in complex with topoisomerase IIIα (TOP3α), which together catalyse the HJ 
dissolution to yield non-crossover products (Sung and Klein, 2006).  
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1.3.1.2 Non-homologous end-joining 
Despite it being an error-prone pathway, the prevailing repair pathway in the G1 phase of the 
cell cycle is non-homologous end-joining (NHEJ). Initially, broken ends of the DNA 
molecule are tethered in a process that requires the Ku70/Ku80 heterodimer to bind to the 
DNA broken end first. The complex consisting of the Ku heterodimer and DNA mediates the 
recruitment of  DNA-PKcs (Gottlieb and Jackson, 1993). The association of DNA-PKCS with 
the Ku heterodimer-DNA complex  results in a  molecular bridge being formed and causes the 
two ends of the DNA molecule to be brought closer together (Figure 1.5) (Spagnolo et al., 
2006). The unphosphorylated form of DNA-PKcs acts to block and protect the DNA ends 
from premature degradation or ligation until both ends of the broken DNA molecule are 
brought into closer proximity (Calsou et al., 1999).  Once this occurs, DNA-PKcs becomes 
activated by autophosphorylation and undergoes a conformational change at the synaptic 
complex that relieves the blockage and allows processing enzymes and ligases to access the 
DNA ends (Reddy et al., 2004). 
Often, non-compatible DNA ends will be produced by a DSB and these cannot be directly 
ligated because at least one of the strands will possess a 3’ or 5’ single strand overhang. These 
overhangs need to be processed before ligation can occur and it is this stage of NHEJ that 
renders it an imprecise pathway since loss of nucleotides at the site of the break often occurs 
during processing of the DNA ends (Smith et al., 2001). Artemis is the only known nuclease 
to date that is involved in NHEJ and is required to process the DNA overhangs by resection at 
the position where the single strand extends from the double-strand helix (Weterings and 
Chen, 2008). The modes of activation of Artemis have been the cause of controversy; 
although it is known that Artemis becomes phosphorylated by both DNA-PK and ATM after  
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Figure 1.5 Non-homologous end-joining 
The Ku70/Ku80 heterodimer binds to broken DNA ends and recruits DNA-PKcs to tether the 
two ends together. Autophosphorylation of DNA-PKcs results in a conformational change 
that makes the DNA ends accessible to processing enzymes. Non-ligatable ends are processed 
by Artemis, while polymerases synthesis nucleotides at compatible ends. Ligase IV/XRCC4, 
in concert with XLF, mediates re-ligation of DNA ends (adapted from Ciccia and Elledge, 
2010, Weterings and Chen, 2008). 
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IR, it is not known whether phosphorylation is needed for its nuclease activity (Goodarzi et 
al., 2006, Niewolik et al., 2006).  While Artemis is responsible for processing non-compatible 
ends by resection, polymerases are required to synthesise complementary nucleotides in 
another process to remove single-strand overhangs. Such polymerases include DNA 
polymerase µ (Pol µ), DNA polymerase λ (Pol λ) and the human terminal 
deoxynucleotidyltransferase (TdT) (Hartlerode and Scully, 2009). 
Once DNA ends have been sufficiently processed and non-compatible ends converted into 5’ 
ligatable ends, re-ligation can occur. This stage of NHEJ is mediated by DNA ligase IV and 
XRCC4, which exist in a complex and are recruited together to the DNA-Ku scaffold. It has 
been suggested that the interaction between the ligase IV/XRCC4 complex and Ku70/Ku80 
increases the ligase activity of the former complex (Nick McElhinny et al., 2000). Studies 
have also shown that another protein, XRCC4-like factor or Cernunnos (XLF/Cernunnos) can 
stimulate the ligation ability of ligase IV/XRCC4 (Ahnesorg et al., 2006). Together, these 
proteins are able to mediate the repair of the DSBs. 
1.3.1.3 Alternative non-homologous end-joining 
Studies have implicated another pathway in the repair of DSB, and this is more error-prone 
than the classical NHEJ pathway. This is known as alternative NHEJ (alt-NHEJ) or 
microhomology mediated end-joining (MMEJ) since junctions that are repaired by this 
pathway are characterised by deletions, insertions and relatively large regions of 
microhomology.  Alt-NHEJ requires limited DSB resection, which occurs in G1 and is 
facilitated by CtIP and the MRN complex (Yun and Hiom, 2009). Other components involved 
in alt-NHEJ have not been fully characterised, yet several proteins have been implicated. 
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Poly(ADP-ribose) polymerase 1 (PARP1) has been shown to bind to resected DSBs, 
particularly in the absence of Ku (Wang et al., 2006). The mammalian polynucleotide kinase, 
PNK, has been implicated in the processing of the DNA ends (Audabert et al., 2006). Finally, 
the DNA ligase IIIα/XRCC1 complex has been found to possess the end-joining activity 
required in this pathway (Della-Maria et al., 2011). 
1.3.1.4 Single-strand annealing 
A DSB that occurs between closely-repeated sequences can also be repaired during HR using 
a process called single-strand annealing (SSA). The first step in this pathway is DNA 
resection, which utilises the same components as in HR, after which, RAD52 binds the 
3’ssDNA ends to promote the annealing of two repeated sequences (Ciccia and Elledge, 
2010). It is interesting that the N-terminal region of RAD52 is responsible for promoting SSA 
in vitro, a region which is unable to stimulate the recombinase activity of RAD51 in HR 
(Singleton et al., 2002). The non-homologous 3’ssDNA ends that are left are cleaved by the 
mammalian ERCC1/XPF endonuclease complex and, incidentally, this process does not 
require strand invasion since the DSB ends are processed so they can anneal with each other 
(Al-Minawi et al., 2008). 
1.3.1.5 Regulation of DSB repair 
The balance between DSBR pathways shifts during the cell cycle since HR, largely an error-
free process, relies on the presence of an intact sister chromatid and, therefore, occurs 
primarily during S/G2 phases of the cell cycle whereas NHEJ predominates mainly during 
G0, G1 and early S phase and is an error-prone repair pathway (Takata et al., 1998). One 
process known to influence which repair pathway to use is resection of DNA ends 
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surrounding the break. HR-mediated repair is dependent on DSB resection during the S/G2 
phases of the cell cycle, which generates ssDNA through the digestion of 5’ends of DNA.  
Initially, MRN is recruited to a DSB and binds broken DNA ends. MRN alone is not 
sufficient for DNA-end resection and requires additional proteins, including CtIP, which 
associates with the MRN complex (Figure 1.6) (Takeda et al., 2007). The role of the MRN 
complex in DNA-end resection relies on the endonuclease activity of MRE11, although, 
interestingly, this function is not required for the ability of the MRN complex to sense DSBs 
as described in 1.2.1 (Buis et al., 2008). There is evidence to suggest that binding of CtIP to 
MRN could influence the function of MRN such that it is directed toward end resection 
(Sartori et al., 2007).  
It is important that resection and HR occur at the same stage of the cell cycle since HR is 
dependent on end resection; therefore the activity of CtIP in end resection is highly regulated 
at the post-translational level. Both phosphorylation and ubiquitylation play a role in this and 
these processes are mediated by CDK2 and BRCA1, respectively (Chen et al., 2008, Huertas 
and Jackson, 2009, Yu et al., 2006). This occurs in the S/G2 phases of the cell cycle to 
promote the association of CtIP with DSBs, which subsequently promotes end resection. 
Limited resection can occur in G1, which is facilitated by CtIP, indicating that CtIP is able to 
promote DSB resection in the absence of its activation by CDK and BRCA1 in S phase (Yun 
and Hiom, 2009). The MRN complex initiates the unwinding of DNA ends; CtIP and the 
MRN complex are then thought to promote resection by endonucleolytic cleavage of 
5’ssDNA ends.  
Extensive resection is further conducted by the concerted activities of exonuclease-1 (EXO-
1), DNA replication helicase 2 (DNA2) and BLM, after which, RPA is recruited to the  
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Figure 1.6 DNA-end resection 
The MRN complex is recruited to DSBs and binds to DNA ends where is becomes bound by 
CtIP. CDK2-dependent phosphorylation of CtIP mediates its association with BRCA1, which 
consequently ubiquitinates CtIP. Both phosphorylation and ubiquitylation of CtIP facilitates 
its association with DSBs. MRN promotes the initial unwinding of DNA. Endonucleolytic 
cleavage of 5’ ends is then mediated by CtIP and MRN before extensive DNA processing is 
conducted by EXO1, DNA2 and BLM. ssDNA from DSB resection is bound by RPA, which 
activates DNA repair by HR (adapted from Ciccia and Elledge, 2010). 
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ssDNA ends generated by DNA resection and prevents these ends from annealing or from 
forming secondary structures (Ciccia and Elledge, 2010, You and Bailis, 2010, Zhu et al., 
2008). During NHEJ, binding of the Ku complex and DNA-PK to DNA ends inhibits HR 
repair since, in their absence, more DSBs undergo end resection (Pierce et al., 2001). In 
addition, the phosphorylation of particular residues of DNA-PKcs has an inhibitory effect on 
HR repair through the prevention of end resection (Cui et al., 2005). 
1.3.2 Single-strand break repair 
Single-strand breaks (SSBs) are the most common type of damage that occurs in cells and 
these can arise directly or indirectly. Direct SSBs can occur from genotoxic insults such as IR 
or reactive oxygen species (ROS), the latter resulting in the ROS-induced disintegration of 
oxidised deoxyribose (sugar damage). SSBs are also generated indirectly during the process 
of base excision repair (BER) or from erroneous TOP1 activity (Caldecott, 2008). If SSBs are 
left unrepaired in proliferating cells they can cause replication forks to stall or collapse, which 
may generate DSBs and induce genomic instability (Kuzminov, 2001).  
The main sensor of SSBs in the process of single-strand break repair (SSBR) is PARP1, 
which becomes activated upon binding to SSBs and facilitates a number of processes that are 
fundamental to SSBR. The binding of PARP1 to sites of SSBs results in its activation, which 
causes the synthesis of poly(ADP-ribose) (PAR) chains on itself and other target proteins. 
Chromatin structure is also regulated by PARP1 since the latter assembles PAR chains onto 
histones H1 and H2B, a modification that serves to recruit other components of the SSBR 
pathway to SSB sites (Schreiber et al., 2006). This process is transient since PAR 
glycohydrolase (PARG) rapidly degrades PAR chains to allow PARP1 to be restored for 
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further SSB detection (Davidovic et al., 2001). PAR chains serve as a signal for the 
recruitment of other factors to promote SSBR (Ciccia and Elledge, 2010). X-ray repair cross-
complementary protein (XRCC1) is recruited to SSBs in a PARP1-dependent manner and 
promotes SSBR through the recruitment of XRCC1-interacting proteins (Masson et al., 1998). 
End-processing follows the detection of such lesions and this restores damaged 3’-termini to 
the proper hydroxyl state. This stage of SSBR is conducted by many enzymes and is 
dependent on the type of SSB that arises. End-processing enzymes include DNA polymerase 
β (Pol β), polynucleotide kinase 3’-phosphatase (PNKP) and the nucleases, apurinic-
apyrimidinic endonuclease 1 (APE1) and aprataxin (APTX). These are all recruited to sites of 
SSBs through interaction with XRCC1 (Caldecott et al., 1996, Clements et al., 2004, 
Whitehouse et al., 2001, Winters et al., 1994). 
After end-processing, gap-filling of the missing nucleotides must occur. The insertion of one 
nucleotide is termed short-patch repair, whereas gap-filling that needs to be extended for 2-12 
nucleotides constitutes long-patch repair. Pol β mediates both types of gap-filling but may 
require additional accessory proteins for long-patch repair such as flap endonuclease 1 
(FEN1) (Liu et al., 2005). The final step of SSBR is DNA ligation, which is catalysed by 
DNA ligase 3 (LIG3) for short-patch repair and DNA ligase 1 (LIG1) for long-patch repair 
(Caldecott, 2007). 
1.3.3 Repair of DNA base adducts 
DNA adducts are generated by exposure to alkylating agents or through endogenous 
compounds. Small alterations of DNA bases can be removed and repaired before they 
encounter replication forks by base excision repair (BER) or nucleotide excision (NER) repair 
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pathways. The mismatch repair (MMR) pathway replaces mis-repaired DNA bases with 
correct bases during DNA replication. 
1.3.3.1 Direct repair 
Repair of a damaged base can be conducted without removal of the damage. This occurs by 
the action of enzymes such as alkyltransferases and DNA dioxygenases that revert the 
damaged base back to its unmodified form (Sedgwick, 2004). The main alkyltransferase to 
function in direct reversal is O
6
-methylguanine-DNA methyltransferase (MGMT), which 
demethylates the mutagenic lesion O
6
-methylguanine: the methyl group of the lesion is 
transferred to a cysteine residue in the active site of MGMT (Sedgwick et al., 2007). Alpha-
ketoglutarate-dependent dioxygenase alkB homologues 2 and 3 (ALKBH2 and ALKBH3) 
catalyse the oxidative demethylation of N-alkyl lesions such as 1-methyladenine and 3-
methylcytosine (Duncan et al., 2002). Incidentally, these are the main lesions that are induced 
in ssDNA by alkylating agents. 
1.3.3.2 Base excision repair 
BER acts to remove a damaged DNA base through a series of coordinated steps. Simple 
alkylation adducts are recognised by lesion-specific DNA glycosylases, which catalyse the 
hydrolysis of the N-glycosyl bond thus resulting in the removal of the base in question. The 
loss of a pyrimidine or purine base leaves an apyrimidinic or apurinic (AP) site, respectively, 
which is recognised by the AP endonuclease (APE1). This enzyme incises the DNA backbone 
of the AP site to generate a 3’hydroxyl and a 5’deoxyribose phosphate (5’-dRP) group. The 
latter is removed by the 5’-dRP lyase activity of Pol β, which also mediates the single 
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nucleotide gap filling, followed by re-ligation of the nicked DNA strand catalysed by LIG1 or 
LIG3 (Matsumoto and Kim, 1995).  
1.3.3.3 Nucleotide excision repair 
Larger DNA adducts or lesions that are able to distort the double-stranded DNA helix are 
removed and repaired by the NER pathway. Lesions that are recognised by NER include 
cyclobutane pyrimidine dimers (CPDs) and 6,4 photoproducts (6,4PPs), both of which are 
induced by UV damage. Defects in components of NER display the same photosensitivity and 
predisposition to skin cancer observed with the repair syndrome Xeroderma Pigmentosum 
(XP) (de Laat et al., 1999). There are two types of NER: global genome NER (GG-NER), 
which is used to repair lesions over the entire genome, and transcription-coupled NER (TC-
NER) that targets transcription-blocking lesions in actively-transcribing DNA (de Laat et al., 
1999). The two types of NER also differ in the manner of substrate lesion recognition; 
otherwise a common set of steps exist to complete the repair process.  
In TC-NER, lesions are detected by the elongating RNA polymerase II, whereas the primary 
sensor of damaged DNA in GG-NER is the complex of XPC and hRAD23B (hR23B) (de 
Laat et al., 1999, Masutani et al., 1994, Sugasawa et al., 1998). RPA and XPA are also known 
as damage recognition proteins in NER and both are required for the recruitment of other 
repair factors (de Laat et al., 1999, Evans et al., 1997). The initial recognition of helix-
distorting lesions is via the XPC-hR23B complex, which then recruits the transcription factor, 
TFIIH, to the damaged DNA; indeed, both TFIIH and XPC-hR23B have been found to be 
essential for catalysing an open formation around the lesion, which is consequently required 
for dual incision on either side of the lesion (Evans et al., 1997). Incidentally, TFIIH 
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functions in both types of NER and contains XPB and XPD DNA helicases that allow TFIIH 
to generate an open complex around the lesion (Roy et al., 1994, Schaeffer et al., 1993). The 
unwinding of the damaged DNA region results in a junction between ssDNA and dsDNA, 
which is recognised by the endonucleases XPG and ERCC1-XPF for the dual incision of the 
3’ and 5’ ends respectively (Matsunaga et al., 1995, O'Donovan et al., 1994).  
After the removal of the damaged strand of DNA, various enzymes function to catalyse the 
gap-filling repair synthesis and ligation, which constitute the later steps of NER. The 
replicative polymerases Pol δ and Pol ε are responsible for NER repair synthesis and require 
the processivity factor PCNA, although evidence has shown that Pol κ may also play a role 
(de Laat et al., 1999, Ogi et al., 2010). The nick sealing step that allows the ligation of the 
5’end of the new strand to the original DNA is conducted by LIG1 (de Laat et al., 1999). 
1.3.3.4 Mismatch Repair 
The MMR pathway functions during S phase to detect and repair mismatched base pairs that 
arise during DNA replication. Mismatches during replication include base mis-pairing that 
arise from errors of DNA polymerases as well as insertion/deletion (ID) mis-pairs that occur 
when primer and template strands re-anneal incorrectly; these are present in microsatellite 
sequences (Kunkel, 1993). The MMR pathway occurs at replication fork sites themselves and 
is, therefore, different to BER and NER in that MMR cannot repair damage before replication 
(Helleday et al., 2008). Whilst defects in MMR can lead to an increase in the spontaneous 
mutation rate and can result in resistance to some anti-cancer agents, the MMR process itself 
can mediate the toxicity of some compounds.  
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In humans, the MutS ATPase complexes recognise mismatched DNA. Two such complexes 
exist: MutSα, which is a heterodimer of MSH2 and MSH6, and MutSβ, a heterodimer 
consisting of MSH2 and MSH3. MutSα is responsible for recognising mismatched base pairs 
and very small ID mispairs that are 1 or 2 nucleotides long, whereas longer ID mis-pairs are 
sensed by MutSβ (Kunkel and Erie, 2005). The binding of one of the MutS complexes to the 
mismatch leads to the recruitment of a second heterodimer, MutLα, a complex of MLH1 and 
PMS2 that possesses ATPase activity and facilitates mismatch recognition (Figure 1.7) 
(Jiricny, 2006). Excision has a bi-directional capacity that is dependent on the presence of a 
‘nick’ or incision in the daughter strand; this can be located 3’ or 5’ to the mis-paired base 
(Modrich, 1997). This allows the excision of the area between the nick and the mispair to 
occur in a strand-specific manner to direct repair to the new strand. EXO-1 mediates the 
hydrolysis of the aforementioned DNA and requires the presence of MutSα/MutSβ and RPA 
to conduct 5’ nick-directed excision, whereas the concerted activities of MutLα, PCNA and 
RCF are needed for EXO-1 to be able to take part in 3’ nick-directed excision (Genschel and 
Modrich, 2003).  
DNA re-synthesis and ligation occur once the mismatch has been removed and this process is 
catalysed by replicative polymerases such as DNA polymerase δ (Pol δ), which requires the 
processivity factor, PCNA and LIG1 respectively. It is clear that PCNA does not only 
function at the re-synthesis step of MMR: it is also thought to play a role in the first steps of 
MMR since it is able to interact with both MutS complexes (Umar et al., 1996). Another 
protein that appears to act throughout MMR is RPA since it not only protects the ssDNA that 
is generated during excision, it also binds to ‘nicked’ DNA before MutS and MutLα (Guo et 
al., 2006). 
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Figure 1.7 Mismatch Repair 
The mis-paired base or nucleotides are recognised by MutSα or MutSβ respectively. MutS 
binding recruits MutLα, leading to an ATP-dependent conformational change to allow 
excision to occur. The daughter strand is distinguished by nicks and MMR can be directed 
from a nick 5’ or 3’ of the mismatch. EXO-1 mediates the excision of the mismatch in a 5’ 
directed manner, whereas it requires PCNA and RCF to conduct 3’ directed excision (adapted 
from Jiricny, 2006, Li, 2008). 
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1.3.4 DNA damage tolerance and repair of ICLs 
1.3.4.1 Translesion synthesis 
Mechanisms must exist to overcome lesions such as unrepaired breaks that could block the 
replication machinery and lead to the stalling of replication forks. Cells have developed 
tolerance pathways to respond to this potentially catastrophic damage during replication to 
either avoid the lesion or to replicate past it. One of these damage tolerance mechanisms is 
known as translesion DNA synthesis (TLS), where non-replicative DNA polymerases are 
used to bypass damaged bases during replication (Friedberg, 2005). The TLS polymerases 
include several from the Y family of polymerases: Rev1, Pol κ, Pol η, Pol ι; and a member of 
the B family of polymerase, Pol ζ. They all have different substrate specificities, which enable 
them to mediate replication past a variety of base lesions (Lehmann, 2006).  
The TLS polymerases can accommodate damaged bases within their active sites, unlike the 
more stringent replicative polymerases (Lehmann, 2005). The homotrimeric processivity 
factor, PCNA, acts as a platform for the TLS polymerases after damage through its mono-
ubiquitylation by Rad6/Rad18 (Hoege et al., 2002). The mono-ubiquitylation of PCNA occurs 
after damage such as UV or other agents that stall replication forks and this post-translational 
modification allows PCNA to preferentially bind TLS polymerases over replicative 
polymerases since the former possess ubiquitin-binding motifs. It has been proposed that 
when a fork stalls, the mono-ubiquitylation of PCNA increases its affinity for TLS 
polymerases, thereby enabling efficient displacement of replicative polymerases (Lehmann, 
2007). However, there is also evidence to suggest that ATR-induced phosphorylation of Pol η 
plays a role in TLS, therefore hinting at another level of regulation of this process (Gohler et 
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al., 2011). Once the TLS polymerases are recruited to the stalled replication fork by mono-
ubiquitylated PCNA, they are able to insert nucleotides across the DNA lesion and extend the 
DNA strand. DNA synthesis across replication-blocking lesions can result in the generation of 
mutations since many TLS polymerases are characterised by low fidelity. Therefore, mono-
ubiquitylation of PCNA is tightly regulated to ensure that the lesion-bypass activity is 
controlled (Avkin et al., 2006). 
1.3.4.2 Interstrand Crosslink Repair 
Lesions that result in interstrand crosslinks (ICLs) cause two replication forks to converge at 
the crosslink; therefore both strands of the DNA helix are affected. The generation of an ICL 
activates the Fanconi anaemia (FA) pathway and involves the coordination of different repair 
pathways such as TLS, NER and HR. 
Core FA proteins, FANCM and FAAP24, recognise blocked replication forks and bind to 
ssDNA regions to recruit the core FA complex to sites of damage (Ciccia et al., 2007, Kim et 
al., 2008). This core complex consists of 12 FA proteins (FANCA, B, C, E, F, G, L, M, 
FAAP24, FAAP20, MHF1 and MHF2) to form an E3 ubiquitin ligase and, once associated 
with a stalled replication fork, this ligase ubiquitylates the FANCD2-FANCI complex 
(Garcia-Higuera et al., 2001, Smogorzewska et al., 2007). Mono-ubiquitylation of FANCI-
FANCD2 is required for its retention at sites of crosslinks as well as for the recruitment of 
further nucleases and polymerases that promote ICL repair.  
Recently, Fanconi-associated nuclease 1 (FAN1) was shown to interact with mono- 
ubiquitylated FANCD2 and to excise DNA that is adjacent to a stalled replication fork (Kratz 
et al., 2010, MacKay et al., 2010). This type of incision is termed ‘unhooking’ and can also 
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be conducted by Mus81-Eme1 and the NER endonuclease, ERCC1-XPF (Kuraoka et al., 
2000, Niedernhofer et al., 2004). After unhooking, the nascent strand is extended past the 
lesion by TLS polymerases, which are recruited to mono-ubiquitylated PCNA (Moldovan and 
D'Andrea, 2009). 
Proteins involved in HR are recruited at later stages in ICL repair to repair DSBs that are 
generated during this process. One example is FANCD1 (BRCA2), which is essential for HR 
as described in 1.3.1.1 (Wang et al., 2004). Another downstream FA protein is FANCJ (also 
known as BRIP1 or BACH1), which can unwind D-loop structures and is, therefore, involved 
in Rad51 resolution in HR (Cantor et al., 2001). FANCN (or PALB2), a BRCA2 interaction 
partner, also functions to promote HR downstream of the FA pathway (Xia et al., 2006). Once 
the lesion has been repaired and the cells commence cycling, the FANCD2-FANCI complex 
becomes de-ubiquitylated by the USP1/UAF1 complex (Cohn et al., 2007, Nijman et al., 
2005). 
1.3.5 Repair Syndromes 
The crucial role of the DDR is highlighted by the fact that genes encoding many of the 
proteins that are involved in these pathways are mutated in a variety of cancers and in a 
number of hereditary disorders. These are generally autosomal recessive genetic syndromes 
and can be a result of both SSBR and DSBR pathway defects. 
1.3.5.1 Ataxia-Telangiectasia 
Classical Ataxia-Telangiectasia (A-T) is caused by a loss of the ATM protein that generally 
arises from two truncating mutations in the ATM gene (Gilad et al., 1996). However, milder 
forms can be caused by missense mutations of splice site mutations (Stewart et al., 2001, 
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Teraoka et al., 1999). The clinical features of A-T include: cerebellar ataxia, cell-mediated 
and humoral immunodeficiency, oculocutaneous telangiectasia (dilated blood vessels), an 
increased predisposition toward developing tumours, an increased sensitivity to IR and speech 
impediment (Taylor et al., 1975). 
1.3.5.2 Ataxia-Telangiectasia-like disorder 
Another recessive neurological disorder with features that are similar to A-T is Ataxia-
Telangiectasia-like disorder (ATLD). ATLD is caused by mutations in the MRE11 gene 
(Stewart et al., 1999). There are different forms of ATLD, corresponding to the homozygous 
and heterozygous mutations in MRE11 that lead to the expression of low-levels of truncated 
or partially active MRE11 protein respectively (Stewart et al., 1999). Apart from a lack of 
conjunctival telangiectasia, overt immunodeficiency and a tumour predisposition, the other 
clinical features of ATLD are difficult to distinguish from A-T patients. 
1.3.5.3 Nijmegen breakage syndrome  
Nijmegen breakage syndrome (NBS) is caused by mutations in the NBS1 gene, which is 
another member of the MRN complex (Varon et al., 1998). This chromosomal instability 
disorder is characterised by a hypersensitivitiy to IR, microcephaly, intellectual impairment, 
dysmorphic facial features, growth retardation, immunodeficiency, developmental delays and 
a susceptibility to lymphoid tumours, particularly lymphoma .This syndrome is also 
characterised by a defect in the intra-S phase DNA damage checkpoint, which is consistent 
with the fact that the phosphorylation of NBS1 by ATM plays a role in this branch of the 
checkpoint. 
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1.3.5.4 Nijmegan breakage syndrome-like disorder 
Mutation in the third component of the MRN complex, the RAD50 gene, was found to result 
in a clinical phenotype, termed Nijmegan breakage syndrome-like disorder (NBSLD) (Waltes 
et al., 2009). The only identified NBSLD patient presented with clinical features, comparable 
to those of patients with NBS, which include microcephaly, a hypersensitivity to IR and 
chromosomal instability, although immunoglobulin levels appeared to be normal (Waltes et 
al., 2009). 
1.3.5.5 Seckel syndrome 
Mutations in ATR are much rarer than mutations in ATM since the disruption of the ATR gene 
severely compromises genomic integrity and results in early embryonic lethality in mice 
(Brown and Baltimore, 2000). However, mutations in the ATR gene have been identified in a 
single family with Seckel syndrome (O'Driscoll et al., 2003). This homozygous mutation 
results in abnormal splicing of exon 9 of ATR, leading to the reduced expression of ATR. The 
characteristics of Seckel syndrome include proportional dwarfism, microcephaly, a ‘bird-
headed’ facial appearance and mental retardation. Recently, mutations in ATR have been 
reported to occur in an autosomal dominant manner and were reported to be present in a 
cancer syndrome (Tanaka et al., 2012).  Non-ATR Seckel patient cell lines have also been 
found, indicating that the mutations of other genes can also cause this syndrome. Mutations in 
the PCNT gene that encodes for pericentrin (a structural and centrosomal protein) were found 
to result in a Seckel-like syndrome (Griffith et al., 2008). 
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1.3.5.6 Fanconi Anaemia 
Fanconi Anaemia (FA) is also a recessive disorder that is very rare and is characterised by the 
following: a predisposition to both haematological and solid cancers, progressive bone 
marrow failure, congenital malformations and a hypersensitivity to cross-linking agents. At 
least 20 proteins have been identified to function in the repair of DNA ICLs, 15 of which have 
been found to be mutated in FA. Of the known 20 ICL repair proteins, 12 constitute the core 
E3 ubiquitin ligase complex of the FA pathway, which ubiquitylates the FANCI-FANCD2 
complex. The 12 FA genes that form the E3 ubiquitin ligase are: FANCA, FANCB, FANCC, 
FANCE, FANCF, FANCG, FANCL, FANCM, FAAP24, FAAP20, MHF1, MHF2, with the 
majority of mutations residing in FANCA (Moldovan and D'Andrea, 2009). Other FA genes 
known to be mutated in FA include FANCJ, FANCN, RAD51C (FANCO), SLX4 (FANCP) 
and FANCD1 (BRCA2) (Kim et al., 2011). 
1.3.5.7 Xeroderma Pigmentosum 
Xeroderma Pigmentosum (XP) is caused by mutations in genes that are involved in the repair 
of UV-induced DNA lesions. XP is an autosomal recessive disorder and was, incidentally, the 
first DNA repair disorder to be discovered. The phenotype of XP includes a severe sensitivity 
to sunlight and sun-induced skin abnormalities that can range from extensive freckling to 
malignant skin neoplasia. The majority of XP patients have defects in NER genes; there are 7 
complementation groups that are deficient in NER. These include XPA, XPB (also known as 
ERCC3), XPC, XPD (also known as ERCC2), XPE (also known as DDB2), XPF (also known 
as ERCC4) and XPG (also known as ERCC5). Another hereditary photosensitive disorder 
arises from mutations in XPV, which is known as XP variant and encodes DNA Pol η. XP 
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variant cells exhibit a functional NER pathway but show a delay in post-replication recovery 
after UV exposure (Lehmann et al., 1975). XPA individuals have the most severe clinical 
features that develop at an early age and are completely deficient in NER, whereas XPD 
patients are less sensitive to UV than XPA patients although still more sensitive than cells of 
other complementation groups (Lehmann, 2001). 
1.4 P53 
One of the most important proteins that is involved in the complex array of pathways of the 
DDR is p53, the ‘guardian of the genome’ (Lane, 1992).  p53 is at the centre of these 
pathways and orchestrates numerous responses that determine cell fate. The fact that more 
than 50% of sporadic tumours harbour a mutation or deletion in the p53 gene underscores its 
crucial role in coordinating the cellular response to genotoxic stress.  
1.4.1 Structure of p53 
Wildtype (WT) p53 contains 393 amino acids and has an apparent molecular weight of 53 
kDa. In an active form it exists as a tetramer where each monomer consists of 3 functional 
domains: the N-terminal domain, a core DNA binding domain (DBD) and a C-terminal 
tetramerisation domain. The N-terminal region of p53 contains its transactivation domains 
(TAD) and also comprises a proline-rich domain (Figure 1.8). 
The TAD contains 2 subdomains, denoted as TAD1 and TAD2, which are responsible for 
interacting with components of the basal transcription machinery and also comprise the 
binding site of mouse double minute protein 2 (MDM2), the main E3 ubiquitin ligase for p53. 
In addition, the N-terminal TAD contains the binding site for MDMX, another negative 
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regulator of p53. The proline-rich domain (PRD) within the N-terminal domain contains four 
copies of a PXXP motif, where P denotes proline and X denotes any amino acid. This motif 
has been shown to mediate binding of proteins that contain Src-homology-3 (SH3) domains 
(Yu et al., 1994). 
The central DBD allows p53 to bind to its target genes in a sequence-specific manner. The 
DNA consensus binding site for WT p53 in these target genes was found to consist of two 
repeated decameric sequences of the following: PuPuPuC(A/T)(A/T)GPyPyPy, where Pu 
denotes a purine base and Py denotes a pyrimidine (El-Deiry et al., 1992). Most cancer-
associated p53 mutations are found within this central conserved domain since such proteins 
exhibit defective sequence-specific binding, which highlights the importance of p53 
transactivation. Unusually for a transcription factor, p53 contains a second DNA binding site; 
this is located within its C-terminal region. This second binding site allows p53 to bind DNA, 
not in a sequence-specific, but rather a structure-specific manner where ssDNA, dsDNA and 
mismatched DNA are all recognised (Javaraman and Prives, 1995, Lee et al., 1995). The non-
specific DNA binding domain of p53 has been shown to positively regulate its specific DNA 
binding activities (McKinney et al., 2004). Therefore, this region undergoes many post-
translational modifications that render it able to influence the efficiency of p53 to act as a 
transcription factor.  
1.4.2 Post-translational modifications of p53 
While it has a short half life and is maintained at a low level in unstressed cells, p53 must be 
activated in response to genotoxic stress. Its stability and activation are under tight regulation, 
mediated, in part, by various post-translational modifications; indeed, both the C- and the N-
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terminal regions of p53 are subject to extensive post-translational modifications following 
DNA damage (Figure 1.8) (Kruse and Gu, 2009a).  Many of these covalent modifications can 
occur on the same residues; therefore, an element of cross-talk exists. This adds a further level 
of complexity to the regulation of p53 through post-translational modifications and ensures 
that in the absence of specific residues, other mechanisms are in place to regulate p53 
function. 
1.4.2.1 Ubiquitylation 
The regulation of its protein level (half life) through ubiquitylation is one of the key 
mechanisms whereby p53 activity is modulated. Upon genotoxic stress, the levels of p53 are 
greatly elevated and become stabilised, leading to the activation of its transcriptional activity 
(Brooks and Gu, 2006). It is vital that p53 is maintained at low basal levels to prevent 
abnormal activity. In unstressed cells, p53 protein levels are largely controlled by two 
functions of MDM2. Firstly, MDM2 binds to the N-terminal TAD of p53 and blocks the 
interaction between p53 and members of the transcriptional machinery to inhibit p53-
mediated transactivation (Chen et al., 1993, Oliner et al., 1993).  
The second function by which p53 stabilisation is regulated by MDM2 is through the latter’s 
E3 ubiquitin ligase activity that targets the C-terminal region of p53 (Haupt et al., 1997). 
Under stress-free conditions, MDM2-mediated ubiquitylation predominantly occurs within 
six C-terminal lysine (K) residues: on p53: K370, K372, K373, K381, K382 and K386 
(Figure 1.8) (Lohrum et al., 2001). However, a study by Feng et al. in 2005 showed that the 
mutation of these lysine residues did not affect p53 stabilisation. This indicates that additional  
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Figure 1.8 p53 domains and post-translational modifications 
The main domains of the tumour suppressor protein, p53, comprise the transactivation domain 
(TAD), the DNA binding domain (DBD), the tetramerisation domain (TET) and the C-
terminal domain. Many sites within these domains are modified by different enzymes. Major 
phosphorylation, acetylation and ubiquitylation sites are shown. In addition, sites for 
methylation, neddylation and sumoylation are depicted (adapted from Kruse and Gu, 2009a). 
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lysines within p53 may be targeted by MDM2 or that other E3 ligases exist for p53 (Feng et 
al., 2005). The discovery of E3 ubiquitin ligases such as ARF-BP1, COP1 and Pirh2 lends 
support to this idea and indicates that p53 stability can be regulated in an MDM2-independent 
manner (Chen et al., 2005, Dornan et al., 2004, Leng et al., 2003). 
There is evidence to suggest that the MDM2-mediated mono-ubiquitylation of p53 promotes 
its nuclear export compared to poly-ubiquitylation, which leads to its degradation (Li et al., 
2003). While the former leads to the inhibition of p53 transcriptional activity, the 
accumulation of cytoplasmic p53 may actually benefit transcriptionally-independent functions 
of p53, including the induction of apoptosis and the inhibition of autophagy. In addition, other 
E3 ligases have been shown to drive the cytoplasmic localisation of p53, including MSL2, 
which ubiquitylates p53 at lysine residues, K351 and K357 (Kruse and Gu, 2009b). 
The control of MDM2 expression itself is critical to control p53 stability and this process 
involves numerous proteins. MDM2 is regulated by p53 itself and both proteins function in an 
autoregulatory feedback loop; therefore, whilst p53 positively regulates MDM2 gene 
expression, functional MDM2 protein negatively regulates p53 stability (Wu et al., 1993). 
One positive regulator of MDM2 is MDMX (also known as MDM4), which exists in a 
complex with MDM2 to form a dimer. MDMX does not possess E3 ligase activity itself but 
appears to promote that of MDM2 and, therefore, negatively regulates p53 stability (Okamoto 
et al., 2009). 
 Interestingly, another member of the MDM family of proteins actually functions positively 
towards p53. In addition to the full length MDM2 protein (p90
MDM2
), the MDM2 gene also 
codes for a smaller protein, p76
 MDM2 
, which has been shown not only to inhibit the 
interaction between MDM2 and MDMX, but also to ubiquitylate MDMX and target it for 
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proteasomal degradation (Giglio et al., 2010). Another regulator of MDM2 is p14ARF, a 
tumour suppressor whose levels are increased during genotoxic stress. p14ARF is able to bind 
to MDM2 and disrupts the interaction between p53 and MDM2, resulting in the stabilisation 
of p53 upon DNA damage (Sherr, 2006). 
It is clear that the ubiquitylation of p53 plays a major role in determining its stability. The 
process of deubiquitylation has also been shown to regulate the stabilisation of p53, which is 
mediated by deubiquitylases (DUBs). The ubiquitin-specific protease, HAUSP (also known as 
USP7), was first shown to stabilise p53 by directly deubiquitylating it. However, it was later 
found to directly target MDM2 rather than p53 for  deubiquitylation  (Li et al., 2004, Li et al., 
2002a). Brooks et al. (2007) proposed that the preferred substrate for HAUSP in unstressed 
cells is MDM2, whereas under conditions of DNA damage, the binding of HAUSP to MDM2 
is reduced to favour p53 stabilisation (Brooks et al., 2007). Another DUB that regulates p53 
stability is USP10, which was found to deubiquitylate p53 in the nucleus after genotoxic 
stress (Yuan et al., 2010). 
1.4.2.2 Phosphorylation 
A number of stress-activated kinases mediate the phosphorylation of p53 on key residues 
(Figure 1.8). The main sites that undergo phosphorylation reside in the N-terminal of p53 and 
include serine residues (S6, S9, S15, S20, S33, S36, S37 and S46) as well as threonine 
residues (T18, T55 and T81) (Kruse and Gu, 2009a). Those kinases primarily involved in N-
terminal phosphorylation include ATM, ATR and DNA-PK, which phosphorylate S15 of p53 
(Banin et al., 1998, Canman et al., 1998, Lees-Miller et al., 1992, Tibbetts et al., 1999). The 
downstream kinases, Chk1 and Chk2, also target N-terminal serine residues, namely S20 
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(Shieh et al., 2000). The phosphorylation of N-terminal residues of p53 disrupts the p53-
MDM2 interaction and, therefore, allows p53 to associate with its co-factors for 
transactivation of its target genes.  While the phosphorylation of S15 and S20 have been 
shown not to disrupt the binding of MDM2 to p53, the phosphorylation of T18 does reduce 
this interaction, indicating that the latter residue is important for determining the interaction 
between MDM2 and p53 (Dumaz and Meek, 1999, Schon et al., 2002). However, the 
importance of the other N-terminal residues cannot be discounted because of this. The 
phosphorylation of S15 and S20 stimulates the recruitment of p53 co-activators, p300/CBP, 
which results in the acetylation of C-terminal lysines that enhance specific DNA binding of 
p53 (Dumaz and Meek, 1999, Lavin and Guevan, 2006). In addition, S15-phosphorylation is a 
prerequisite for phosphorylation of T18 and S20 (Saito et al., 2003). This highlights the level 
of interdependency that exists among the N-terminal phosphorylation sites of p53.  
Another N-terminal serine phosphorylation site, S46, has been shown to be phosphorylated by 
a number of kinases including homeodomain interacting protein kinase 2 (HIPK2), ATM, 
dual-specificity tyrosine-phosphorylation-regulated kinase (DYRK) and protein kinase C δ 
(PKC δ) (D'Orazi et al., 2002, Kodama et al., 2010, Taira et al., 2007, Yoshida et al., 2006). 
This particular residue contributes to the selectivity of p53 activation since its 
phosphorylation by the specific kinases is linked to the up-regulation of pro-apoptotic target 
genes. 
Phosphorylation is not restricted to the N-terminal region and some serine sites in the DBD 
(S149, S150 and S155) and some in the C-terminal region (S315, S376, S378 and S392) are 
also targeted by various kinases. The C-terminal serine sites, S376 and S378, are 
constitutively phosphorylated by PKC in unstressed cells and the dephosphorylation of S376 
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after IR causes p53 to have an increased affinity for sequence-specific DNA (Waterman et al., 
1998). Therefore, it is clear that phosphorylation of C-terminal residues does not necessarily 
enhance the DNA binding ability of p53. In contrast, the phosphorylation of the other C-
terminal residue, S392, stimulates sequence-specific binding of p53, by promoting its 
tetramerisation  (Sakaguchi et al., 1997). This site is phosphorylated by casein kinase 2 (CK2) 
in response to genotoxic stress (mainly in the form of UV),  although the exact nature of this 
modification is not fully understood (Cox and Meek, 2010).  
If phosphorylation of p53 is important, the process of dephosphorylation cannot be 
overlooked. Although less is known about the dephosphorylation of p53, a few phosphatases 
have been found to target certain serine residues within p53. One of these enzymes is dual-
specificity phosphatase 26 (DUSP26), which has been shown to dephosphorylate serine 
residues S20 and S37 and to consequently inhibit p53 activity in response to DNA damage 
(Shang et al., 2010a).  Another p53 phosphatase is protein serine/threonine phosphatase-1 
(PP-1), which has been demonstrated to dephosphorylate S37, as well as S15, to negatively 
regulate pro-apoptotic p53 functions (Li et al., 2006). WT p53-induced phosphatase 1 (WIP1 
or PPM1D) controls p53 levels by dephosphorylating MDM2 at S395 and thus stabilising this 
negative regulator of p53 (Lu et al., 2007). 
1.4.2.3 Acetylation 
The acetylation of histones is a well accepted mechanism of regulating transcription but p53 
was the first non-histone protein that was shown to undergo acetylation and deacetlyation  
(Gu and Roeder, 1997). The levels of acetylated p53 increase upon damage, which is 
consistent with an increase in p53 activation in response to stress. The acetylation of p53 
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comprises an extremely important element in the regulation its activity and is mediated by a 
number of histone acetyltransferase (HAT) enzymes, the main ones being its transcriptional 
co-activators, p300/CREB-binding protein (CBP) (Gu and Roeder, 1997, Lill et al., 1997). 
p300, together with its family member, CBP, predominantly target the cluster of six C-
terminal lysine residues, K370, K372, K373, K381, K382 and K386 (Kruse and Gu, 2009a). 
Although these are the main sites of acetylation, two lysine residues in the DBD are also 
targeted, which imparts a level of redundancy to the activation of target genes since only the 
mutation of all 8 lysine sites abolishes the ability of p53 to activate the p21 promoter (Figure 
1.8) (Tang et al., 2008). The sites in the DBD include K120 and K164, which are acetylated 
by another histone acetyltransferase, Tip60/hMof, and p300/CBP respectively (Sykes et al., 
2006, Tang et al., 2006, Tang et al., 2008). Tip60/hMof-mediated acetylation of K120 is 
enhanced after genotoxic stress; mutation of this site disrupts p53-mediated pro-apoptotic 
functions but does not have a significant effect on cell cycle arrest (Sykes et al., 2006, Tang et 
al., 2006). This indicates that K120 acetylation may provide a mechanism by which p53 can 
preferentially activate a subset of its target genes. Another histone acetyltransferase, PCAF, 
also acetylates p53 following DNA damage, at a site distant to the cluster of six C-terminal 
lysines, on the lysine residue, K320, which resides in the tetramerisation domain (Figure 1.8) 
(Liu et al., 1999). Another lysine residue targeted by acetyltransferases that is distinct from 
the C-terminal lysines is K305, which is modified by p300 (Wang et al., 2003). 
The interplay between the different post-translational modifications of p53 is again evident, 
this time regarding acetylation and ubiquitylation. Acetylation in the C-terminal region of p53 
has been shown to inhibit MDM2 ubiquitylation of these residues and, therefore, increases the 
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stability of p53 (Li et al., 2002b). This is unsurprising considering the C-terminal lysines can 
be targeted by both acetyltransferases and E3 ubiquitin ligases. 
Like many post-translational modifications, acetylation is reversible. Consequently, up-
regulation of activated p53 can be reversed by deacetylation, which is catalysed by histone 
deacetylases (HDACs) (Luo et al., 2001, Luo et al., 2000, Vaziri et al., 2001). 
1.4.2.4 Methylation 
p53 is one of the few transcription factors that is regulated by protein methylation and 
demethylation. Lysine methyltransferases target certain C-terminal lysine residues of p53 and 
there exists an element of crosstalk between methylation of these residues and other post-
translational modifications of p53 (Figure 1.8). The transfer of a methyl group onto lysine 
residue, K372 by the lysine methyltransferase, Set7/9, was shown to positively regulate p53 
stability and to promote its activity (Chuikov et al., 2004). The relevance of Set7/9-mediated 
methylation is underscored by the fact that it is required for p53 acetylation and that Set7/9 is 
involved in p53-mediated G2/M arrest following DNA damage (Ivanov et al., 2007). In 
contrast, the methylation of K370 by Smyd2 lysine methyltransferase represses p53 activity 
and, interestingly, methylation at this site is inhibited by Set7/9-mediated methylation of 
K372 (Huang et al., 2006). The third lysine methyltransferase, Set8, catalyses the mono-
methylation of the K382 residue; this enzyme acts in a similar manner to Smyd2 and 
represses p53-mediated transactivation (Shi et al., 2007). Interestingly, the depletion of Set8 
leads to an increase in p53 pro-apoptotic and checkpoint functions, which is consistent with 
the observation that methylation at K382 prevents p53 binding to promoters of the PUMA and 
p21 genes respectively (Shi et al., 2007). 
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The lysine residue, K370, is also subject to di-methylation although the enzyme that mediates 
this is, as yet, unknown (Huang et al., 2006). Lysine methylation is also subject to its 
reversible process, demethylation, which, in p53, is catalysed by the demethylase, LSD1; 
however, LSD1 only demethylates K370 if it has been di-methylated (Huang et al., 2006). 
Arginine methyltransferases also play a role in the regulation of p53; this is achieved by the 
activity of protein arginine methyltransferase 5 (PRMT5) (Jansson et al., 2008). The majority 
of arginine residues in p53 reside within its DBD. Indeed, common ‘contact site’ hotspot 
mutations (i.e. those that affect the interaction between p53 and DNA) include arginine 
residues, R248 and R278 in the central DBD of p53 (Harms and Chen, 2006). 
1.4.2.5 Sumoylation and Neddylation 
The C-terminal sites of p53 are also subject to other post-translational modifications such as 
sumoylation and neddylation. The sumoylation of p53 occurs at the C-terminal lysine residue, 
K386 (Figure 1.8) (Wu and Chiang, 2009). Less than 5% of p53 is sumoylated in vivo and as 
such, it is difficult to assess the relevance of SUMO-conjugated p53 (Melchior and Hengst, 
2002). Indeed, there have been conflicting reports on the effect that sumoylation has on p53 
activity. While some results show that the sumoylation of p53 enhances its transcriptional 
activity, others report that this modification by SUMO-1 inhibits p53 function (Rodriguez et 
al., 1999, Wu and Chiang, 2009).  
The mechanism of neddylation of p53 is also unclear. Both FBXO11 and MDM2 have been 
shown to mediate the conjugation of Nedd8 to p53 on C-terminal lysine residues, K320/K321  
and K370/K372 respectively (Figure 1.8) (Abida et al., 2007, Xirodimas et al., 2004). 
Interestingly, modification by both proteins inhibits the transcriptional activity of p53. 
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1.4.3 Co-factors of p53 
A number of co-factors, comprising co-activators and co-repressors, are known to influence 
p53 activity without post-translationally modifying it and some of these co-factors play a role 
in the promoter-specific activity of p53 (Figure 1.9, Table 1.1). The main co-factors of p53 
have already been mentioned: MDM2, MDMX and p300/CBP. These all bind directly to p53 
to influence its stability and transcriptional activity. Conversely, indirect co-factors, such as 
stress-responsive activator of p300 (Strap), can act by affecting the recruitment of other p53 
co-factors (Demonacos et al., 2001). Interestingly, a number of p53 co-activators are 
themselves tumour suppressors since their loss can increase the onset of tumourigenesis. 
Conversely, co-repressors could be classed as oncogenes because they inhibit the tumour 
suppressive function of p53. 
1.4.3.1 Co-factors that affect cell cycle arrest gene expression 
Recently, a loss-of-function screen identified bromodomain-containing 7 (BRD7) as a p53-
interacting protein that is required for the transcriptional activation of a subset of cell cycle 
genes, including p21, but not pro-apoptotic genes (Drost et al., 2010). BRD7 is an example of 
a co-factor that can also indirectly influence p53 since BRD7 is able to interact with p300 and 
enhance p300-mediated acetylation of p53 as well as that of the histones surrounding specific 
target promoters (Drost et al., 2010). This correlates with the fact that p300-mediated 
acetylation is crucial for the activation of p21. 
Another indirect p53 co-factor, Strap, facilitates the recruitment of the p53 co-activator p300 
to enhance p53 activation and also indirectly inhibits MDM2-mediated degradation of p53 
(Demonacos et al., 2001). 
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BRCA1 is also a p53 co-factor and is itself a tumour suppressor. By interacting directly with 
the C-terminus of p53 it drives p53-mediated transcription (Ouchi et al., 1998, Zhang et al., 
1998). BRCA1 is another co-factor that promotes the selective expression of cell cycle arrest 
genes over pro-apoptotic genes (MacLachlan et al., 2002). In addition, BRCA1, in 
conjunction with its binding partner BARD1, is thought to act as an adaptor for p53 to enable 
ATM/ATR-mediated phosphorylation of serine residue S15 of p53 (Fabbro et al., 2004). The  
phosphorylation of this residue of p53 is known to be required for the recruitment of the 
tumour suppressor’s acetyltransferases (Dumaz and Meek, 1999). 
The haematopoietic zinc finger protein, Hzf, is a p53-responsive gene and selectively 
promotes the p53-dependent expression of cell cycle arrest genes (Das et al., 2007). Similarly, 
the membrane glycoprotein, MUC1, is also able to associate with p53 and act as a co-
activator to induce its transcription of the p21 gene (Figure 1.9, Table 1.1) (Wei et al., 2005). 
1.4.3.2 Co-factors that affect apoptotic gene expression 
The apoptosis-stimulating proteins of p53 (ASPP) family are ankyrin-repeat-SH3-domain and 
proline-rich-region-containing proteins and are important co-factors that regulate p53 activity, 
specifically its apoptotic functions (Samuels-Lev et al., 2001). This family includes two pro-
apoptotic co-factors, ASPP1 and ASPP2, and an anti-apoptotic co-factor, iASPP. The latter 
functions as a p53 co-repressor and interacts with the PRD and DBD of p53 to prevent it from 
binding to pro-apoptotic promoters (Bergamaschi et al., 2003).  In contrast, 
Chapter 1 
51 
 
 
 
 
 
 
 
 
 
Figure 1.9 p53 co-factors exert selective influences on p53 responses 
Co-factors can influence p53’s ability to activate or repress its target genes in a non-covalent 
manner. Some co-factors can bind directly to p53 to promote different p53-dependent cellular 
responses. These direct co-factors interact with the p53 DBD or C-terminal domain as shown. 
Indirect co-factors that facilitate either p53-dependent cell cycle arrest or apoptosis are also 
shown. Co-activators are depicted in red, whereas co-repressors are depicted in red (adapted 
from Vousden and Prives, 2009). 
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ASPP1 and ASPP2 selectively promote p53 binding to pro-apoptotic promoter regions by 
mediating the dissociation of iASPP (Samuels-Lev et al., 2001). However, there are 
conflicting reports regarding the function of cytoplasmic ASPP1 since it has also been shown 
to inhibit apoptosis, thus highlighting an oncogenic role of cytoplasmic ASPP1 compared to 
the tumour suppressive properties of nuclear ASPP1 (Vigneron et al., 2010). Recently 
however, new findings have suggested additional roles of cytoplasmic ASPP1 in which it 
increases the activity of YES-associated protein (YAP) to indirectly inhibit the ability of p53 
to stimulate expression of p21 (Vigneron and Vousden, 2011).  This indicates that the 
subcellular localisation of these proteins is also important for their function.  
The ATM and p53-associated KRAB-type zinc-finger (KZNF) protein, APAK, was identified 
as a co-repressor of p53 whereby it binds to p53 in unstressed cells and regulates the 
modification of p53 to enable selective repression of pro-apoptotic genes (Tian et al., 2009).  
Recently, additional mechanisms of APAK have come to light where it has been shown that it 
selectively binds to the intron of the p53 pro-apoptotic target, p53AIP1, which also happens to 
overlap the p53 binding site within this gene (Yuan et al., 2012). Therefore, by blocking p53 
binding to the p53AIP1 gene, APAK prevents p53AIP1 transcription and inhibits p53-
mediated apoptosis. 
Another co-factor that can determine a different cellular outcome through promoter-selective 
transactivation of p53 is human cellular apoptosis susceptibility protein (hCAS). The down-
regulation of hCAS results in the significant reduction of p53 induction of pro-apoptotic 
genes such as PIG3 and p53AIP1, whereas little effect was observed for p21 (Tanaka et al., 
2007). This implicates hCAS as being able to predispose p53 toward its apoptotic function 
rather than mediating its cell cycle arrest effects. 
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The p38 mitogen-activated protein kinase (MAPK) family constitute an important signalling 
pathway in response to cellular stress and can interact with a number of proteins. One of these 
interacting proteins, p18
Hamlet
 was found to bind to p53 upon DNA damage and activate the 
p53 pro-apoptotic genes, NOXA and PUMA (Figure 1.9, Table 1.1) (Cuadrado et al., 2007). 
1.4.3.3 Other p53 co-factors 
Brn3A is an unusual p53 co-factor in that it acts to stimulate and repress p53-mediated 
responses. It has been shown that Brn3A represses the apoptotic function of p53 by inhibiting 
its ability to activate pro-apoptotic promoters of genes such as Bax and NOXA (Table 1.1) 
(Budhram-Mahadeo et al., 2002, Hudson et al., 2005). Conversely, co-expression of p53 and 
Brn3A has a stimulatory effect on the p21 promoter, thus indicating that Brn3A can activate 
the cell cycle effects of p53 (Budhram-Mahadeo et al., 2002). Therefore, it seems that Brn3A 
can co-operate with p53 to determine the fate of those cells that co-express both proteins.  
The Brn3B transcription factor, although related to Brn3A, displays strikingly different 
cellular properties. While Brn3A antagonises Bax expression and positively regulates p21 
expression, Brn3B interacts with p53 and stimulates the expression of Bax but not p21, 
therefore functioning in the opposite manner to Brn3A (Budhram-Mahadeo et al., 2006). 
Ribosomal proteins also play a role in regulating p53, mainly by functioning in the MDM2-
p53 feedback loop. The ribosomal proteins L5, L23 and L11 have all been found to inhibit 
MDM2 and prevent its ubiquitylation of p53 (Dai and Lu, 2004, Jin et al., 2004, Lohrum et 
al., 2003).These proteins are therefore co-activators of p53. 
In addition, a member of the heterogeneous nuclear ribonucleoprotein (hnRNP) family has 
been shown to function as a p53 transcriptional co-activator. Heterogeneous nuclear 
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ribonucleoprotein K (hnRNPK) was found to interact with p53 before and after DNA damage 
and is recruited along with p53 to p53-responsive promoters of p21 and MDM2 (Moumen et 
al., 2005). Since the effect of hnRNPK on apoptotic genes has not been investigated, it is 
unclear whether this co-activator functions to confer specificity to the p53 response to 
genotoxic stress. 
Through over-expression studies, Barral et al. (2005) revealed that increasing exogenous 
levels of another hnRNP member, hnRNPUL-1, results in the repression of p53-dependent 
transcriptional activity although the exact mechanism by which this occurs remains unknown 
(Barral et al., 2005). 
1.4.4 Additional factors that promote specific activation of target genes 
The responses that are elicited upon p53 activation can be divided into those that result in the 
survival of the cell through the inhibition of its proliferation and subsequent repair of damage, 
and those that lead to cell death. These outcomes contribute to the role of p53 as a tumour 
suppressor since the onset of oncogenicity would be halted as a result of both responses.  
There are numerous mechanisms that exist to promote the specific transactivation of certain 
p53-regulated genes, many of which have already been discussed. The abundance of p53, as 
well as its various post-translational modifications and the plethora of co-factors, determine 
whether a given p53-dependent promoter is activated or repressed. 
 An additional factor that contributes to the specificity of the p53 response is the core 
promoter structure of actual p53 target genes. Target promoters display structural differences 
such that higher levels of elements of the basal transcriptional machinery are found at 
promoters of cell cycle arrest genes such as p21 compared to those promoters belonging to 
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apoptotic targets (Espinosa et al., 2003). This is further supported by the observation that 
there is a rapid formation of pre-initiation complexes (PIC) at the p21 promoter, which is 
critical for gene activation; however, re-initiation is intrinsically inefficient at this particular 
promoter (Morachis et al., 2010). In contrast, the Fas promoter undergoes slow PIC formation 
but once trancriptionally engaged, becomes very efficient at re-initation (Morachis et al., 
2010). This phenomenon is consistent with the observations that cell cycle arrest genes are 
activated more rapidly than apoptotic genes and confirms that timing of the regulation of p53 
is critical during the course of the stress response. The latter fact also lends support to the 
concept that promoters of cell cycle arrest genes contain high-affinity sites for p53 compared 
to the promoters of apoptotic genes, which contain lower-affinity binding sites (Chen et al., 
1996).  However, this is not always the case since p53 can bind to the promoter of PUMA 
with a similar binding affinity to that of p21 and MDM2 (Vousden and Lu, 2002). 
1.4.5 Functions of p53 
p53 functions to efficiently mediate cell cycle arrest and to promote apoptotic cell death or 
senescence. The ability of p53 to act as a transcription factor allows it to bind to specific 
regions in the promoters of p53-responsive genes to mediate the response to genotoxic stress. 
Principal p53-responsive genes include those involved in inhibiting cell cycle progression and 
also a subset of apoptotic genes (Table 1.1). These properties define it as a tumour suppressor. 
1.4.5.1 Cell cycle arrest 
Cell cycle progression is regulated by the cell cycle checkpoints at G1, S and G2/M, which 
become activated upon DNA damage as described in 1.2.4. The activation of p53-induced cell 
cycle checkpoints after genotoxic stress preferentially promotes cell survival rather than cell 
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death; therefore many genes that become activated to co-ordinate cell cycle arrest also 
function to inhibit apoptosis (Table 1.1) (Vousden and Prives, 2009). 
The primary regulator of p53-mediated G1 arrest in response to DNA damage is p21
WAF1/CIP1
, 
a CKI and a p53 target gene (El-Deiry et al., 1993). p21 primarily inhibits the kinase activity 
of CDK2 and CDK4, thus disrupting the CDK2/cyclin E and CDK4/cyclin D1 complexes, 
respectively (Sherr and Roberts, 1995). This inhibits both Rb phosphorylation and the 
consequent activation of E2F, which would otherwise mediate the expression of proliferative 
genes required for progression through G1 (Delavaine and La Thangue, 1999, Dimri et al., 
1996). In addition, p21 possesses anti-apoptotic effects, which allows the cell to repair or 
remove any damage without the death of the cell (Dotto, 2000). However, this additional 
function of  p21 may also be viewed as oncogenic rather than tumour suppressive if tumour 
cells are allowed to resume proliferation rather than being eliminated (Roninson, 2002). 
Although there are reports that a p53 isoform, Δp53, is involved in the transactivation of p21 
during the ATR-mediated intra-S checkpoint, there appears to be no role for full length p53 
(Rohaly et al., 2005). During this phase of the cell cycle, however, p53 primarily mediates 
DNA repair, which is vital to protect the integrity of the genome at a stage when the cell is 
particularly vulnerable (Helton and Chen, 2007). 
The product of the 14-3-3σ gene, which is induced by p53 following cellular stress, sequesters 
CDK1/cyclin B1 complexes away from their substrates in the nucleus into the cytoplasm 
(Hermeking and Benzinger, 2006). Since the inhibition of the progression of cells through G2 
is dependent on the disruption of the CDK1/cyclin B1 complex, 14-3-3σ is involved in p53-
mediated cell cycle arrest in G2 and is transactivated by p53 in response to DNA damage 
(Hermeking et al., 1997). Another gene that is involved in controlling p53-mediated G2/M 
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arrest is GADD45, which is induced by p53 after exposure to IR (Kastan et al., 1992). In a 
manner similar to 14-3-3σ, GADD45 has also been shown to negatively regulate the levels of 
nuclear cyclin B1, therefore inhibiting cellular progression through the G2 phase of the cycle 
(Jin et al., 2002). 
1.4.5.2 Apoptosis 
Programmed cell death, or apoptosis, is an essential process for multi-cellular organisms and 
must be stringently regulated. Apoptosis is activated in response to a variety of signals 
through two major pathways; the extrinsic pathway and the intrinsic pathway. p53 participates 
in both of these pathways in response to high levels of DNA damage that cannot be repaired. 
Therefore, the extent of DNA damage affects the p53 response and the subsequent activation 
of apoptotic genes (Table 1.1). Interestingly, it is not only the transcriptional function of p53 
that plays a role in promoting apoptosis; it may also mediate this process in a direct manner 
(Mihara et al., 2003). 
1.4.5.2.1 Role of p53 in the extrinsic apoptotic pathway 
The extrinsic pathway or death receptor pathway is so named because it is stimulated by 
binding of death ligands to cell surface death receptors (Jin and El-Deiry, 2005). This causes 
receptor oligomerisation and the consequent recruitment of the adaptor molecule, Fas-
associated death domain (FADD), which when bound to the death domain of the activated 
receptor, forms the death-inducing signalling complex (DISC). Procaspase 8 is sequestered to 
the DISC where, upon its autocatalytic activation, caspase 8 is released, resulting in the 
processing of downstream effector caspases, caspase 3, 6 and 7. These effector caspases 
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DNA damage Function Genes Co-activators Co-repressors 
 
Cell cycle arrest 
 
p21 
14-3-3σ 
GADD45 
p300/CBP 
BRD7 
Hzf 
Brn3A 
MUC1 
Strap 
hnRNPK 
ZBTB2 
DNA repair 
XPC 
MSH2 
MLH1 
PCNA 
PMS2 
  
Apoptosis 
 
Bax 
PUMA 
NOXA 
Fas/APO-1 
DR4/5 
 
 
ASPP1/2 
hCAS 
Brn3B 
P18
hamlet
 
Brn3A 
iASPP 
APAK 
 
Table 1.1 p53-activated genes and p53 co-factors 
At low levels of DNA damage, p53 promotes cell survival by activating cell cycle arrest and 
DNA repair. At high levels of damage, p53 promotes apoptosis (adapted from Helton and 
Chen, 2007). 
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cleave specific substrates to induce cell death. The extrinsic apoptotic pathway can be 
promoted in a p53-dependent manner since p53 has been found to transactivate genes that 
code for some of the death receptors. These include death receptor 4 (DR4) and death receptor 
5 (DR5 or KILLER) (Liu et al., 2004, Takimoto and El-Deiry, 2000). p53 also upregulates the 
expression of the Fas death receptor and, interestingly, also increases the expression of its 
death ligand, Fas ligand/APO-1 (Owen-Schaub et al., 1995). 
1.4.5.2.2 Role of p53 in the intrinsic apoptotic pathway 
The intrinsic apoptotic pathway is also known as the mitochondrial pathway and can be 
activated by intracellular stresses, such as growth factor withdrawal, direct DNA damage and 
hypoxia. In response to these stress signals, pro-apoptotic Bcl-2 family members disrupt the 
mitochondrial membrane, resulting in the release of apoptogenic factors such as cytochrome 
c. The latter, together with apoptosis protease-activating factor 1 (Apaf-1) and procaspase 9, 
form the apoptosome. This is an intracellular multi-protein DISC-like complex and its 
formation leads to the activation of caspase 9, which consequently cleaves and activates the 
effector caspase, caspase 3.  
p53 also induces the expression of the BH3-only Bcl-2 family members  and therefore 
activates the intrinsic apoptotic pathway in a transcription-dependent manner. The BH3-only 
Bcl-2 family members promote apoptosis by binding to and displacing pro-apoptotic Bcl-2-
like proteins such as Bax and Bak from inhibitory complexes with pro-survival proteins like 
Bcl-2 and Bcl-xL (Jin and El-Deiry, 2005). One such pro-apoptotic BH3-only protein is p53 
upregulated modulator of apoptosis or Bcl-2 binding component 3 (PUMA or bbc3) and is a 
direct transcriptional target of p53(Nakano and Vousden, 2001). Similarly, NOXA encodes 
another BH3-only pro-apoptotic protein and is also a p53 target gene (Oda et al., 2000). Upon 
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their activation, these BH3-only proteins allow the other pro-apoptotic Bcl-2 family members 
to permeabilise the outer mitochondrial membrane and to trigger the onset of the caspase 
cascade, leading to mitochondrial apoptosis.  
p53 also  functions in a transcriptional-independent manner in the mitochondrial apoptotic 
pathway. It is known that a significant amount of p53 is translocated to the mitochondria upon 
DNA damage where it can initiate apoptosis without the transactivation of pro-apoptotic 
target genes (Mihara et al., 2003). It has been shown that regulatory factors can aid p53 
localisation to the mitochondria to trigger apoptosis independent of its role as a transcription 
factor. One such ‘chaperone’ protein is Tid1, which interacts with p53 in response to hypoxic 
stress and mediates its translocation to the mitochondria (Ahn et al., 2010). Once p53 is 
retained at the mitochondria, it is able to directly activate Bax and Bak, allowing the release 
of cytochrome c (Chipuk et al., 2004, Leu et al., 2004). In addition, p53 is able to directly 
interact with pro-survival proteins, Bcl-2 and Bcl-xL, which leads to the release of pro-
apoptotic proteins (Mihara et al., 2003). 
1.4.5.3 DNA repair 
The onset of DNA repair is critical for the completion of the cell cycle; therefore, p53 plays a 
vital role in modulating DNA repair processes in response to a plethora of genotoxic insults. 
Many p53 target genes participate in DNA repair pathways but p53 is also directly involved 
in these processes via transcriptionally-independent mechanisms. 
The NER gene, XPC, is expressed following p53 activation after DNA damage, indicating a 
transcriptional role for p53 in the regulation of NER (Adimoolam and Ford, 2002). However, 
there are also reports that p53 can regulate NER via protein-protein interactions such as direct 
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binding to the helicases, XPB and XPD (Wang et al., 1995). Therefore, p53 has both a 
transcriptional and a direct impact on the process of NER. 
Another example of the direct involvement of p53 in repair processes can be seen in its ability 
to interact with AP endonuclease and Pol β, both of which are vital to BER pathway (Zhou et 
al., 2001). Several components of the MMR pathway are p53-regulated genes, including the 
crucial MSH2 gene, which forms the core of two complexes involved in the recognition of 
mismatches (Warnick et al., 2001). In addition, MLH1 and PMS2 have also been shown to be 
upregulated by p53 transactivation (Chen and Sadowski, 2005). 
In addition to its role in replication, the processivity factor, PCNA, participates in many repair 
processes. p53 binds to the promoter of PCNA and modulates its expression; interestingly, 
this depends on the concentration of p53 and occurs in a damage-dependent manner (Table 
1.1) (Morris et al., 1996, Xu and Morris, 1999). 
1.5 HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN U-LIKE-1 
1.5.1 The heterogeneous nuclear ribonucleoprotein family 
In eukaryotes, precursor mRNA transcripts produced by RNA polymerase II are called pre-
mRNAs or  heterogeneous nuclear RNAs (hnRNAs) (Dreyfuss et al., 1988a). The proteins 
that bind these primary transcripts are known as the heterogeneous nuclear ribonucleoproteins 
(hnRNPs) and remain associated with this mRNA through the entire process of eukaryotic 
gene expression. The family of hnRNPs were first identified in a complex of RNA-binding 
proteins (Choi and Dreyfuss, 1984). To date, at least 20 major hnRNPs have been identified in 
humans (designated hnRNPA to hnRNPU) and it is interesting that most of these appear to be 
highly conserved among vertebrates (Dreyfuss et al., 1993). Many of these proteins are 
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involved in processes such as pre-mRNA processing, nucleocytoplasmic mRNA transport and 
mRNA localisation, translation and stability (Dreyfuss et al., 2002). Notably, there are many 
isoforms of these major proteins and less abundant hnRNPs exist as well (Dreyfuss et al., 
2002). 
Most, if not all, hnRNP proteins are able to bind to RNA and, therefore, possess an RNA 
binding motif (Dreyfuss et al., 1993). The most common motif of this kind in the hnRNP 
family is the RNP consensus RNA-binding domain (RNA motif) (Dreyfuss et al., 1988b).  
This domain is approximately 90 amino acids in length and consists of two consensus 
sequences that are located 30 amino acids apart: RNP1 and RNP2 (Dreyfuss et al., 1988b). 
RNP1 is a highly conserved octapeptide sequence consisting of the following: Lys/Arg-Gly-
Phe/Tyr-Gly/Ala-Phe-Val-X-Phe/Tyr; whereas the hexapeptide, RNP2 is less conserved and 
is rich in aromatic and aliphatic amino acids (Adam et al., 1986, Dreyfuss et al., 1988b). 
1.5.1.1 hnRNPs and DNA damage 
It has been reported that a number of hnRNP proteins are implicated in mediating DNA 
repair, and are, consequently involved in the DDR. The hnRNP family member, hnRNPB1, 
interacts with DNA-PK and inhibits its activity in vitro, implying that this member of the 
hnRNP family is a negative regulator of NHEJ in DNA repair (Iwanaga et al., 2005). There is  
also evidence that hnRNPC1/C2 is implicated in DNA repair since both bind to chromatin in 
a DNA damage-dependent manner and both isoforms are phosphorylated by DNA-PK in an 
RNA-dependent manner (Lee et al., 2005, Zhang et al., 2004). Similarly, hnRNPU/SAF-A, is 
phosphorylated by DNA-PK in response to DNA damaging agents that cause DSBs, and is 
implicated as a marker of DNA-PK activity (Berglund and Clarke, 2009). 
Chapter 1 
63 
 
Interestingly, hnRNPA18 levels are induced upon exposure to UV, which is unusual since 
most hnRNPs are constitutively expressed (Yang and Carrier, 2001). Another isoform of 
hnRNPA, hnRNPA1, plays a role in the stress response to oxidative damage, osmotic or heat 
shock. It localises to the cytoplasm following these extracellular stresses whereupon it 
mediates the recruitment of translationally-arrested mRNA to stress granules (SGs) (Guil et 
al., 2006). 
1.5.1.2 hnRNPs and transcriptional regulation  
Previous work has implicated other members of the hnRNP family in the regulation of 
transcription, which is unsurprising considering that many proteins belonging to the hnRNP 
family are able to bind ssDNA (Dreyfuss et al., 1993). hnRNPU has been found to inhibit the 
basal transcription machinery by hindering the phosphorylation of RNA Polymerase II, thus 
inhibiting the process of transcriptional elongation (Kim and Nikoderm, 1999). There are also 
studies that implicate hnRNPU in the repression of glucocorticoid receptor (GR)-driven 
transcription (Eggert et al., 2001, Eggert et al., 1997). Both hnRNPU and hnRNPD have been 
found to interact with the transcriptional co-activator, p300, implicating these proteins in the 
regulation of transcription (Martens et al., 2002, Tolnay et al., 2002). hnRNPU also binds to 
the promoter of Oct4, a transcription factor whose activation is required for the formation of 
the inner cell mass (ICM) where embryonic stem cells originate from (Vizlin-Hodzic et al., 
2011). Another transcription factor, WT1, directly associates with hnRNPU; its 
transcriptional activity is reduced upon this interaction (Spraggon et al., 2007). Furthermore, 
hnRNPU constitutively binds to IKKβ, which is a component of the IκB kinase (IKK) 
complex that phosphorylates IκB to allow the activation of the transcription factor, NF-κB 
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(Tsuchiya et al., 2010).  In addition, another hnRNP family member, hnRNPK, serves as a 
transcriptional co-activator for p53 (Moumen et al., 2005). In addition to its role in the 
cellular response to stress, hnRNPA1 is implicated in transcription through its interaction with 
IκBα, an inhibitor of NF-κB; this is required for the activation of NF-κB (Hay et al., 2001). 
1.5.2 Heterogeneous nuclear ribonucleoprotein U-like-1 
A novel member of the hnRNP family was first identified as adenovirus 5 (Ad5) E1B-55K-
associated protein 5 (E1B-AP5 or AP5) (Gabler et al., 1998). Because of its striking sequence 
homology to hnRNPU/scaffold attachment factor A (SAF-A), this protein was also known as 
heterogeneous nuclear ribonucleoprotein U-like-1 (hnRNPUL-1) (Gabler et al., 1998). For the 
purpose of this study this protein will be referred to as hnRNPUL-1.  
1.5.2.1 Structure of hnRNPUL-1 
The predicted molecular mass of hnRNPUL-1 is 95,805 Da, although it migrates at a 
molecular weight of 120 k under SDS-PAGE, which may be due to post-translational 
modifications or to structural idiosyncrasies such as the polyproline region (Gabler et al., 
1998). In total, hnRNPUL-1 consists of 856 amino acids and possesses several domains, most 
of which are shared with hnRNPU/SAF-A but not all (Figure 1.10) (Gabler et al., 1998). The 
N-terminal region of hnRNPUL-1 contains a scaffold attachment factor (SAF) box, which is 
present in many proteins involved in mRNA metabolism. hnRNPU/SAF-A was found to have 
a high binding specificity for specialised AT-rich regions of DNA called scaffold attachment 
regions (SAR) (Fackelmayer et al., 1994). Later, the SAF-box was shown to be the domain 
responsible for binding to these regions (Kipp et al., 2000). This interaction is critical for 
nuclear architecture since it allows chromatin to be organised into discrete structures. The 
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SAF-box of hnRNPUL-1 is considered to be the region that allows this protein to bind to 
dsDNA. Notably, the SAF domain is found in several proteins that are involved in the DDR: 
it is also known as SAF-A/B, Acinus and PIAS (SAP) regions since these proteins were found 
to contain a similar domain (Aravind and Koonin, 2000). Another DNA damage protein that 
contains a SAF-box is PARP1, which is unsurprising considering it is an abundant nuclear 
protein that is involved in the regulation of chromatin structure and in transcription (Aravind 
and Koonin, 2000). The SAF-box has also been found in the C-terminal regions of Ku70 and 
in Rad18, which allows the latter protein to bind to DNA and leads to its consequent 
recruitment to stalled replication forks (Aravind and Koonin, 2000, Tsuji et al., 2008). SAR 
DNA has been found to reside near enhancer elements, which may implicate proteins that 
bind to SAR in the regulation of gene expression (Gasser and Laemmli, 1986). 
Another domain present in hnRNPUL-1 is the spore lysis A/ryanodine receptor (SPRY) 
domain. The SPRY domain is responsible for the recognition of a specific protein partner 
rather than a consensus sequence motif (Woo et al., 2006). The central region of hnRNPUL-1 
comprises a predicted kinase domain, clusters of orthologous groups of proteins 4639 
(COG4639). This central region was found to contain sequence homology to a guanine 
nucleotide-binding motif, suggesting that it possesses a potential GTP/ATP binding site 
(Gabler et al., 1998). Interestingly, this domain also corresponds to the kinase domain of 
PNK, imparting sequence homology between hnRNPUL-1 and this enzyme (Bernstein et al., 
2005, Wang and Shuman, 2001). Whether hnRNPUL-1 actually has DNA kinase activity is a 
very interesting and unanswered question that will have to await further investigation. It has 
also been demonstrated that the central region of hnRNPUL-1 contains a BRD7 binding site 
(BBS) (Kzhyshkowska et al., 2003). 
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 Like many members of the hnRNP family, hnRNPUL-1 contains an RNA binding domain. 
Unlike the common RNA motif that exists in numerous hnRNPs, the RNA-binding domain of 
hnRNPUL-1 resides in an arginine/glycine-rich region termed the RGG box and this is the 
same domain that is used by hnRNPU to bind RNA (Kiledjian and Dreyfuss, 1992). 
Interestingly, hnRNPUL-1 has been found to be methylated within this RGG box by the 
arginine methyltransferase, PRMT2 (Kzhyshkowska et al., 2001). hnRNPUL-1 also possesses 
a polyproline (PP) region, which is widely believed to mediate protein-protein interactions 
and is also characteristic of many other RNA-binding proteins.  
The hnRNPUL-1-related protein, hnRNPUL-2 (also known as scaffold attachment factor A2, 
SAF-A2), is structurally and functionally similar to hnRNPUL-1 (Polo et al., 2012). Like 
hnRNPUL-1, hnRNPUL-2 contains a SAF domain, a SPRY domain, a putative kinase domain 
and an RGG box. However, it lacks a PP region and is smaller than hnRNPUL-1, consisting 
of 747 amino acids. Its functional similarity to hnRNPUL-1 will be discussed in 1.5.2.2. 
1.5.2.2 The role of hnRNPUL-1 in DNA damage 
The functions of hnRNPUL-1 are not limited to mRNA metabolism; this is, perhaps, to be 
expected since many studies that have shown that other members of the hnRNP family are 
involved in other pathways such as those that involve DDR components. It has been found 
that hnRNPUL-1 is required for the ATR-dependent phosphorylation of RPA32 during  
adenovirus infection, implicating hnRNPUL-1 in the ATR-dependent signalling pathway in 
response to DNA damage (Blackford et al., 2008). 
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Figure 1.10 Schematic representation of the structure of hnRNPUL-1 
The known domains of hnRNPUL-1 are depicted, including their function and the site of 
post-translational modification by PRMT2. Those domains that share sequence homology 
with hnRNPU/SAF-A are highlighted. 
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Both hnRNPUL-1 and hnRNPUL-2 have recently been identified as binding partners for the 
MRN complex, specifically binding to the C-terminal region of NBS1; they are recruited to 
sites of DNA damage in an MRN-dependent manner (Polo et al., 2012). The binding site on 
hnRNPUL-1 that is required for the interaction with NBS1 was mapped to its central region 
and overlaps its BBS and RGG box (Polo et al., 2012). In addition, hnRNPUL-1 and 
hnRNPUL-2 have been found to play a role in DNA-end resection and function downstream 
of the MRN complex and CtIP to mediate the recruitment of BLM helicase to sites of damage 
(Polo et al., 2012). This suggests that both hnRNPUL proteins promote HR in the repair of 
DSBs. Interestingly, it was found that although the hnRNPUL proteins were recruited to sites 
of damage, both also moved away from sites of laser-induced damage, events that rely on the 
RGG box of hnRNPUL-1 (Polo et al., 2012). It was hypothesised that this phenomenon 
allowed the hnRNPUL proteins to remove inhibitory proteins away from sites of damage 
(Polo et al., 2012). 
1.5.2.3 The role of hnRNPUL-1 in transcription 
The involvement of hnRNPUL-1 at the level of transcriptional regulation has previously been 
shown to be mediated by its interaction with BRD7 (Kzhyshkowska et al., 2003). The 
bromodomain is present in many proteins that are involved in transcriptional regulation and 
mutations in this domain contribute to the onset of carcinogenesis (Peng et al., 2006). BRD7 
itself has been implicated in the transcriptional regulation of a number of genes, including 
those involved in the important cell signalling pathways, such as those involving 
ras/MEK/ERK and Rb/E2F (Zhou et al., 2004). In addition, BRD7 has been found to interact 
with the transcription factor, BRCA1, and mediates the recruitment of this protein to specific 
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promoter regions, which is important since BRCA1 itself cannot bind to DNA directly (Harte 
et al., 2010). Notably, BRD7 can also bind to p53 and is required for the transcriptional 
activation of a subset of p53 target genes, not only via its ability to acetylate histones, but also 
through its recruitment of additional co-activators of p53 (Drost et al., 2010).  
It has been established that hnRNPUL-1 can bind directly to p53 via the C-terminal region of 
p53 and also that it has been implicated in regulating the p53-dependent transcriptional 
response (Barral et al., 2005). The over-expression of hnRNPUL-1 was reported to inhibit the 
transcriptional activity of p53, although the exact mechanism by which this occurs is 
unknown (Barral et al., 2005). 
Interestingly, upon the inhibition of transcription, hnRNPUL-1 was still recruited to sites of 
DNA damage, indicating that two pools of the protein might exist: one that is involved in 
DSB repair and the other that is involved in RNA metabolism (Polo et al., 2012). 
1.6 CHEMOTHERAPEUTIC AGENTS 
Cells are constantly exposed to environmental sources of DNA damage: for example, through 
UV irradiation from sunlight and IR from cosmic radiation and medical treatments involving 
x-rays (Ciccia and Elledge, 2010).  
The mechanisms that exist to protect the integrity of the genome are numerous and intricate; 
they are capable of sensing DNA damage and transducing the signal to activate cell cycle 
arrest and repair or, if the damage is too great, initiate cell death. Importantly, however, the 
intentional generation of DNA damage in proliferating cells is the most common mechanism 
of action of chemotherapeutic drugs and has been the basis of such treatment for decades 
(Kastan and Bartek, 2004). Therapeutically, the optimal outcome of treatment with anti-
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cancer agents is the death of cancer cells through apoptosis whilst sparing normal cells. 
Indeed, the efficiency of a chemotherapeutic agent is defined by the therapeutic index, which 
is the ratio of tumour cure:normal tissue complications. Although apoptosis is the preferred 
outcome of many cancer treatments, other cell death responses such as autophagy and mitotic 
catastrophe, have emerged as cellular responses to agents (Al-Ejeh et al., 2010).  
Tumour cells harbour inherent defects in their response to DNA damage that sometimes 
render them particularly vulnerable to DNA damaging agents. However, these same defects 
can also lead to the enhancement of particular repair pathways, which enables the survival 
and continued, or even enhanced growth of cancer cells, which already exhibit damaged 
DNA. Therefore, an alternative approach to chemotherapy is the development of drugs that 
specifically target key components that are involved in the response to DNA damage (Lord 
and Ashworth, 2012). An understanding of the response to DNA damage is becoming 
increasingly important in the development of anti-cancer agents.  
 The number of anti-cancer treatments are numerous and can be divided into several different 
categories, namely alkylating agents, topoisomerase inhibitors (including some 
anthracyclines), platinum compounds, anti-metabolites and anti-tumour antibiotics (Aziz et 
al., 2012). Particular attention will be paid here to alkylating agents and those compounds that 
inhibit the topoisomerase enzymes. However, other classes of anti-cancer agents will be 
described briefly. The mechanisms employed by alkylating agents share some similarities 
with other anti-cancer drugs such as the platinum-based compounds. In addition, various plant 
alkaloids and anthracyclines fall into the topoisomerase inhibitor category of 
chemotherapeutics. The combination of present anti-cancer drugs with those that target 
proteins of the DDR can sensitise tumour cells to DNA damage.  
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1.6.1 Alkylating agents 
Agents that attach alkyl carbon groups onto nitrogen (N) and oxygen (O) atoms of DNA bases 
are known as alkylating agents. Many alkylating agents are among the most commonly 
prescribed chemotherapeutics (Helleday et al., 2008). These drugs can be categorised in terms 
of their mechanism of action and are often used in combination therapy to enhance the killing 
of tumour cells. The structure of the covalent alkyl lesion that forms depends on the type of 
alkylating agent that reacts with the DNA. As such, the response to these agents is variable 
and complex, using different detection and repair pathways. Alkylating agents can be loosely 
classified into different subtypes, which are dependent on the following properties: whether 
the agent is monofunctional or bifunctional, whether it follows a first or second order 
nucleophilic substitution (SN1 or SN2) and the type of alkyl group that is transferred to DNA. 
Monofunctional agents target single atoms on DNA bases using their one reactive site, in 
contrast to bifunctional alkylating agents that contain two reactive sites and can therefore 
generate interstrand crosslinks by targeting different DNA bases. 
1.6.1.1 Alkylating damage to DNA 
DNA contains many nucleophilic sites in the form of its N- and O-atoms that are prone to 
attack by electrophilic alkylators (Shrivastav et al., 2010).These sites display varying degrees 
of reactivity and are differentially targeted by alkylating agents. Those atoms most prone to 
modification by alkylating agents include: N
1
 and N
3
 of adenine (where 1 and 3 depict 
nitrogen at position 1 and 3 respectively), O
6
 and N
7
 (where 6 represents oxygen at position 6) 
of guanine and N
3
 of cytosine (Figure 1.11) (Fu et al., 2012). Minor lesions occur on O
2
, O
4
 
and N
3
 of thymine and N
7 
of adenine (Figure 1.11). 
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Replication-blocking lesions are produced when N
1
 and N
3
 on adenine are methylated to form 
N
1
-methyladenine (1meA) and N
3
-methyladenine (3meA) respectively. The predominant 
methylation adduct occurs on N
7
 of guanine to induce N
7
-methylguanine (7meG). While this 
lesion is not toxic on its own, it is able to undergo spontaneous depurination and the 
subsequent AP site is mutagenic (Fu et al., 2012). The alkyl lesions that form on O
6
 of 
guanine are particularly detrimental due to the miscoding property of the resulting O
6
-
methylguanine (O
6
meG). This lesion is able to mispair with thymine, thereby inducing 
mutagenesis. 
Since alkylating agents are able to transfer alkyl groups onto many biological molecules, it is 
not just DNA that is targeted. Other molecules, including RNA, are also affected by 
alkylating lesions, which alter their biological structure and function (Drabløs et al., 2004). 
1.6.1.2 Chemotherapeutic alkylating agents 
The two main types of agents that fall into the monfunctional class of alkylating agents are the 
triazenes and the chloroethylating agents. The main lesions generated by triazenes such as 
temozolomide are 7meG, 3meA and O
6
meG, while O
6
-chloroethylguanine (O
6
Cl-ethylG) 
usually forms after treatment with the chloroethylating agents (Lord and Ashworth, 2012). 
Bifunctional agents include the nitrogen mustards, such as cyclophosphamide, and aziridines 
like mitomycin C. Both classes of bifunctional alkylators primarily target N
7
 of guanine to 
form interstrand crosslinks and bulky N-monoadducts (Table 1.2). 
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Figure 1.11 DNA bases and their sites of alkylation 
Thymine, adenine, cytosine and guanine are depicted as schematics. The major sites of 
alkylating damage are: N
1
 and N
3
 of adenine; N
7
 and O
6 
of guanine and N
3
 of cytosine. Minor 
sites of alkylation are: O
2
, O
4
 and N
3
 of thymine; N
7
 of adenine; O
2
 of cytosine and N
1
 and N
3 
of guanine (adapted from Fu et al., 2012). 
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1.6.1.3 Repair pathways involved in the response to alkylating damage 
Alkyl lesions are recognised and repaired by a number of pathways, which are discussed in 
detail in 1.3.3.  However, a brief overview is presented here to highlight the redundancy that 
exists between repair processes; a property that is increasingly being manipulated in cancer 
therapies (Table 1.2) (Lord and Ashworth, 2012). 
Repair pathways that remove alkylation-induced damage before cells enter replication include 
direct reversal, BER and NER. Direct reversal is primarily catalysed by the alkyltransferase, 
MGMT, or the DNA dioxygenases, ALKBH2 and ALKBH3 (Duncan et al., 2002, Lindhal et 
al., 1982). The BER pathway removes simple alkylation adducts or a single damaged DNA 
base, whereas the NER pathway excises larger base adducts that distort the dsDNA helix. The 
MMR pathway has been implicated in the response to some alkylation-induced lesions, such 
as O
6
meG (Table 1.2). The MMR pathway recognises and removes misincorporated 
nucleotides and it has been found that resistance to some alkylating agents occurs in cells that 
are defective in components of this pathway (Branch et al., 1993, de Wind et al., 1995).  
Numerous other repair processes can become activated in response to alkylating damage due 
to secondary lesions such as SSBs, DSBs and crosslinks. These include TLS, the FA pathway 
and HR (Fu et al., 2012). 
The inhibition of components of the DNA repair pathways that act on alkylation-induced 
damage is important in anti-cancer treatment to convert these lesions into fatal replication 
lesions to kill the tumour cell (Helleday et al., 2008). Indeed, it has been found that the 
chemotherapeutic activity of temozolomide is effective in tumour cells where the promoter of 
the MGMT gene is methylated. Therefore, the expression of MGMT is greatly reduced, which 
causes alkyl lesions that would normally be reversed by the activity of the enzyme, to persist 
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(Lord and Ashworth, 2012). However, it is also important that the MMR pathway in these 
tumour cells is fully functional since the mismatches that are generated after temozolomide 
treatment are recognised by this pathway, which only targets the newly synthesised strand and 
does not repair the damaged base in the template strand. Therefore, DSBs are eventually 
generated, which results in the activation of the ATM/ATR pathway to promote cell cycle 
arrest and/or apoptosis in these tumour cells (Li, 2008). 
1.6.2 Topoisomerase inhibitors 
Another type of damaging agent that can be used as a chemotherapeutic drug is the class of 
compounds known as the topoisomerase inhibitors. These agents exploit DNA SSBs or DSBs 
that naturally arise within the cell (Helleday et al., 2008). Human topoisomerases fall into two 
catergories: type I or type II. The type I family can be further sub-divided into types IA and 
IB. Similarly, the type II family consists of types IIA and IIB (Wang, 2002). Topoisomerase I 
(TOP1), topoisomerase IIIα (TOP3α) and topoisomerase IIIβ (TOP3β) belong to the type IB 
family, whereas topoisomerase IIα (TOP2α) and topoisomerase IIβ (TOP2β) fall into the type 
IIA category. Each family of topoisomerases has a slightly different biological role but as a 
group of enzymes, they generally resolve topological difficulties that occur during processes 
that require DNA-unwinding such as transcription and replication. By introducing transient 
breaks in DNA, these enzymes relax supercoiled DNA or allow the DNA strands to pass 
through each other (Wang, 2002). Here, the biological roles of TOP1, TOP2α and TOP2β and 
the function of their respective inhibitors will be discussed. Particular detail will be attached 
to the TOP2 enzymes. Specific drugs are used to target the different types of topisomerase 
enzymes. 
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Agent Lesion Repair 
Monofunctional Triazenes 
Temozolomide 
 
 
1meA ALKBH2/ALKBH3 
3meA BER/NER 
7meG BER 
O
6
meG MGMT/NER 
O
6
meG:T MGMT/NER/MMR 
Monofunctional chloroethylating 
Lomustine 
O
6
Cl-ethylG MGMT/NER 
G-C crosslink FA/NER 
Bifunctional nitrogen mustards 
Cyclophosphamide 
 
Bifunctional Aziridines 
Mitomycin C 
 
 
G-G crosslink 
 
 
FA/NER 
 
Table 1.2 DNA lesions caused by different alkylating agents.  
The repair pathway for each lesion is shown. Secondary repair pathways for the DNA lesions 
include HR and NHEJ (adapted from Fu et al., 2012). 
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Notably, topoisomerases can also be inhibited by endogenous sources such as base 
mismatches, pyrimidine dimers and oxidative stress (Lanza et al., 1996, Li et al., 1999, 
Pouquier et al., 1997). 
1.6.2.1 Biological role of topoisomerase I 
TOP1 covalently binds to one DNA strand of the double helix and induces a SSB in the 
unbound strand. This allows the latter strand to rotate freely around the intact TOP1-bound 
DNA strand. Once the DNA is relaxed, TOP1 reverses the covalent binding to initiate the re-
ligation of the break; this process is quicker than the cleavage step (Pommier et al., 2003). 
The activity of TOP1, therefore, generates transient covalent TOP1-cleaved intermediates, 
which are known as TOP1 cleavage complexes (TOP1cc)  (Pommier, 2006). 
1.6.2.2 Topoisomerase I inhibitors 
The cleavage complex that is generated during TOP1-mediated relaxation of DNA supercoils 
is a target for anti-cancer drugs. The main inhibitor of TOP1 is camptothecin, which exists in 
a naturally active form and binds reversibly to TOP1cc. By displacing the 5’hydroxyl group 
of the cleaved strand and preventing its re-ligation, camptothecin converts these cleavage 
complexes into DNA damage. However, continued exposure to camptothecin is required for 
DNA lesions to be generated since the drug rapidly diffuses away from the TOP1cc. The 
cleavage complexes are readily reversible once camptothecin is removed (Pommier et al., 
2003). 
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1.6.2.3 Biological role of topoisomerase II 
TOP2 enzymes function in an ATP-dependent manner to remove DNA catenation and allow 
an intact DNA duplex to pass through another by generating a transient DSB in a second 
double-stranded DNA segment (Nitiss, 2009a). Two isoforms of the enzyme exist in 
mammalian cells - TOP2α and TOP2β. These are structurally similar; each one exists as a 
homodimer and they share 68% sequence homology (Austin et al., 1993). The N-terminal 
domain and the central domain are similar between the two isoforms, whereas the C-terminal 
region differs slightly. The N-terminal region contains the site of ATP binding and hydrolysis 
that is vital for the cellular function of both isoforms.  An active site tyrosine in the central 
domain drives the cleavage of the phosphodiester bond during TOP2 activity. 
 Despite their sequence homology, TOP2α and TOP2β possess different biological functions 
and these differences are often attributed to the differences in the C-terminal region of each 
enzyme (Gilroy and Austin, 2011, Linka et al., 2007). TOP2α primarily functions in 
chromosome segregation and in replication and therefore acts in a cell cycle regulated 
manner. In contrast, TOP2β is the only TOP2 enzyme expressed in quiescent cells and does 
not play a vital role in proliferating cells. However, it has been shown that TOP2β-null mice 
are not viable and the defects observed led to the conclusion that TOP2β is implicated in 
transcription of essential genes involved in neuronal development (Ju et al., 2006, Yang et al., 
2000). It is interesting that the expression of each isoform reflects their different roles: TOP2β 
appears to be constitutively expressed in all cells, whereas the expression of TOP2α is 
repressed in non-proliferating cells (Turley et al., 1997). 
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1.6.2.4 Topoisomerase II inhibitors 
The TOP2 enzymes are targets of a number of inhibitors, some of which have been exploited 
as the most effective clinical anti-cancer drugs. Inhibitors of these enzymes can be divided 
into two classes: the TOP2 poisons and the TOP2 catalytic inhibitors. 
1.6.2.4.1 Topoisomerase II poisons 
Drugs such as etoposide, doxorubicin and mitoxantrone belong to the class of TOP2 ‘poisons’ 
(Nitiss, 2009b). Their common mode of action is the blocking of the re-ligation step of the 
cleaved DNA duplex following the passage of an intact DNA duplex (described as the G and 
T segments) through the transient DSB (Figure 1.12). By binding reversibly, these drugs 
effectively ‘trap’ TOP2α/TOP2β-DNA cleavage complexes (TOP2cc) where DNA strands are 
attached by their 5’ ends through the TOP2 dimer and each end of the DNA is attached to a 
TOP2 monomer. In this way, these poisons convert the enzyme into a highly toxic DNA 
damaging agent. It is interesting to note, therefore, that TOP2 poisons are restricted to act at a 
certain stage of the TOP2 catalytic cycle. 
Etoposide (also known as VP-16), belongs to the epipodophyllotoxin class of TOP2 poisons.  
Low doses of this drug result in the accumulation of TOP2cc that become cytotoxic at high 
concentrations. Therefore, etoposide treatment generates a number of TOP2-mediated DNA 
DSBs, which activate a DDR. However, the cellular processes that are involved in detecting 
and processing these cleavage complexes remain unclear. Although etoposide has been shown 
to induce the formation of both the TOP2α and TOP2β cleavage complexes, there have been 
studies to suggest that TOP2α rather than TOP2β is the mediator of etoposide-induced 
cytotoxicity (Azarova et al., 2007). In addition, these studies showed that the development of 
secondary malignancies that arise from chromosomal rearrangements and DSBs after 
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etoposide treatment is mediated through TOP2β (Azarova et al., 2007). The fact that these 
effects can be reversed by proteasomal degradation is supported by the findings that 
preferential degradation of TOP2β by the 26S proteasome pathway can occur after formation 
of TOP2cc (Mao et al., 2001). 
There are also reports that an isoform-specific poison exists in the form of NK314, a synthetic 
benzo[c]phenanthridine alkaloid. This agent was found to induce DSBs and exert anti-tumour 
effects in a TOP2α-dependent manner (Toyoda et al., 2008). 
1.6.2.4.2 Topoisomerase II catalytic inhibitors 
 The other class of agents are termed the TOP2 ‘catalytic inhibitors’ and comprise a 
heterogeneous range of compounds that affect TOP2 activity at several different stages during 
the catalytic cycle of the enzyme. As their name suggests, these compounds exert their 
cytotoxicity by inhibiting the activity of TOP2, which results in abnormal mitosis and mitotic 
catastrophe (Jensen and Sehested, 1997, Larsen et al., 2003). The mechanisms of action of 
catalytic inhibitors are diverse and are sometimes non-specific (Larsen et al., 2003). 
One mode of inhibition is the disruption of the binding between DNA and TOP2 by 
compounds such as the intercalator, aclarubicin (Figure 1.12). Incidentally, this compound is 
one of the few members of the class of catalytic inhibitors to be developed as a clinical agent.  
It has been found that aclarubicin inhibits the DNA poisons such as etoposide because it 
reduces the amount of TOP2 cleavage complex that is the substrate for etoposide (Peterson et 
al., 1994). Thus, the rationale advanced by a number of studies is that the antagonistic 
behaviour of a catalytic inhibitor of TOP2 should selectively protect normal tissue and not 
tumour cells (Jensen and Sehested, 1997). 
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Figure 1.12 The catalytic cycle of TOP2 and its poisons and catalytic inhibitors 
The TOP2 catalytic cycle is activated upon binding of the enzyme to two double-stranded 
DNA segments – the G and the T segments. Upon ATP binding, the two ATP domains 
dimerise and the G segment becomes cleaved. The T segment is transported through the break 
in the G segment and the latter is re-ligated. The T segment is then transported through the 
opening in the C-terminal region. Etoposide acts at the indicated step and traps TOP2 in 
complexes where the DNA strands of the cleaved segment are attached to each TOP2 
monomer. Novobiocin blocks ATP binding; merbarone inhibits TOP2-mediated cleavage of 
the G segment and ICRF-193 stabilised a non-covalent form of TOP2 where it is closed 
around DNA (adapted from Wang 2002; Larson et al., 2003). 
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The inhibition of ATP binding is another mode of TOP2 catalytic inhibition. Novobiocin is an 
example of a drug that acts via this mechanism and blocks the ATP binding site on TOP2 
(Figure 1.12) (Larsen et al., 2003). However, the action of novobiocin is not restricted to 
TOP2; it can also disrupt the activity of certain ABC transporters and, interestingly, has been 
found to potentiate the action of etoposide via the inhibition of its transporter (Rappa et al., 
1993). 
Finally, some agents belonging to this class of TOP2 inhibitors can also act to disrupt TOP2-
mediated DNA cleavage and, therefore, stabilise TOP2-DNA complexes. In this way, drugs 
such as merbarone compete with TOP2 poisons like etoposide, which leads to the possibility 
that some catalytic inhibitors and some TOP2 poisons bind to the same site on TOP2. In 
addition, some bisdioxopiperazine derivatives like ICRF-193 can also act to inhibit TOP2 by 
stabilising a non-covalent form of the enzyme (Figure 1.12). Both merbarone and the 
bisdioxopiperazine derivatives show some selectivity towards TOP2α (Drake et al., 1989, 
Perrin et al., 1998). 
1.6.3 Other classes of anti-cancer drugs 
1.6.3.1 Platinum salts 
Platinum-based drugs, notably cisplatin and carboplatin, are amongst the most commonly 
used chemotherapeutics. The platinum atom in these drugs specifically forms covalent bonds 
with N
7
 of purine bases and results in platinum-DNA adducts, including DNA ICLs (Deans 
and West, 2011). In this respect, the mechanism of toxicity of cisplatin resembles that of 
bifunctional alkylating agents in 1.6.1 and similarly, the resulting adducts cause lethal 
disruption to replication and transcription.  
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The main pathways that recognise and repair platinum drug-induced lesions are a combination 
of NER and HR. Therefore, agents like cisplatin are effective in tumours that harbour 
mutations in either of these pathways. For example, in some high-grade ovarian tumours, the 
HR genes, BRCA1 or BRCA2 may be mutated. In addition, mutations in enzymes involved in 
the NER pathway are associated with an increased level of cisplatin-induced adducts and 
therefore exhibit a heightened apoptotic response to such drugs (Lord and Ashworth, 2012). 
1.6.3.2 Anti-metabolites 
Another class of anti-cancer drug is the chemotherapeutic anti-metabolites. These include 
methotrexate (MTX), 5-fluorouracil (5-FU) and hydroxyurea (HU). The general mechanism 
of action of this group of compounds is the inhibition of specific enzymes that catalyse 
reactions in the biosynthesis of purines and pyrimidines. The rationale behind such treatment 
is that tumour cells have a higher rate of proliferation than normal cells and may, therefore, be 
more sensitive to such drugs (Kinsella et al., 1997). MTX is a specific inhibitor of 
dihydrofolate reductase and prevents the production of reduced folate, which is a co-factor for 
a number of enzymes involved in purine and pyrimidine synthesis. The pyrimidine antagonist, 
5-FU, was specifically developed to resemble uracil. It rapidly enters the cell where it is 
converted into numerous metabolites, resulting in the fraudulent nucleotide, 5FdUMP that 
inhibits thymidylate synthase (TS). Thymidylate synthesis is subsequently blocked, disrupting 
DNA synthesis. Furthermore, the fraudulent nucleotide incorporates itself into DNA (Longley 
et al., 2003). 
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1.6.3.3 Anti-tumour antibiotics 
A number of compounds isolated from Streptomyces cultures were found to contain anti-
tumour activity (Waksman and Woodruff, 1940). Therefore, drugs such as mitoxantrone and 
doxorubicin were designed from these natural precursors (Sparreboom et al., 2005). 
Doxorubicin belongs to the anthracycline family of anti-tumour drugs, which are highly 
reactive molecules, possessing a high affinity for DNA (Sparreboom et al., 2005). The main 
mode of cytotoxicity is their ability to bind TOP2, the implications of which are described in 
1.6.2.4.1. Anthracyclines are limited in their use due to multi-drug resistance and the 
cardiotoxicity that often accompanies such treatment Therefore, the development of 
derivatives that are not substrates for resistance mechanisms and that have reduced toxicities 
is ongoing. 
1.6.4 Resistance to chemotherapeutic agents 
Many chemotherapeutics are limited in their effectiveness due to the problem of drug 
resistance. Drug resistance can occur through a number of mechanisms such as the over-
expression of drug efflux transporters, increased drug inactivation and the enhanced repair of 
DNA damage that is induced by chemotherapeutics. The latter is often linked to secondary 
mutations that are acquired by the tumour cell to render it capable of repairing the drug-
mediated damage. Therefore, resistance can be divided into those tumours that have an 
intrinsic resistance and those that acquire it throughout treatment. Indeed, acquired resistance 
is often associated with patients who are undergoing chemotherapy. 
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1.6.4.1 Over-expression of drug transporter proteins 
The up-regulation of drug efflux ATP-binding cassette (ABC) transporters presents a serious 
obstacle to the use of chemotherapeutic drugs. The main transporters that are over-expressed 
in tumour cells are: P-glycoprotein (ABCB1/MDR1), multi-drug resistance protein 
(ABCC1/MRP1) and breast cancer resistance protein (ABCG2/BCRP) (Longley and 
Johnston, 2005). A large number of compounds make up the substrates of these efflux 
transporters, which is a concern considering the range of anti-cancer drugs that are available. 
Many strategies are in place to inhibit drug transporters. In addition, the need for designing 
drugs that are not substrates for such transporters is becoming increasingly important.  
1.6.4.2 Increased drug inactivation 
The inactivation of the reactive group of some anti-cancer drugs is often due to the over-
expression of glutathione-S-transferase (GST), which catalyses the formation of conjugates 
between glutathione and some anti-cancer drugs (Townsend and Tew, 2003). This enzyme-
mediated process is actually a mechanism that inhibits oxidative stress caused to DNA by 
endogenous and exogenous agents. However, since the rationale behind chemotherapy is the 
induction of DNA damage, the over-expression of GST is detrimental to the activity of such 
agents and causes resistance.  
1.6.4.3 Secondary mutations 
Drugs that target proteins involved in the DDR are often limited by resistance that is acquired 
through secondary mutations in other DDR genes. These secondary mutations can lead to an 
increase in the repair of damaging lesions. For example, resistance to PARP inhibitors is often 
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caused by secondary mutations in BRCA2 that is vital to the process of HR (Edwards et al., 
2008, Sakai et al., 2008). These mutations restore the open reading frame of these genes, 
which allows the generation of a partially functional protein; therefore, the damage resulting 
from PARP inhibition can be repaired. PARP inhibitors are usually particularly effective in 
tumours harbouring mutations in BRCA1 or BRCA2 (Bryant et al., 2005, Farmer et al., 2005). 
These mutations would normally render them defective and unable to repair DSBs. 
1.7 AIMS AND OBJECTIVES 
The main tumour suppressor activities of p53 include its ability to enforce growth arrest or 
apoptosis through the transcriptional activation or repression of various genes in response to 
differing degrees and types of stress. Many mechanisms exist to control this transcription 
factor, including co-factors that often exert discriminatory effects on the ability of p53 to 
regulate its targets. The involvement of hnRNPUL-1 in transcriptional regulation has 
previously been reported as well as the finding that it interacts with p53 and negatively 
regulates its transcriptional activity, although the mechanism by which this occurs was 
unknown (Barral et al., 2005, Kzhyshkowska et al., 2003). Taken together, these observations 
suggest that hnRNPUL-1, in addition to its RNA-processing properties, may also function as 
a transcriptional co-factor for p53. Therefore, the aims and objectives of this part of the study 
were: 
 To investigate the site of interaction on hnRNPUL-1 for p53 and to confirm the 
inhibitory effects of hnRNPUL-1 on the transcriptional activity of p53. 
 To determine which p53 target genes and consequent cellular responses are affected 
by the action of hnRNPUL-1. 
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p53 is the most commonly mutated tumour suppressor and is inactivated in nearly 50% of 
sporadic tumours (Levine et al., 1991, Nigro et al., 1989). Although a key event in the 
onset of tumourigenesis, p53 inactivation in tumours renders them particularly refractory 
to anti-cancer treatment since it is a mediator of chemosensitivity. Inactivating mutations 
in TP53 are not the only means by which tumours become resistance to treatment: 
mutations in numerous repair genes and key damage sensors are commonly found in 
different types of tumours and are often the cause of treatment with anti-cancer agents 
being ineffectual. The need for agents to overcome such resistance mechanisms has led to 
the development of compounds derived from the anthracycline family. One such 
derivative, ALX, is a TOP2 inhibitor that also possesses an alkylating side-chain. Notably, 
ALX displays anti-cancer activity in treatment-resistant cell lines (Pors et al., 2004, Pors 
et al., 2003). However, any mechanistic insight into the mode of action of ALX remains 
poor. Therefore, the aims and objectives of this section of the study were: 
 To identify the DDR pathway that becomes activated in response to ALX and to 
establish the mode of cell death. 
 To determine which functions of ALX contribute to its anti-tumour activity. 
 To determine whether the inactivation of key DDR components results in ALX 
resistance. 
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CHAPTER 2 MATERIALS AND METHODS 
2.1 TISSUE CULTURE TECHNIQUES 
2.1.1 Cell Lines  
All cell lines used in this study are summarised in (Table 2.1). DLD1 Seckel/Seckel Rescue 
cells were obtained from F. Bunz and tetracycline-inducible U2OS cells were obtained from 
E. Petermann. All other cell lines were commercially-available and originally obtained from 
the ATCC. All cell lines were checked routinely for mycoplasma. 
2.1.2 Tissue culture media and solutions  
The following cell lines were grown in Dulbecco’s modified Eagle’s medium (DMEM) 
(Invitrogen), supplemented with 10% fetal calf serum (FCS) (PAA), glutamine and 
penicillin/streptomycin (pen/strep) (Invitrogen): H1299, HeLa, HCT116 and hTERT-RPE1. 
U2OS osteosarcoma cells were grown in McCoy’s medium (Invitrogen), supplemented with 
10% FCS and pen/strep. Other cell lines that also required McCoy’s medium included DLD1 
parental, DLD1 Seckel, DLD1 Seckel Rescue and DLD1 Chk1 S317A.  
2.1.3 Maintenance of cell cultures 
The adherent cell lines above were maintained in 75 cm
2
 tissue culture flasks (Corning) and 
subcultured in humidified incubators in a 95% air and 5% carbon dioxide environment at 37 
o
C. When cells reached confluency, the medium was removed and cells were subsequently 
washed in PBS (5.5 mL). Detachment of cells was performed by the addition of trypsin 
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Cell Line Origin Mutation/other comment 
DLD1 parental Colorectal carcinoma  MSH6 mutant; TP53 mutant 
DLD1-Seckel Colorectal carcinoma  Reduced ATR  
DLD1-Seckel 
Rescue 
Colorectal carcinoma  Engineered to re-express 
ATR 
DLD1 Chk1 S317A Colorectal carcinoma Chk1 mutant 
H1299 Non-small cell lung carcinoma TP53 null 
HCT116 Colorectal carcinoma  TP53 WT; MRE11 mutant; 
MLH1 mutant 
HeLa Cervical carcinoma  Low levels of p53  
RPE1 hTERT-immortalised retinal 
pigment epithelial  
Immortal cell line with an 
extended replicative capacity 
U2OS Osteosarcoma  TP53 WT 
U2OS -Tet Inducible osteosarcoma  Overexpresses Cyclin E 
(Tet-off) 
U2OS +Tet Inducible osteosarcoma  Normal levels of Cyclin E 
(Tet-on) 
2008+vector Ovarian carcinoma FANCF deficient 
2008+FANCF Ovarian carcinoma  Engineered to re-express 
FANCF 
 
Table 2.1 Cell lines used in this study 
All cell lines orginate from humans unless otherwise stated. 
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(Invitrogen) (1.5 mL) before incubating cells for 5 min at 37 
o
C. After confirming detachment 
of cells under the microscope, the trypsin was inactivated by resuspending with appropriate 
media containing FCS (8 mL). Cells were then re-plated to the required density.  
To synchronise hTERT-RPE1 cells in G0/G1 phase of the cell cycle, cells were grown to 
confluency and then maintained in media lacking FCS for 2 weeks prior to use. In the 
tetracycline-inducible U2OS cells, cyclin E expression was suppressed by the addition of 1 
μg/mL tetracycline (Sigma) to growth media. To induce cyclin E expression, cells were 
maintained for 48 h in growth media lacking tetracycline. 
2.1.4 Cryopreservation of cells 
Cells were cultured to 80% confluency and trypsinised as before (2.1.3). The trypsin was 
inactivated by fresh media (5 mL) and centrifuged at 1200 rpm for 5 min. The media was 
gently removed and the remaining cell pellet was resuspended with 1 mL of freezing mixture 
containing 50% FCS, 40% media and 10% DMSO The cells were then transferred to a 1.5 mL 
cryovial (Nunc) and stored at -80 
o
C before being moved to storage in liquid nitrogen.. 
2.1.5 Cell Resuscitation 
A 1.5 mL cryovial containing the cells was taken from liquid nitrogen tanks and opened under 
sterile conditions to let out any remaining liquid nitrogen. Once re-capped, the cryovial was 
warmed at 37 
o
C and a sterile Pasteur pipette was used to transfer the contents of the cryovial 
to a Falcon tube. The cells were resuspended in 10 mL of pre-warmed media, which was 
added drop-wise, and centrifuged at 1500 rpm for 5 min to remove any residual DMSO. The 
media was gently removed and the remaining cell pellet was resuspended in media before 
being transferred to a 75 cm
2
 tissue culture flask to be incubated at 37 
o
C. 
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2.2 CYTOTOXIC AGENTS AND INHIBITORS 
2.2.1 Chemotherapeutic drugs 
The alkylating anthraquinone, Alchemix (ALX, 50 nM), was a gift from Klaus Pors 
(University of Bradford). A derivative of ALX lacking the alkylating side-chain, ZP275, was 
a gift from Klaus Pors and was used at a concentration of 50 nM. These cytotoxic agents were 
dissolved in dimethyl sulphoxide (DMSO) (Sigma) and aliquots were stored at -80 
o
C.   
2.2.2 DNA damaging agents and kinase inhibitors 
Cells were irradiated with ionising radiation (IR) to promote DNA double strand breaks at the 
following doses unless otherwise stated: 2, 5, 10 Gy. Ultraviolet light (UV) was used to 
promote the formation of intrastrand crosslinks (ICLs). Prior to UV irradiation, culture 
medium was removed and cells were exposed to UVC irradiation (254 nm) at a dose of 20 
Joules m
-2
 unless otherwise stated. Camptothecin (CPT) inhibits the catalytic activity of 
mammalian DNA TOP1 and stabilises the TOP1cc. It was used at a concentration of 1 µM to 
induce DNA lesions at replication forks. An inhibitor of TOP2, Etoposide (Sigma Aldrich), 
was also used at a concentration of 1 µM. The ATM inhibitor, KU-55933 (Merck) was used 
at a concentration of 10 µM. The MRN-ATM pathway inhibitor, Mirin (Merck) was also used 
at a concentration of 10 µM. The DNA-PK inhibitor, DMNB was also obtained from Merck 
and used at a concentration of 50 µM. Cisplatin (EBEWE pharma, 10 µg/mL) was used to 
induce apoptosis. All inhibitors were reconstituted in DMSO and aliquots were stored at -20 
o
C.  
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2.3 PROTEIN CHEMISTRY TECHNIQUES 
2.3.1 Protein extraction 
Adherent cancer cell lines were cultured as appropriate to 80% confluency. After culture 
media was removed, the cells were washed in pre-warmed PBS and treated with trypsin as 
before (2.1.3). Once fresh media was added, cells were pooled and centrifuged at 1500 rpm 
for 5 min at room temperature. The cell pellet was resuspended in ice-cold PBS and 
centrifuged at 1500 rpm at 4 
o
C, after which the supernatant was removed. Whole cell extracts 
were prepared in a volume of UTB lysis buffer (8 M Urea, 50 mM Tris-HCl, [pH 7.5], and 
150 mM β-mercaptoethanol), and transferred to a 1.5 mL microfuge tube. Samples were 
subsequently sonicated for 2 x 10 sec and then centrifuged at 16, 400 rpm for 20 min at 4 
o
C 
to remove the cellular debris. The supernatant containing the protein was transferred to a 0.5 
mL microfuge tube and snap frozen in liquid nitrogen before being stored at -80 
o
C. 
2.3.2 Bradford Assay 
Protein extracts were prepared as described above (2.3.1). A standard protein curve was 
constructed using BSA (Sigma) made up in sterile distilled water: 0, 100, 200, 300, 400, 500 
µg/mL. The BSA standards were aliquotted (10 µL), in quadruplicate, into a 96-well flat 
bottom plate (Iwaki). Protein samples were diuted 1:10 with distilled water and aliquotted (10 
µL), in quadruplicate, into the same 96-well flat bottom plate. Bradford reagent (Bio-Rad) 
was diluted 1:5 with sterile distilled water and 200 µL was added to each well containing the 
protein sample and to wells containing the standards. The reaction was left at room 
temperature for 5 min before the absorbance was measured at a wavelength of 595 nm. A 
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standard curve was plotted from which protein concentrations of the samples were 
determined. 
2.3.3 SDS-PAGE 
Samples were separated on polyacrylamide gels consisting of 1M Tris/1M Bicine, 30% 
acrylamide (N, N’-methylene-bis-acrylamide) (Bio-Rad), 10% SDS solution (Sodium dodecyl 
sulphate w/v) (Bio-Rad), Temed (N, N, N’. N’-tetra-methyl-ethylenediamine) (Bio-Rad) and 
10% APS (Ammonium Persulphate) (Bio-Rad). The polyacrylamide gels were made up to 
different percentages based on the volume of acrylamide used, which was dependent on the 
relative molecular weight of the protein of interest: >80 kDa – 6%, >40 kDa – 10% and <40 
kDa - 12% (8 mL, 13.36 mL and 16 mL respectively). The polyacrylamide gel was diluted 
with sterile distilled water to give the desired final percentage with APS added last to initiate 
polymerisation. The gel apparatus was filled before inserting a well-forming plastic comb and 
then left to polymerise. The comb was removed once the gel had set and the wells were rinsed 
with running buffer (0.1M Tris/0.1M Bicine, 0.1% SDS). Protein samples were diluted 1:1 in 
2x sample buffer (0.125 M Tris/HCl pH 6.8, 4% (w/v) SDS, 20% Glycerol, 0.2 M DTT, 
0.02% Bromophenol blue) and denatured at 95 
o
C for 5 min. Samples were loaded (30 µg per 
well) onto the gel alongside a  protein molecular weight marker (Fermentas). The gel was 
placed in the bottom reservoir containing running buffer before the top reservoir (also 
containing running buffer) was clamped on top of the gel. Samples were typically 
electrophoresed for 5-6 h at 20mA. 
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2.3.4 Biphasic gel 
A biphasic polyacrylamide gel was used to separate very high and very low molecular weight 
proteins on the same gel. A 12% acrylamide gel (10 mL) was poured into the bottom half of 
the gel apparatus and the surface was overlaid with 1 mL water saturated butan-2-ol to ensure 
an even layer. Once the 12% gel had set, the water saturated butanol was removed and the gel 
plates rinsed in distilled water three times. A 6% acrylamide gel was poured on top of the 
12% gel and the well-forming plastic comb was inserted as before. 
2.3.5 Electrophoretic transfer of proteins 
Following electrophoresis, cell lysates were electrophorectically transferred onto a 
nitrocellulose membrane (Thermo Scientific) using a blotting cassette consisting of electrode 
panels and foam sponges. The nitrocellulose membrane was pre-soaked in transfer buffer 
(0.02 M Tris, 0.19 M glycine and 20% v/v methanol) and placed onto a sheet of Whatman 
3MM filter paper that had also been pre-soaked in transfer buffer. The gel was placed on top 
of the nitrocellulose membrane and then covered with another sheet of pre-soaked Whatman 
filter paper. All the air bubbles were removed to ensure even transfer. The complete blotting 
cassette was then placed in a Hoefer Transfer Gel Electrophoresis Unit and filled with transfer 
buffer. The cassette had to be placed in the correct orientation, with the nitrocellulose 
membrane facing the anode. The transfer of proteins was typically conducted overnight at 200 
mA. 
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2.3.6 Immunodetection of proteins 
After the proteins had transferred, the nitrocellulose membrane was stained with Ponceau S 
solution (Sigma) to visualise even loading and accurate transfer of proteins after 
electroblotting. Ponceau S solution was completely removed by washing the membrane in 
Tris-buffered saline with 0.1% Tween-20 (TBS-T). The membrane was then incubated in 5% 
skimmed milk powder (Marvel) at room temperature on a shaker to ensure that all 
hydrophobic binding sites were blocked with milk protein. The primary antibody was diluted 
to the appropriate concentration and the membrane was incubated in primary antibody in a 
sealed bag for 1 h at room temperature or overnight at 4 
o
C with gentle rocking (Table 2.2). 
Excess primary antibody was removed by 3 x 10 min washes in TBS-T, after which the 
membrane was incubated in a relevant secondary antibody (Table 2.2). The latter was 
conjugated with the horseradish peroxidase and directed against the IgG of the species that the 
primary antibody was raised from. After washing, the membrane was incubated with equal 
volumes of enhanced chemiluminescence system (ECL) (GE Healthcare) solutions 1 and 2 for 
1 min. The horseradish peroxidise catalysed the oxidation of the chemiluminescent substrate, 
luminol. This resulted in an excited state product of luminol, which was consequently 
converted into a lower energy state, releasing photons of light in the process. The presence of 
a chemical enhancer increased the chemiluminescent signal, which was detected as explained 
next.  Excess ECL reagents were removed and the membrane was then placed in an X-ray 
cassette and exposed to X-ray film (Kodak) for a varying amount of time, dependent on the 
strength of the signal, and consequently developed (Xograph Imaging Systems Compact X4).  
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2.3.7 Immunoprecipitation 
U2OS cells were washed in PBS after removing culture media. Cells were then pooled into a 
pre-cooled Falcon tube and centrifuged at 1500 rpm for 5 mins. The pelleted cells were 
resuspended in NETN lysis buffer (150 mM NaCl, 1 mM EDTA, 50 mM Tris-HCl [pH 7.5] 
1% Nonidet P-40) before being homogenised and cleared by ultracentrifugation at 40, 000 x g 
for 30 min at 4 
o
C. The lysates were immunoprecipitated with anti-hnRNPUL-1 antibody 
overnight at 4 
o
C (Table 2.2). Following this, the immunocomplexes were isolated by 
incubating with protein G-Sepharose (Sigma) for 1 h at 4 
o
C. Bead-bound immunoprecipitates 
were washed four times in NETN buffer and boiled in SDS sample buffer. Samples were 
separated by SDS-PAGE and analysed by immunoblotting as described before (2.3.3-2.3.6).  
2.3.8 Immunofluorescence microscopy 
Cells were cultured in 10 cm dishes on either 12 well poly-L-lysine coated glass slides 
(Hendley) or on poly-L-lysine coverslips (BD Biosciences) and grown to 70% confluency. 
Cells on slides were permeabilised in ice-cold extraction buffer (10 mM PIPES, 300 mM 
sucrose, 20 mM NaCl, 3 mM Mg Cl2, 0.5% Triton X-100, pH6.8) for 7 min and then fixed in 
ice-cold paraformaldehyde (3.6% paraformaldehyde in PBS, pH 7.2) for 10 min. If cells were 
grown on coverslips, these were extracted using ice-cold methanol at -20 
o
C for 15 min. Cells 
on both slides and coverslips were subsequently washed in PBS (3 x 5 min) and then blocked 
in 10% FCS (that had been filter-sterilised) in PBS at room temperature for 1 h or at 4 
o
C 
overnight. Cells were then washed in PBS (3 x 5 min) and incubated in primary antibody for 1 
h (Table 2.2). After this, excess antibody was removed by 3 x 5 min washes in PBS and cells 
were then incubated in secondary antibody in the dark for 1 h (Table 2.2). Following 
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incubation, excess secondary antibody was removed by 3 x 5 min washes in PBS. Cells on 
coverslips were mounted on glass slides (Surgipath) using a drop of Vectashield Mounting 
Medium (Vector Laboratories) that contained 4’, 6-diamidino-2-phenylindole (DAPI). Cells 
on slides were protected by glass coverslips (Surgipath) and mounted using the same medium. 
Nail varnish was used to seal the edges and slides were kept in the dark at 4 
o
C until ready to 
visualise. Visualisation of cells was conducted using a Nikon Eclipse E600 Microscope. 
Images were recorded using the Hamamatsu C4742-95 digital camera, and analysed using the 
image analysis software, Velocity version 4. 
2.3.9 GST-pull down assay with radioactive proteins 
GST pull-down assays were conducted using GST-fusion proteins and [
35
S]-labelled proteins 
(Table 2.3). [
35
S]-labelled in vitro translated protein (5 µL) was incubated with GST-fusion 
protein (20 µg) that had been diluted with 300 µL GST lysis buffer (buffer A; 1mM EDTA in 
PBS, 1% Triton-X100) on ice for 2 h. Protein complexes were isolated by incubation with 
glutathione-agarose beads (50 µL) at 4 
o
C with rotation for 1 h. Beads were washed three 
times with buffer A and twice with GST wash buffer (buffer B; 1mM EDTA in PBS). 
After washing, GST-protein complexes were released by the addition of GST elution buffer 
(25mM glutathione, 50mM Tris, pH 8.0) at 4 
o
C for 30 min. Samples were analysed by SDS-
PAGE after being boiled with sample buffer. After electrophoresis, gels were stained with a 
solution of 0.1% (w/v) Coomassie Brilliant Blue R-250 (Sigma Aldrich), 10% glacial acetic 
acid and 20% methanol in deionised water at room temperature on a shaker for 30 min. To 
visualise protein bands, gels were placed in a destaining solution (10% glacial acetic acid and 
20% methanol in deionised water) until bands were clearly visible. Destained gels were 
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Antibody (Species) Use Source 
hnRNPUL-1 (rabbit) WB, IP Made in-house 
HA (mouse) WB Sigma 
-Actin (mouse) WB Sigma 
p53 (DO-1) (mouse) WB Dr R. Grand 
p53 S15-P (rabbit) WB Cell Signalling 
p21 (mouse) WB Cell Signalling 
MDM2 (2A10) (mouse) WB Dr R. Grand 
Caspase 3 (rabbit) WB New England biolabs 
PARP1 (mouse) WB Santa Cruz 
ATM (11G12) (mouse) WB Dr J. Last 
ATM S1981-P (rabbit) WB R and D Systems 
ATR (mouse) WB Santa Cruz 
DNA-PK (mouse) WB Santa Cruz 
DNA-PK S2056-P (rabbit) WB Abcam 
KAP-1 (mouse) WB Bethyl Laboratories 
KAP-1 S824-P (rabbit) WB Bethyl Laboratories 
SMC1(rabbit) WB Bethyl Laboratories 
SMC1 S966-P (rabbit) WB Bethyl Laboratories 
NBS1 (mouse) WB Novus Biologicals 
NBS1 S343-P (rabbit) WB Cell Signalling 
Chk1 (mouse) WB Santa Cruz 
Chk1 S345-P (rabbit) WB Cell Signalling 
Chk2 (rabbit) WB Dr S. Elledge 
Chk2 T68-P (rabbit) WB R and D Systems 
RPA32 (mouse) WB NeoMarkers Fremont 
RPA32 S4/8-P (rabbit) WB Bethyl Laboratories 
H2A (rabbit) WB Millipore 
γH2AX (mouse) WB, IF Millipore 
TOP2α (rabbit) WB Bethyl Laboratories 
TOP2β (rabbit) WB Bethyl Laboratories 
PCNA (PC10) (mouse) WB Santa Cruz 
FANCD2 (mouse) WB Santa Cruz 
Lamin B (goat) WB, IF Santa Cruz 
Cyclin A (mouse)/ Cyclin B (rabbit) WB Santa Cruz 
Cyclin E (mouse) WB Santa Cruz 
53BP1 (rabbit) IF Novus Biologicals 
Histone H3 (rabbit) WB New England biolabs 
Histone H3 S10-P (rabbit) WB, IF Santa Cruz, New England biolabs 
Polyclonal swine anti-rabbit IgG-HRP WB DAKO 
Polyclonal goat anti-mouse IgG- HRP WB DAKO 
Alexa Fluor® 594 goat anti-mouse IgG IF Invitrogen  
Alexa Fluor® 488 goat anti-rabbit IgG IF Invitrogen 
 
Table 2.2 Antibodies used in this study 
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 incubated in Amplify Reagent (GE Healthcare) at room temperature on a shaker for 30 min. 
Gels were dried under a vacuum at 80 
o
C for 2 h before being exposed to autoradiography 
using Kodak X-Ray film. 
2.4 CELL BIOLOGY TECHNIQUES 
2.4.1 Transient transfection of mammalian cells using Lipofectamine LTX 
Cells were added to a 24-well plate at a density of 0.7 x 10
5
 cells per well into a volume of 0.5 
mL media or to a 6-well plate at 3.5 x 10
5 
cells per well in a volume of 2 mL media. The next 
day, 500 ng DNA (Table 2.4) was diluted in 100 µL Optimem (Invitrogen) or 2.5 µg DNA 
was diluted in 500 µL Optimem for a 24-well and a 6-well plate respectively. The solution 
was gently mixed with 0.5 µL or 2.5 µL Plus™ reagent (Invitrogen) and left to incubate at 
room temperature for 5 mins. Lipofectamine™ LTX (Invitrogen) was added at a 1:4 DNA: 
Lipofectamine™ LTX ratio and the solution was mixed and left to incubate for 30 mins at 
room temperature. After this, 100 µL or 500 µL of the DNA-Lipid complex was added 
dropwise to the cells in the 24-well or 6-well plate respectively. The plate was rocked gently 
back and forth to mix and left to incubate for 4-6 h at 37 
oC. Lipofectamine™ LTX was then 
removed from the cells and fresh media containing 10% FCS was added to each well. 
2.4.2 RNA Interference 
Duplexes of RNA (approximately 21-nucleotides in length) known as short-interfering RNAs 
(siRNAs) inhibit endogenous gene expression in a sequence-specific manner. siRNA 
duplexes used in this study are shown in Table 2.5 (Dharmacon). 
Chapter 2 
101 
 
 
Protein Vector Amino acids Source 
hnRNPUL-1 full length pcDNA3 1-856 Prof. T. Dobner 
hnRNPUL-1 N-terminal pcDNA3 1-453 Prof. T. Dobner 
hnRNPUL-1 Middle-terminal pcDNA3 213-732 Prof. T. Dobner 
hnRNPUL-1 C-terminal pcDNA3 400-856 Prof. T. Dobner 
hnRNPUL-1 ΔBBS pcDNA3 Δ454-611 Prof. J. Kzhyshkowska 
hnRNPUL-1 ΔBBS2a/b pcDNA3 Δ456-594 Prof. J. Kzhyshkowska 
hnRNPUL-1 ΔBBS3 pcDNA3 Δ456-570 Prof. J. Kzhyshkowska 
hnRNPUL-1 ΔBBS4 pcDNA3 Δ456-495 Prof. J. Kzhyshkowska 
hnRNPUL-1 ΔRGG pcDNA3 Δ612-685 Prof. J. Kzhyshkowska 
hnRNPUL-1 BBS-RGG pcDNA3 445-695 Prof. J. Kzhyshkowska 
hnRNPUL-1 splice variant pcDNA3 100-856 Dr A. Rusch 
hnRNPUL-2 full length pcDNA3 1-747 Dr S. Polo 
p53 full length pBK-CMV 1-393 Dr E. Hammond 
NBS1 pSG5 1-754 Dr M. Lavin 
 
Table 2.3 Proteins expressed in in vitro transcription/translation assays in this study 
Gene Vector  Application Source 
hnRNPUL-1  
full length (HA) 
pcDNA3 
 
DNA transfections Prof. T. Dobner 
hnRNPUL-1  
full length (GST) 
pGEX 5X-1 GST pull-down with 
radiolabelled proteins 
Prof. T. Dobner 
hnRNPUL-1 
BBS-RGG (GST) 
 
pGEX 4T-1 
 
GST pull-down with 
radiolabelled proteins 
Prof. J. 
Kzhyshkowska 
hnRNPUL-2  
full length (GST) 
pGEX 4T-1 
 
GST pull-down with 
radiolabelled proteins 
Prof. J. 
Kzhyshkowska 
GST pGEX 4T-1 GST pull-down with 
radiolabelled proteins 
Dr R. Grand 
p53 full length pBK-CMV DNA transfections, 
luciferase reporter assays, 
Dr E. Hammond 
p53 full length (GST) pGEX GST pull-down with 
radiolabelled proteins 
Dr A. Turnell 
p53 luciferase reporter PG13-Luc luciferase reporter assays Dr E. Hammond 
p21 luciferase reporter p21-
Luc/WWP-
Luc 
luciferase reporter assays Dr A. Turnell 
MDM2 luciferase 
reporter 
pGL3-Basic luciferase reporter assays Dr A. Turnell 
Renilla pRL-TK luciferase reporter assays Dr J. O’Neill 
 
Table 2.4 Plasmids used in this study 
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siRNA Sense sequence 
Non-silencing 5’-CGUACGCGGAAUACUUCGAdTdT-3’ 
hnRNPUL-1 5’-GCAGUGGAACCAGUACUAUdTdT-3’ 
MSH2 5’-UCCAGGCAUGCUUGUCUUGAAdTdT-3’ 
TOP2α 5’-AAAGACUGUCUGUUGAAAGAAdTdT-3’ 
TOP2β ON-TARGET plus SMART pool TOP2β 
 
Table 2.5 siRNA sequences used in this study 
2.4.2.1 Transfection of siRNA into H1299 cells 
Twenty four hours prior to transfection, H1299 cells were added to 6 cm dishes at a density of 
3.5 x 10
5
 cells per dish in a volume of 3.5 mL. The dishes were rocked gently to establish an 
even distribution of cells. Transient transfection of siRNA (Dharmacon) was performed the 
next day using Oligofectamine (Invitrogen). The transfection mixture was prepared using the 
following amounts per well: a volume of 2 µL of 40 µM control or 5 µL of 75 µM  
hnRNPUL-1 siRNA was mixed with 10 µL Oligofectamine in 1 mL Optimem (Invitrogen) 
and left for 30 min. After this time, 1 mL of the solution was added to each 6 cm dish 
containing H1299 cells that had been washed with 2 mL Optimem. After 4-6 h incubation at 
37 
o
C, 1 mL of media supplemented with 30% FCS was added to each dish. siRNA 
transfections were repeated 24 h later to bring about down-regulation.  
2.4.2.2 Transfection of siRNA into U2OS cells 
U2OS cells were plated in 6 cm dishes twenty four hours prior to transfection at a density of 
4.0 x 10
5
 cells per dish in a volume of 3.5 mL and rocked as above. The transfection mixture 
was prepared using the following amounts per well: 2 µL of 40 µM control or 5 µL of 75 µM  
hnRNPUL-1 siRNA was diluted in 368 µL or 365 µL Optimem respectively to a total volume 
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of 370 µL. In a separate 1.5 mL microfuge tube, the Oligofectamine (8 µL) was diluted in 
Optimem (22 µL), mixed and left for 5-10 min at room temperature. The diluted 
oligofectamine (30 µL) was added to the diluted siRNA to make a total volume of 400 µL, 
mixed gently and left to incubate for 20 min at room temperature. After this time, 400 µL of 
transfection mixture was added to each 6 cm dish containing U2OS cells that had been 
washed with 2 mL Optimem and left with 1.6 mL Optimem. After 4-6 h incubation at 37 
o
C, 
1 mL of media supplemented with 30% FCS was added to each dish.  Transfections were 
repeated 24 h later to bring about down-regulation. 
2.4.3 Luciferase Reporter Assay 
Luciferase expression was determined using a Dual-Luciferase® Reporter (DLR™) Assay 
System (Promega) according to the protocol provided. This system allows the co-transfection 
of two different luciferase vectors, firefly and Renilla (Table 2.4). 
H1299 cells were seeded in a 24-well plate (2.4.1) and transfected with the appropriate 
reporter construct, plus the Renilla luciferase gene as a transfection control and an untagged 
p53 expression plasmid in pcDNA3. Transfection of a total of 500 ng DNA in a volume of 0.5 
mL media was performed using Lipofectamine™ LTX according to the manufacturer’s 
instructions (Invitrogen). After 4-6 h incubation at 37 
o
C, culture media was removed from 
each well and replaced with 0.5 mL fresh media supplemented with 10% FCS before being 
incubated overnight at 37 
o
C.  
After culture media was removed from each well, cells were washed in 0.5 mL PBS and lysed 
using 100 µL 1X passive lysis buffer (PLB) (Promega) with gentle rocking for 15 min at 
room temperature. Lysates were transferred into sterile 1.5 mL microfuge tubes and stored at -
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20
 o
C. The activities of firefly and Renilla luciferases were both measured sequentially from a 
single sample. Cell lysates (20 µL) were added to each well of a white 96-well flat-bottomed 
plate (Nunc.) in which the DLR™ Assay was conducted. The activity of the firefly luciferase 
reporter was measured first by the addition of 50 µL Luciferase Assay Reagent II (LARII) to 
each well containing the lysate. The luminescent signal generated was quantified by a plate 
reader (Victor 1420) and the reaction was subsequently quenched by the addition of 50 µL 
Stop and Glo® Reagent to the same samples. This simultaneously initiated the Renilla 
luciferase reaction, generating a luminescent signal, which was also measured using the plate 
reader. Relative luciferase units were calculated by dividing the firefly luciferase activity by 
the corresponding Renilla luciferase assay. This resulted in normalised values since the 
Renilla reporter provided the internal control. The DLR™ Assay was performed 3 times to 
ensure reproducibility.  
2.4.4 Flow Cytometric Analysis by Propidium Iodide (PI) staining 
Flow cytometry was used to assess the cell cycle distribution of cells either transfected with 
hnRNPUL-1 siRNA (2.4.2) or treated with drugs (2.2.1). This technique involved passing a 
constant thin stream of fluid containing individual cells that had been labelled with a 
fluorescent dye through a laser beam. The amount of light that was scattered from the beam 
was recorded and was an indication of cell size. The beam also caused the fluorescent dye to 
emit light at various frequencies, which was also recorded and was a measure of DNA 
content. In these studies, the DNA-binding dye, propidium iodide (PI) (Sigma Aldrich) was 
used, which is a stoichiometric dye that enters the nuclei of cells and intercalates with 
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dsDNA.  Therefore, in combination with the light scatter, PI can be used to quantify the 
relative DNA content during the cell cycle.  
Cells were trypsinised and washed as before (2.1.3). After washing with ice-cold PBS, cells 
were resuspended in 3 mL ice-cold PBS and fixed by the addition of 7 mL ice-cold ethanol 
whilst vortexing. Fixation in alcohol enabled the uptake of PI dye, which would otherwise be 
pumped out of cells. Samples were stored at -20 
o
C until required. On the day of analysis, 
samples were centrifuged at 1300 x g at 4 
o
C for 5 min, after which the supernatant was 
discarded. The cell pellet was rehydrated with 20 mL ice-cold PBS and centrifuged again at 
1300 x g at 4 
o
C for 5 min. This process was repeated and the resulting cell pellet was 
resuspended in 1 mL PI/RNase solution (25 µg/mL PI, 0.1 mg/mL RNase to ensure the dye 
intercalated to DNA only), transferred to FACS tubes (Sarstedt) and incubated at 37 
o
C in the 
dark until analysis. DNA profiles were produced by running the samples through a Coulter 
XL-MCL flow cytometer at a wavelength of 488 nm. The proportion of cells in G1, S and G2 
phases of the cell cycle were calculated using Windows Multiple Document Interface flow 
cytometry application (WinMDI version 2.9). A sub-G1 peak was also seen in certain samples 
and these were taken as ‘dead cells’ (Figure 2.1). 
2.5 MOLECULAR BIOLOGY TECHNIQUES  
2.5.1 Antibiotics, Bacterial strains and Media 
Ampicillin and kanamycin were prepared as stock solutions in sterile distilled water (100 
mg/mL) and stored at -20 
o
C until required. Ampicillin was used at a final concentration of 50 
µg/mL and kanamycin was used at a final concentration of 25 µg/mL. Bacterial cultures were 
grown in Luria broth (LB) (Sigma). LB (50 g) was dissolved in 2 L distilled water (pH 7.5)  
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and sterilised before use. LB-agar was used to make up LB-agar plates, which were made by 
adding 1.2% agar (Sigma) to LB and sterilising the mixture prior to use. The LB-agar was 
boiled and allowed to cool before the addition of the appropriate antibiotic, after which the 
liquid LB-agar was poured into sterile 9 cm diameter plastic Petri dishes (Corning). The 
newly poured plates were allowed to set at room temperature before being used for bacterial 
transformation.  
2.5.2 Transformation of bacteria 
Bacterial transformations were conducted in competent Escherichia coli (E. coli) cells. MAX 
efficiency Stbl2 and DH5α competent cells (Invitrogen) were used for plasmid production, 
and BL21-Gold competent cells (Stratagene) were used to generate recombinant proteins. For 
each transformation, competent cells were initially thawed on ice and a 50 µL aliquot was 
then combined with approximately 50 ng DNA and mixed gently. Following incubation on 
ice for 30 min, samples were heat-shocked at 42 
o
C for either 20, 25 or 30 sec (for BL21, 
Stbl2 and DH5α cells respectively),  and cooled on ice for 2 min. After the addition of 450 µL 
S.O.C Medium (Invitrogen), the transformation mixture was incubated at 30 
o
C for either 90 
min (Stbl2), or at 37 
o
C for 1 h (DH5α and BL21), with shaking (225 rpm). Cells were then 
spread onto L-agar plates, containing the appropriate antibiotic (2.5.1), which were then 
incubated at 37 
o
C overnight. 
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Figure 2.1 Representation of a cell cycle profile 
M1 represents cells in sub-G1, M2 represents cells in G1, M3 represents cells in S and M4 
represents cells in G2/M. 
 
 
 
 
 
 
 
 
Figure 2.2 Agarose gel to determine integrity of RNA 
Intact RNA exhibits 28S and 18S rRNA bands with the 28S band being approximately twice 
as intense as the 18S band. 
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2.5.3 Growth of overnight cultures from colonies 
Colonies of competent cells from the L-agar plates above (2.5.2) were picked using a sterile 
tip and transferred to a well of a 96-well flat-bottomed plate containing 150 µL LB with 
appropriate antibiotic. The plate was sealed and incubated for 2 h at 37 
o
C, after which time it 
was stored at 4 
o
C until required. 
2.5.4 Preparation of plasmid DNA 
2.5.4.1 Small Scale preparation 
Plamid DNA was extracted using the GenElute™ Plasmid Miniprep Kit (Sigma) according to 
the protocol provided. Twenty four hours prior to extraction, a single colony (10 µL of each 
well of the 96-well flat-bottomed plate in 2.5.3containing the desired plasmid was used to 
inoculate 5 mL of LB supplemented with appropriate antibiotic (2.5.1). This was incubated at 
37 
o
C overnight with shaking (225 rpm). The following day, 3 mL of the culture was pelleted 
at 13, 000 x g for 1 min (the remaining culture was stored at -20 
o
C). Bacterial pellets were 
completely resuspended in 200 µL Resuspension Solution with RNase A. The resuspended 
pellets were then lysed with 200 µL Lysis Solution for 5 min. The solution was neutralised 
with 300 µL Neutralisation/Binding Solution and pelleted at 13, 000 x g for 10 min. The 
supernatant was transferred to a GenElute Miniprep Binding Column that had been prepared 
with 500 µL Column Preparation Solution. Transferred lysate was centrifuged at 13, 000 x g 
for 1 min. Following washing with 750 µL Wash Solution and centrifugation at 13, 000 x g 
for 30 sec, the DNA was eluted into a fresh collection tube with 100 µL Elution Solution and 
centrifugation at 13, 000 x g for 1 min. The eluted DNA was subsequently stored at -20 
o
C. 
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2.5.4.2 Large Scale preparation 
Plasmid DNA was purified using the PureLink™ HiPure Plasmid Filter Maxiprep Kit 
(Invitrogen) according to the protocol provided. Initially, a single colony (10 µL of each well 
of the 96-well flat-bottomed plate in 2.5.3) containing the desired plasmid was used to 
inoculate 5 mL of LB supplemented with appropriate antibiotic (2.5.1). This was incubated at 
37 
o
C overnight with shaking (225 rpm). Sixteen hours prior to purification, 250 µL of this 
was used to inoculate 200 mL LB broth supplemented with appropriate antibiotic (2.5.1) and 
incubated at 37 
o
C for 16 h with shaking. After this, the culture was transferred to a sterile 
centrifuge tube and centrifuged at 4000 x g at 4 
o
C for 10 min. The pellet was completely 
resuspended in 20 mL Resuspension Buffer with RNase (R3) before being lysed in 20 mL 
Lysis Buffer (L7). The cell suspension was left at room temperature for 5 min and neutralised 
with 10 mL Precipitation Buffer (N3). The precipitated lysate was transferred to a HiPure 
Filter Maxi Column, which had already been primed for adsorption of DNA by the addition of 
30 mL Equilibration Buffer (EQ1), which was allowed to run by gravity flow. Bacterial lysate 
in the HiPure Filter Maxi Column was washed with 50 mL Wash Buffer (W8) and allowed to 
drain by gravity flow. Elution Buffer (E4) (15 mL) was added to elute the DNA into a fresh 
tube. The DNA was precipitated by the addition of 5.2 mL isopropanol (Fisher Scientific) and 
the purified DNA was then centrifuged at 5000 x g at 4 
o
C for 1 h. DNA pellets were 
resuspended in 5 mL 70% ethanol (Fisher Scientific) and centrifuged at 5000 x g at 4 
o
C for 1 
h. The pellets were air dried, resuspended in 200-500 µL TE Buffer and stored at -20 
o
C.  
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2.5.5 Determination of DNA purity and concentration 
DNA concentration and purity was determined using a nanodrop spectrophotometer. The 
concentration of DNA was quantified by measuring the absorbance at OD260nm and calculated 
against 1 OD260nm unit being an equivalent of 50 µg of DNA in 1 mL. The DNA was 
considered pure and free from protein and RNA contamination if the ratio of OD260nm/280nm 
was more than 1.8. 
2.5.6 Preparation of GST-fusion protein 
Plasmids encoding GST-tagged proteins were used to transform BL21 bacteria cells as 
described in 2.5.2.  A 10 mL culture of the successful transformation was grown overnight at 
37 
o
C overnight with shaking (200 rpm). The following day, this was divided between 2 
flasks, each containing 500 mL LB with the appropriate antibiotic (2.5.1). These bacterial 
cultures were incubated at 37 
o
C overnight with shaking (200 rpm) until the optical density at 
600 nm had reached 0.6-0.8. Isopropyl-β-thiogalactopyranoside (IPTG) was added to a final 
concentration of 0.5 mM to induce the expression of the GST-fusion protein. After incubation 
at 30 
o
C for 3 h with shaking (200 rpm), cultures were centrifuged at 5000 rpm for 15 min. 
The supernatant was discarded and the bacterial pellet stored at -80 
o
C until required. 
To purify the GST-fusion protein, the pellet was thawed, resuspended in 50 mL ice-cold 
buffer A (2 mM EDTA, 1% Triton X-100 in PBS) and sonicated on ice for 3 x 30 sec. Cell 
debris was removed by centrifugation at 18000 rpm for 30 min. Glutathione-agarose beads (3 
mL of a 50%  slurry, Sigma) were added to the clarified supernatant and rotated at 4 
o
C for 3 
h. Following this, the beads were pelleted by centrifugation at 1500 rpm for 5 min and the 
supernatant was incubated with a second batch of glutathione-agarose beads as before. The 
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beads were washed three times with buffer A and once with buffer B (2 mM EDTA in PBS). 
GST-fusion proteins were eluted from the washed beads by the addition of 5 mL GST elution 
buffer (25 mM glutathione pH 8.2) and rotation for 1.5 h. After this time, the beads were 
removed by centrifugation at 1500 rpm for 5 min. The supernatant containing the eluted GST-
fusion protein was dialysed overnight at 4 
o
C against a solution of 0.15 M NaCl, 20 mM Tris 
pH 7.4, 2 mM DTT). The following day, dialysis was repeated for 3 h in fresh buffer and 
GST-fusion proteins were collected, aliquoted and stored at -80 
o
C until required.  
2.5.7 In-vitro transcription/translation 
Eukaryotic in vitro transcription/translation was conducted using the TNT
® 
Coupled 
Reticulocyte Lysate System according to the manufacturer’s instructions (Promega). Each 
reaction mixture contained 25 µL TNT
® 
rabbit reticulocyte lysate, 2 µL TNT
® 
reaction buffer, 
1 µL RNasin
® 
ribonuclease inhibitor (Promega), 1 µL amino acid mixture minus methionine, 
2 µL [
35
S]-methionine (1000Ci/mmol at 10mCi/mL; MP Biomedicals), 0.5 µg/ µL DNA 
template, 1 µL TNT
® 
T7 RNA polymerase and nuclease-free water to a final volume of 50 
µL. The reaction mixture was incubated at 30
 o
C for 90 min. To determine the expression of 
in vitro translated protein, 1-2
 
µL of the sample was subjected to SDS-PAGE, stained with 
Coomassie blue, destained, incubated in Amplify and dried under vacuum to visualise 
proteins as described in 2.3.9. 
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2.5.8 Site directed mutagenesis 
2.5.8.1 Primer design 
To generate hnRNPUL-1 constructs resistant to hnRNPUL-1 siRNA, silent mutations were 
introduced in hnRNPUL-1 siRNA sequence using site-directed mutagenesis (Stratagene) 
according to the manufacturer’s instructions. The hnRNPUL-1 siRNA sequence is shown by 
sequence (A). Silent mutations were introduced (depicted as the underlined bases on the 
bottom sequence) as shown by sequence (B) using the forward primer 5’-
AGTATGCCCAGCAATGGAATCAATACTATCAGAACCAGGG-3’ and the reverse 
primer 5’- CCCTGGTTCTGATAGTATTGATTCCATTGCTCGGCATACT-3’. The 
hnRNPUL-1 siRNA-resistant construct was then generated following steps 2.5.8.2-2.5.8.8. 
 
(A) 5’-GCAGUGGAACCAGUACUAU-dTdT-3’ 
(B) 5’-GCAAUGGAAUCAAUACUAU- dTdT -3’ 
2.5.8.2 QuikChange Site-Directed Mutagenesis parameters 
The mutant strand synthesis reaction was performed in thin-walled tubes using Pfu Ultra 
DNA polymerase (Stratagene). A 50 µL reaction was made up containing 5 µL 10X Buffer, 1 
µL DNA (40 ng), 1.25 µL forward primer (125 ng), 1.25 µL reverse primer (125 ng), 1 µL 
dNTP mix (each dNTP at 10 mM) and 40.5 µL injection water (Fannin). The Pfu Ultra DNA 
polymerase (1 µL) was added last and the reaction mixture was spun down. The tubes were 
placed in a thermal cycler (Applied Biosystems, Veriti 96-well thermal cycler) and the 
following cycling parameters were applied: 1 cycle (heatshock) of 95 
o
C for 30 sec; 18 cycles 
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(elongation) of 95 
o
C for 30 sec, 55 
o
C for 1 min, 68 
o
C for 8 min (1 min/Kb of plasmid DNA 
length). 
2.5.8.3 Dpn I Digestion of the amplification product 
Dpn I restriction enzyme (Stratagene) (1 µL) was added directly to each tube to digest the 
supercoiled DNA from the amplification product. The contents were mixed, transferred to 0.5 
mL microfuge tubes and incubated for 1 h at 37 
o
C. 
2.5.8.4 Transformation of XL1-Blue Supercompetent Cells 
Transformation of XL1-Blue Supercompetent Cells (Stratagene) was performed according to 
the protocol provided and in a manner similar to 2.5.2. Dpn I-treated DNA (1 µL) was added 
to 50 µL thawed competent cells and incubated on ice for 30 min. Samples were heat-shocked 
for 45 sec at 42 
o
C, cooled on ice for 2 min and then incubated with S.O.C Medium (500 µL) 
for 90 min at 30 
o
C with shaking (225 rpm). Cells were subsequently spread onto L-agar 
plates (250 µL on each of two plates) as before (2.5.2). 
2.5.8.5 Polymerase Chain Reaction using bacterial culture 
Single colonies of competent cells from 2.5.8.4were picked as described before and grown in 
LB with appropriate antibiotic in a 96-well flat-bottomed plate for 2 hours at 37 
o
C (2.5.3). 
PCR amplication was conducted in thin-walled PCR tubes using Taq polymerase (Roche) and 
pcDNA3 primers (company). A 25 µL reaction was set up containing 0.25 µL Taq 
polymerase, 2.5 µL 10X Buffer, 1 µL forward primer 1 µL reverse primer, 0.75 µL dNTP mix 
(each dNTP at 10 mM), 18.5 µL injection water and finally 1 µL culture from the appropriate 
well of the 96-well flat-bottomed plate. The tubes were placed in a thermal cycler and the 
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following cycling parameters were applied: 1 cycle of 94 
o
C for 4 min; 37 cycles of 94 
o
C for 
15 sec, 60 
o
C for 30 sec, 68 
o
C for 3 min followed by a final 10 min extension at 68 
o
C.  
2.5.8.6 Purification of PCR product 
Amplified DNA was purified using the PureLink™ PCR Purification Kit (Invitrogen) 
according to the protocol provided. This allowed primers, dNTPs, enzymes and salts to be 
removed from the PCR products before the DNA was used. Initially, 4 volumes of Binding 
Buffer was added to 1 volume of PCR product, mixed and transferred to a collection tube in a 
PureLink® Spin Column to allow the dsDNA to bind to the column. The mixture was 
centrifuged at 10,000 x g at room tempterature for 1 min after which, the flow-through was 
discarded. Wash Buffer with ethanol (650 µL) was added to the spin column and centrifuged 
at 10,000 x g at room temperature for 1 min to remove any impurities from the DNA. The 
flow-through was discarded and any remaining Wash Buffer was removed by further 
centrifugation at maximum speed. The collection tube was consequently discarded and the 
spin column placed into a fresh elution tube. Elution Buffer (50 µL) was added to the spin 
column and the contents were incubated for 1 min at room temperature before being 
centrifuged at maximum speed for 2 min. The purified DNA was stored at -20 
o
C until 
required.  
2.5.8.7 Agarose gel electrophoresis 
DNA was viewed on a 0.8% agarose gel. Agarose powder (0.8 g) (Sigma) was dissolved in 
100 mL 1X TBE buffer (89 mM Tris, 89 mM Boric Acid, 2 mM EDTA) and heated to boiling 
point. The agarose was allowed to cool before 1 µL Sybr Safe DNA gel stain (Invitrogen) was 
added. PCR product (1 µL) or DNA from a miniprep (5 µL) was diluted with 6X loading 
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buffer (0.25% Bromophenol blue, 30% glycerol in a 10 mM Tris, 1 mM EDTA, [pH 8.0] 
solution). The electrophoresis tank was filled with 1X TBE and diluted samples were loaded 
onto the agarose gel alongside a DNA molecular weight marker (Roche). Electrophoresis was 
conducted at 120 V for 30 min – 1 h after which, the DNA was visualised using a Safe Image 
blue-light transilluminator. 
2.5.8.8 DNA sequencing 
Mutations in plasmid DNA were validated by sequencing using the Big Dye® Terminator 
v3.1 Cycle Sequencing kit (Applied Biosystems). A 20 µL sequencing reaction was made up 
containing 7 µL 5X sequencing buffer, 1 µL BigDye® terminator v3.1 Ready Reaction mix 
and 10 µL water. The reaction was placed in a thermal cycler and the following cycling 
parameters were applied; 25 cycles of 95 
o
C for 10 sec, 55 
o
C for 5 sec and 60 
o
C for 4 min. 
Precipitation of the PCR product (20 µL) was conducted by adding 2 µL 3 M sodium acetate 
and 50 µL 100% ethanol and incubating for 5 min at room temperature. The sample was 
centrifuged at 13,000 rpm for 20 min after which, the supernatant was discarded. Ethanol 
(70%) (250 µL) was added and the sample was centrifuged at 13,000 rpm for 5 min at room 
temperature. The supernatant was discarded and the sample was air-dried for at least 10 min 
to remove any residual ethanol. Hi-Dye (10 µL) (Applied Biosystems) was added to the 
sample to dissolve the DNA pellet, which was then denatured for 5 min at 95 
o
C. The sample 
was consequently placed on ice to quench any re-duplexing of DNA. Sequencing was 
performed in a 96-well plate in a ABI Prism 337 Automated DNA Sequencer using the 
Applied Biosystems, 3130xl Genetic Analyser. Sequences were analysed using FinchTV 
version 1.4.0 (Geospiza Inc.) software programme. Once the mutations in the sequence had 
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been analysed, plasmid DNA was purified using the PureLink™ HiPure Plasmid Filter 
Maxiprep Kit (2.5.4.2). 
2.5.9 Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) 
2.5.9.1 RNA Extraction 
Cell were pelleted as before (2.3.1) except for the final wash in cold PBS, which was omitted, 
and stored at -80 
o
C until total RNA was extracted from cell lysates using the RNeasy Mini 
kit (Qiagen) according to the protocol provided. A maximum of 1 x 10
7
 cells were lysed in 
RNeasy Lysis Buffer (buffer RLT) provided by passing the lysate at least 5 times through a 
20-gauge needle (0.9 mm diameter) fitted to an RNase-free 1 mL syringe. One volume of 
70% ethanol was added to the homogenised lysate and mixed by pipetting. This was 
transferred to an RNeasy spin column and centrifuged for 15 sec at 8000 x g. RNeasy Wash 
buffer (buffer RW1) was added to the RNeasy spin column and centrifuged for 15 sec at 8000 
x g. Concentrated Wash Buffer (buffer RPE) (500 L) was added to the RNeasy spin column 
and centrifuged for 15 sec at 8000 x g. Buffer RPE (500 L) was added again to the RNeasy 
spin column and subjected to a longer centrifugation for 2 min at 8000 x g. RNA was eluted 
using RNase-free water (30-50 L), incubated with DNase (1 L) for 20 min at 37 oC and 
stored at -80 
o
C until further required.  
2.5.9.2 Determination of RNA purity and concentration 
The extracted RNA was run on 0.8% agarose gel to determine its integrity. When visualised 
using the Safe Image blue-light transilluminator, two clear bands should have been seen; these 
correspond to the 28S and 18S rRNA bands of intact RNA where the 28S band should be 
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approximately twice as intense as the 18S band (Figure 2.2). RNA concentration was 
determined by spectrophometric analysis where the absorbance at OD260nm m was measured 
and calculated against 1 OD260nm unit being an equivalent of 40 g of RNA in 1 mL. The 
RNA was considered to be pure and free from DNA and protein concentration if the ratio of 
OD260nm/280nm was more than 1.7. 
2.5.9.3 Production of genomic cDNA 
Total RNA (1 g) was converted into single-strand cDNA using the Reverse Transcriptase 
System (Promega). RNA from 2.5.9.1 was incubated for 10 min at 70 
o
C, centrifuged and 
placed on ice until further required.  The reverse transcription reaction was prepared as 
follows: 4 L MgCl2, 2 L 10X Reverse Transcriptase Buffer, 2 L dNTP mix (each dNTP at 
10 mM), 0.5 LRecombinant RNasin® Ribonuclease Inhibitor, 0.7 L AMV (reverse 
transcriptase), 1 L Random primers and 1 g RNA that had been prepared previously. The 
reaction was made up to a volume of 20 L with RNase-free water. The reaction was mixed, 
incubated for 10 min at room temperature to allow primer extension and then for a further 15 
min at 42 
o
C. To inactivate the reverse transcriptase and to degrade the RNA, the reaction was 
incubated for 5 min at 95 
o
C before incubating it on ice for 5 min. The resulting cDNA was 
used as a template for the PCR assay using primers for specific genes (Table 2.6). All primers 
for qRT-PCR were obtained from Invitrogen and designed to anneal at 60 
o
C and were at a 
stock concentration of 200 M.  
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2.5.9.4 Real-time PCR: SYBR® green detection 
The PCR was performed in the Applied Biosytem 7500 Fast Real-Time PCR System using 
Fast SYBR
®
 green as recommended by the manufacturer (Applied Biosystems). Fast SYBR
®
 
green containing SYBR Green I dye, (which binds to double-stranded DNA and allows its 
detection), AmpliTaq
® 
Fast DNA polymerase Ultra Pure (UP) (amplifies the target sequence), 
dNTPs, Uracil-DNA Glycosylase (UDG) (prevents the reamplification of carryover PCR 
products) and ROX™ dye (internal reference to which the reporter-dye signal can be 
normalised during data analysis) was supplied as a 2X concentration in an optimised buffer.  
Each reaction contained the following: 0.25 L Forward primer (200 nM), 0.25 L Reverse 
primer (200 nM), 5.5 L H2O, 10 L Fast SYBR
®
 green and 4 L cDNA (20 ng), to make the 
reaction volume up to 20 L. The reactions were performed in MicroAmp™ Fast Optical 96-
Well Reaction Plates (Applied Biosystems) according to the following thermal cycling 
conditions: 1 cycle of 95 
o
C for 20 sec (AmpliTaq
®
Fast DNA polymerase UP activation); 40 
cycles of 95 
o
C for 3 sec (denaturing) and 60 
o
C for 30 sec (annealing and extending). The 
PCR reactions were subjected to a heat dissociation protocol present in the Applied Biosytem 
7500 Fast Real-Time PCR System software.  
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Primer Name Sequence 
DDB2 for 
DDB2 rev 
5’-TCAAGGACAAACCCACCTTC-3’ 
5’-GTGACCACCATTCGGCTACT-3’ 
p21 for 
p21 rev 
5’-GACACCACTGGAGGGTGACT-3’ 
5’-GGCGGTTGGAGTGGTAGAAA-3’ 
MDM2 for 
MDM2 rev 
5’-ATGAAAGCCTGGCTCTGTGT-3’ 
5’-TCCTGATCCAACCAATCACCT-3’ 
Bax for 
Bax rev 
5’-TCTGACGGCAACTTCAACTG-3’ 
5’-CTCAGCCCATCTTCTTCCAG-3’ 
Actin for 
Actin rev 
5’-GTCTTCCCCTCCATCGTG-3’ 
5’-TCGCCCACATAGGAATCCTTC-3’ 
pcDNA3.1 for 
pcDNA3.1 rev 
5’-ACTCACTATAGGGAGACCCAAGC-3’ 
5’-GCAACTAGAAGGCACAGTCGAGG-3’ 
 
Table 2.6 Sequences of the primers used in this study 
‘For’ denotes forward primer and ‘rev’ denotes reverse primer.  
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CHAPTER 3 HNRNPUL-1 REPRESSES THE 
TRANSCRIPTIONAL ACTIVITY OF p53 
3.1 INTRODUCTION 
The DDR is of fundamental importance to preserve eukaryotic genome integrity and to 
maintain cell viability. In response to genotoxic stress, numerous key regulators function to 
initiate a cascade of protein recruitment that promotes DNA repair and cell cycle arrest. An 
important component of the DDR is the transcription factor p53, which is described as the 
‘guardian of the genome’ (Lane, 1992). Upon its activation in response to genotoxic stress, 
p53 prevents the propagation of damaged cells by inducing a number of possible cellular 
responses including cell cycle arrest, apoptosis or DNA repair (Vogelstein et al., 2000). One 
of the main mechanisms whereby p53 mediates cell cycle arrest is through the transactivation 
of the CKI, p21. CDKs control progression through the mammalian cell cycle and their 
activities, in turn, are regulated by CKIs (Sherr and Roberts, 1999). The small 165 amino acid 
protein p21 (also known as p21
WAF/Cip1
), inhibits cell cycle progression following DNA 
damage primarily through its ability to inhibit the kinase activity of CDK2 and CDK4. This, 
in turn inhibits the phosphorylation of the retinoblastoma protein, Rb leading to the 
inactivation of E2F1 activity in late G1 (Delavaine and La Thangue, 1999, Dimri et al., 1996). 
Consequently, E2F1-dependent transcription of genes that would normally promote 
proliferation is inhibited and growth arrest in G1 occurs (Dimri et al., 1996). There is also 
evidence to support a role for p21 in the inhibition of PCNA. Indeed, it has been shown that 
different domains of p21 are responsible for binding to and inhibiting different substrates; its 
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amino terminal domain is responsible for inhibiting the kinase activity of the CDKs and its 
carboxy terminal domain inhibits PCNA (Chen et al., 1995). The ability of p21 to bind to 
PCNA makes it unique among the CKIs (Cayrol et al., 1998).  
Since it has a central role in coordinating the DDR, p53 is regulated by numerous mechanisms 
including post-translational modifications such as phosphorylation, acetylation, ubiquitylation 
and methylation (Lavin and Guevan, 2006). Under normal conditions (i.e. in unstressed cells), 
p53 is regulated and kept at low levels by the action of MDM2. As the main E3 ubiquitin 
ligase for p53, MDM2 targets p53 for proteosomal degradation (Haupt et al., 1997). It is not 
only post-translational modifications that are in place to regulate p53; many co-factors exist 
that interact with p53 to stimulate or inhibit its activity and, consequently, affects promoter 
specificity (Kruse and Gu, 2009a). Co-factors can act directly or indirectly to regulate p53 
activity and many are involved in influencing the promoter-specific activity of p53 to result in 
different p53-dependent cellular outcomes (Vousden and Prives, 2009). Some examples of 
p53 co-factors include Hzf, p300/CBP and members of the ASPP family of proteins (Das et 
al., 2007, Lill et al., 1997, Samuels-Lev et al., 2001). 
The cellular protein, hnRNPUL-1, was first identified as an adenovirus 5 (Ad 5) E1B-55K 
interacting protein and was found to share high sequence homology with the hnRNPU/SAF-A 
protein (Gabler et al., 1998). In keeping with its membership of the hnRNP family, 
hnRNPUL-1 is involved in pre-mRNA processing, nucleocytoplasmic mRNA transport and 
mRNA localisation, translation and stability (Krecic and Swanson, 1999). However, its 
functions are not limited to mRNA metabolism; for example there is evidence to suggest that 
hnRNPUL-1 plays an integral part in the ATR-dependent signalling pathway in response to 
cellular stress and more recently, in DNA-end resection (Blackford et al., 2008, Polo et al., 
Chapter 3 
123 
 
2012). In addition, the involvement of hnRNPUL-1 in transcriptional regulation has 
previously been reported with the finding that it inhibits basal transcription in a manner that is 
similar to hnRNPU/SAF-A (Kzhyshkowska et al., 2003). Notably, an interaction between 
hnRNPU/SAF-A and the transcriptional co-factor, p300 has been reported previously, which 
further suggests a role of the hnRNP family and transcriptional regulation (Martens et al., 
2002). The link between the hnRNP family and the regulation of transcription can be further 
studied using p53, since the latter is one of the most widely-studied transcription factors. 
Indeed, it has already been established that another member of the hnRNP family, hnRNPK, 
acts as a transcriptional co-activator for p53 in response to DNA damage (Moumen et al., 
2005). Previous work from our laboratory has shown that hnRNPUL-1 can bind directly to 
p53 via the C-terminal region of p53 and over-expression studies revealed that increasing 
exogenous levels of hnRNPUL-1 resulted in the repression of p53-dependent transcriptional 
activity, although the exact mechanism by which this occurs remains unknown (Barral et al., 
2005). These data suggest that there is a relationship between transcriptional regulation and 
hnRNPUL-1. 
This study aims to:  
 Confirm, using an siRNA approach, whether hnRNPUL-1 is acting to repress p53 
transcriptional activity 
 Ascertain whether hnRNPUL-1 affects p53 target genes and consequent responses that 
are mediated by p53 transcriptional activation  
 Determine the site of interaction on hnRNPUL-1for p53 
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3.2 RESULTS 
3.2.1 hnRNPUL-1 interacts with p53 in vivo before and after DNA damage 
To confirm that hnRNPUL-1 does indeed associate with p53, co-immunoprecipitation assays 
were conducted. These were also undertaken to examine whether the interaction between the 
two proteins would be affected following the induction of DNA damage. Endogenous 
hnRNPUL-1 was, therefore, immunoprecipitated from U2OS cells before and after treatment 
with 10 Gy IR and 50 J m
-2
 UV. Immunoblotting was used to detect any association between 
hnRNPUL-1 and p53 in vivo. The results from the co-immunoprecipitation assay revealed 
that p53 was found in hnRNPUL-1 immunocomplexes before and after both types of damage 
(Figure 3.1A). A reciprocal co-immunoprecipitation experiment was performed to confirm 
these results, where endogenous p53 was immunoprecipitated from similarly-treated U2OS 
cells and immunoblotting was used to detect the amount of complexed hnRNPUL-1. The 
results in Figure 3.1B indicate that hnRNPUL-1 associated with p53 before and after 
treatment with IR and UV. These data indicate that hnRNPUL-1 and p53 associate with each 
other before and after DNA damage. 
 
3.2.2 Depletion of hnRNPUL-1 increases the transcriptional activity of p53  
To investigate further the relationship between hnRNPUL-1 and p53 and because of previous 
over-expression work implicating hnRNPUL-1 in the regulation of the transcriptional activity 
of p53 (Barral et al., 2005), the effect of hnRNPUL-1 depletion on p53 transcriptional activity  
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Figure 3.1 hnRNPUL-1 and p53 associate before and after DNA damage in vivo 
U2OS cells were mock-treated or treated with 10 Gy IR or 50 J m
-2
 UV as indicated and 
harvested 1 h following irradiation. (A) hnRNPUL-1 was immunoprecipitated from whole 
cell extracts and western blotting was used to detect co-immunoprecipitating protein, p53; (B) 
Reciprocal co-immunoprecipitation experiment where p53 was immunoprecipitated and 
western blotting used to detect complexed hnRNPUL-1. Immunoprecipitates performed using 
no antibodies were used as controls. IP and IB denote immunoprecipitation and immunoblot 
respectively. 
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Figure 3.2 hnRNPUL-1 negatively regulates p53 transcriptional activity 
(A) H1299 (p53 null) cells were transfected with siRNA, 150 ng p53 luciferase reporter 
construct, 50 ng Renilla and 5 ng WT p53 as indicated. Luciferase activity was determined 
after 24 h and normalised to Renilla activity. Standard deviations from three independent 
experiments are presented, with P-values depicting significant differences (*=P<0.05 
significant, **=P<0.01 highly significant, ***=P<0.001 very highly significant); (B) H1299 
cells were transfected as before and whole cell lysates were prepared, separated by SDS-
PAGE and immunoblotted with antibodies against hnRNPUL-1 and p53. An antibody against 
β-actin was used as a loading control. 
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Figure 3.3 hnRNPUL-1-mediated effects are reversed by siRNA-resistant hnRNPUL-1 
expression 
(A) H1299 cells were transfected as before (Figure 3.2) with siRNA-resistant hnRNPUL-1 as 
indicated. Luciferase activity was determined and normalised to Renilla activity. Standard 
deviations from three independent experiments are presented, with P-values depicting 
significant differences (*=P<0.05 significant, **=P<0.01 highly significant, ***=P<0.001 
very highly significant); (B) H1299 cells were transfected as before and whole cell lysates 
were prepared, separated by SDS-PAGE and immunoblotted with antibodies against 
hnRNPUL-1 and p53. An antibody against β-actin was used as a loading control. An antibody 
against HA was used to assess the expression of siRNA-resistant hnRNPUL-1. 
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was examined using a luciferase reporter assay. The p53-null H1299 cell line was transfected 
with control or hnRNPUL-1 siRNA, WT p53 as indicated and a reporter construct containing 
p53 responsive elements upstream of the luciferase gene. Following transfection of WT p53 
into the control siRNA-treated cells, a 10-fold increase in luciferase activity was observed 
compared to cells without p53 (Figure 3.2A). This indicates that binding of p53 to the p53 
binding site on the promoter construct resulted in the transcription of the luciferase gene and 
consequent luminescence. The difference between the relative luciferase units was reflected in 
the very highly significant P-value, which indicated that the response was p53-dependent. 
Interestingly, following transfection of p53 in cells depleted of hnRNPUL-1, the p53-
dependent luciferase activity increased 50-fold compared to cells containing endogenous 
hnRNPUL-1, which demonstrated that hnRNPUL-1 negatively regulates p53-dependent 
transcription (Figure 3.2A). Again, a very highly significant P-value revealed the difference 
between the sample transfected with WT p53 containing endogenous hNRNPUL-1 and the 
sample transfected with WT p53 that was depleted of hnRNPUL-1.  
The efficiency of the depletion of hnRNPUL-1 by siRNA was confirmed at the protein level 
by Western blotting (Figure 3.2B). Figure 3.2B also confirmed that the increase in p53 
transcriptional activity after hnPNPUL-1 depletion was not due to an increase in p53 protein 
levels: indeed, there was reproducibly less p53 in samples treated with hnRNPUL-1 siRNA 
compared with samples treated with control siRNA. Reasons for this are not clear at the 
moment. 
To confirm that the results obtained using the hnRNPUL-1 siRNA were not due to ‘off target’ 
effects, an expression vector encoding WT hnRNPUL-1 was designed with 3 point mutations 
within the siRNA-targeting regions to render it resistant to siRNA (2.5.8.1). Luciferase assays 
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were then used to examine whether the expression of siRNA-resistant hnRNPUL-1 could 
restore the phenotype observed in hnRNPUL-1-depleted H1299 cells i.e. whether the increase 
in p53 transcriptional activity observed in Figure 3.2A would be diminished upon transfection 
of siRNA resistant hnRNPUL-1. As expected, expression of siRNA-resistant hnRNPUL-1 
decreased p53 transcriptional activity appreciably, though not entirely, indicating that the 
effect is due to depletion of hnRNPUL-1 (Figure 3.3A). The lack of total suppression may be 
due to an incomplete transfection of siRNA-resistant hnRNPUL-1. The transfection of 
siRNA-resistant hnRNPUL-1 with control or hnRNPUL-1 siRNA and WT p53 was seen at 
the protein level in Figure 3.3B. The expression of HA-tagged siRNA resistant hnRNPUL-1 
was observed using an antibody against HA (Figure 3.3B). Taken together, these data confirm 
that hnRNPUL-1 is acting to negatively regulate p53 transcriptional activity.  
3.2.3 p53-dependent transcription of specific target genes increases after 
hnRNPUL-1 depletion 
Since it was observed that hnRNPUL-1 affected the transcriptional activity of p53, the effect 
of hnRNPUL-1 depletion on specific p53 transcriptional targets was assessed. One major 
transcriptional target of p53 is the CKI, p21, which plays an important role in p53-mediated 
G1 arrest (Deng et al., 1995, El-Deiry et al., 1993). Using the p53 specific response element 
in the p21 promoter in the reporter construct, luciferase assays were conducted again to 
examine whether hnRNPUL-1 affects p53 transactivation of p21. H1299 cells were 
transfected with control or hnRNPUL-1 siRNA, WT p53 and a reporter construct containing 
the gene coding for luciferase under the control of the p53-responsive p21 promoter. 
Luciferase expression was strongly induced in cells that had been transfected with hnRNPUL-
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1 siRNA and WT p53 compared to cells treated with control siRNA and WT p53, therefore 
indicating that hnRNPUL-1 negatively regulates the p53-mediated transactivation of p21 
(Figure 3.4A). This was reflected in the P-value depicting a highly significant difference in 
relative luciferase units in samples containing endogenous hnRNPUL-1 compared to samples 
depleted of hnRNPUL-1 (Figure 3.4A). Surprisingly, Figure 3.4A also showed that when 
hnRNPUL-1 was depleted, there was a small increase in p21 transactivation in the absence of 
p53.  
Evidence of hnRNPUL-1 depletion by siRNA was seen by Western blotting in Figure 3.4B. 
Again, it is of note that p53 protein levels are slightly reduced in samples treated with 
hnRNPUL-1 siRNA despite the very highly significant increase in p53-dependent 
transactivation of p21 in these samples compared to samples containing endogenous 
hnRNPUL-1 (Figure 3.4B). 
A similar experiment was conducted using a reporter construct containing the luciferase gene 
under the control of the p53-responsive MDM2 promoter. Notably, in H1299 cells depleted of 
hnRNPUL-1 and transfected with WT p53, there was an increase in luciferase expression 
compared to cells treated with control siRNA and transfected with WT p53 (Figure 3.5A). 
Again, the P-value represents the highly significant increase in relative luciferase units in 
samples depleted of hnRNPUL-1 compared to those containing endogenouse hnRNPUL-1 
(Figure 3.5A).  
The depletion of hnRNPUL-1 at the protein level was examined by Western blotting in Figure 
3.5B. This also showed that the p53 protein levels were reduced in samples depleted of 
hnRNPUL-1, confirming that the increase in p53-dependent transactivation of MDM2 was  
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Figure 3.4 Depletion of hnRNPUL-1 results in an increase in p53-dependent 
transactivation of p21 
(A) H1299 cells were transfected with siRNA, 150 ng p21 promoter-specific reporter 
construct, 50 ng Renilla  and 5 ng WT p53 as indicated. Luciferase activity was determined 
after 24 h and normalised to Renilla activity. Standard deviations from three independent 
experiments are presented, with P-values depicting significant differences (*=P<0.05 
significant, **=P<0.01 highly significant, ***=P<0.001 very highly significant); (B) H1299 
cells were transfected as before and whole cell lysates were prepared, separated by SDS-
PAGE and immunoblotted with antibodies against hnRNPUL-1 and p53. An antibody against 
β-actin was used as a loading control. 
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Figure 3.5 Depletion of hnRNPUL-1 results in an increase in p53-dependent 
transactivation of MDM2 
(A) H1299 cells were transfected with siRNA, 150 ng MDM2 promoter-specific reporter 
construct, 50 ng Renilla and 5 ng WT p53 as indicated. Luciferase activity was determined 
after 24 h and normalised to Renilla activity. Standard deviations from three independent 
experiments are presented, with P-values depicting significant differences (*=P<0.05 
significant, **=P<0.01 highly significant, ***=P<0.001 very highly significant); (B) H1299 
cells were transfected as before and whole cell lysates were prepared, separated by SDS-
PAGE and immunoblotted with antibodies against hnRNPUL-1 and p53. An antibody against 
β-actin was used as a loading control. 
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not due to an increase in p53 protein levels. These data collectively indicate that the depletion 
of hnRNPUL-1 results in the activation of p53-dependent transactivation of p21 and MDM2. 
It is also possible that the down-regulation of hnRNPUL-1 may be mediating the 
transactivation of p21 in a p53-independent manner and in this regard, may be functioning to 
affect other proteins that are involved in the activation of p21. It is of note that the luciferase 
experiments were all conducted without the presence of a DNA damaging agent, therefore 
these results indicate that hnRNPUL-1 affects p53 transcriptional activity before DNA 
damage. 
3.2.4 hnRNPUL-1 affects p53-dependent target genes in response to DNA damage 
Since p53-dependent transactivation of target genes in response to damage is essential for 
cellular function and viability and that hnRNPUL-1 depletion appears to be affecting specific 
p53 transcriptional targets, the mechanism behind the observations described above was 
examined in a more physiological context and after genotoxic stress. It is known that p53 
regulates the transcription of genes from different pathways (Helton and Chen, 2007). 
Therefore, the effect of hnRNPUL-1 depletion on a set of p53 target genes present in a range 
of pathways was assessed. To further address the role of hnRNPUL-1 in mediating the 
activation of p21 and MDM2, these two genes were included in the panel of p53 target genes 
that were used in the assay. In addition, DDB2 was included as a p53 target gene in qRT-PCR 
since it is involved in p53-mediated DNA repair pathways (Tan and Chu, 2002). Finally, the 
Bcl-2 family member, Bax, was chosen on the basis of its p53-dependent pro-apoptotic 
activity in response to DNA damage (Helton and Chen, 2007).  Quantitative RT-PCR (qRT-
PCR) was conducted on samples derived from U2OS cells that had been depleted of  
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Figure 3.6 The depletion of hnRNPUL-1 affects mRNA levels of p53 target genes before 
and after IR 
(A) U2OS cells were transfected with control or hnRNPUL-1 siRNA and treated with 2 Gy 
IR. qRT-PCR was performed in cDNA with primers recognising sequences within the 
mRNAs for p21,DDB2, MDM2 and Bax. CT values were normalised to β-actin. The results 
are presented as relative mRNA levels of each p53 target gene compared to control siRNA-
treated and unirradiated cells at each time point and represent  three independent experiments; 
(B) Whole cell extracts were prepared from U2OS cells treated in the same way, separated by 
SDS-PAGE and immunoblotted to assess hnRNPUL-1 depletion by siRNA. An antibody 
against β-actin was used as a loading control. 
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Figure 3.7 The depletion of hnRNPUL-1 affects protein expression levels of p53 target 
genes before and after IR 
U2OS cells were transfected with control or hnRNPUL-1 siRNA and mock-treated or treated 
with 5 Gy IR. Whole cell lysates were prepared, separated by SDS-PAGE and immunoblotted 
with antibodies against p53 and its target genes, p21 and MDM2. An antibody against β-actin 
was used as a loading control. The Western blot is a representation of three individual 
experiments. 
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hnRNPUL-1 using siRNA and exposed to 2 Gy IR. The results were presented as relative 
mRNA levels of different p53 target genes at different times following irradiation compared 
to control siRNA-treated and unirradiated cells. 
Interestingly, data from the qRT-PCR experiment showed that hnRNPUL-1 depletion 
increased IR induction of the mRNA for p21 (Figure 3.6A). This is consistent with the results 
shown in Figure 3.4A where luciferase expression from the p21 promoter was strongly 
induced in cells depleted of hnRNPUL-1. There was also an increase in fold change of mRNA 
for the p53 transcriptional target, DDB2, in cells treated with hnRNPUL-1 siRNA and IR 
(Figure 3.6A). Surprisingly, no induction of MDM2 mRNA levels were seen following 
hnRNPUL-1 depletion and damage with IR (Figure 3.6A) despite the increase in p53-
dependent transactivation of MDM2 depicted in the luciferase data (Figure 3.5A). In addition, 
the down-regulation of hnRNPUL-1 did not cause an induction in the fold change in mRNA 
levels of Bax after damage and, in fact, resulted in the decrease of these levels (Figure 3.6A). 
The depletion of hnRNPUL at the protein level was confirmed by Western blotting in Figure 
3.6B at each timepoint following IR.  
To complement these results, protein expression levels of p53 and p53 target genes were 
examined in U2OS cells depleted of hnRNPUL-1 using siRNA and treated with 5 Gy IR. 
Western blot analysis was used to determine the protein expression levels of p53, MDM2 and 
p21. Significantly, following DNA damage by IR, p21 protein levels were increased in cells 
depleted of hnRNPUL-1 compared to cells containing endogenous levels of hnRNPUL-1 
(Figure 3.7). In addition, even before damage with IR, the protein expression of p21 was 
higher in cells depleted of hnRNPUL-1 compared to cells treated with control siRNA (Figure 
3.7). This observation also reflects the appreciable increase in fold change of p21 mRNA 
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levels observed after hnRNPUL-1 depletion and before DNA damage (Figure 3.6A). Notably, 
the down-regulation of hnRNPUL-1 appeared to cause a decrease in MDM2 protein levels 
following DNA damage (Figure 3.7). Although this is contrary to the in vitro luciferase data 
(Figure 3.5A) it does correlate with the lack of induction of this gene at the mRNA level in 
cells lacking hnRNPUL-1 (Figure 3.6A). In addition, hnRNPUL-1 depletion appeared not to 
affect IR-induced p53 stabilisation or indeed, phosphorylation on S15 of p53 following DNA 
damage (Figure 3.7). Taken together, these data suggest that hnRNPUL-1 contributes to the 
regulation of p53-mediated transcription of a subset of genes.   
3.2.5 Cells depleted of hnRNPUL-1 exhibit an elevated G1/S checkpoint arrest  
The depletion of hnRNPUL-1 results in the induction at both the mRNA and protein level of 
p21, which is the main mediator of p53-induced G1 arrest. Therefore, to address the possible 
role of hnRNPUL-1 in regulating cell cycle checkpoints, U2OS cells were transfected with 
control or hnRNPUL-1 siRNA, subjected to genotoxic stress by IR and analysed by flow 
cytometry. Notably, the down-regulation of hnRNPUL-1 resulted in an increase in the 
percentage of cells in G1 compared to cells containing endogenous hnRNPUL-1 (Figure 3.8). 
To confirm this cell cycle effect, the results from three independent experiments were collated 
and are presented using bar chart analysis. The data clearly show that the down-regulation of 
hnRNPUL-1 caused an increase in the percentage of cells that accumulated in G1 (Figure 
3.9A). The P-values represent significant differences in the percentage of G1 cells in samples 
treated with hnRNPUL-1 siRNA compared with those treated with control siRNA at 0, 1, 2, 4  
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Figure 3.9 Depletion of hnRNPUL-1 results in an elevated G1/S checkpoint arrest before 
and after IR 
U2OS cells treated with control or hnRNPUL-1 siRNA and 5 Gy IR were analysed by flow 
cytometry using PI dye to quantify DNA content during the cell cycle. (A) The percentage of 
cells accumulating in G1 is shown for irradiated cells following hnRNPUL-1 depletion. The 
plots represent the mean of four independent experiments with P-values depicting significant 
differences between control siRNA- and hnRNPUL-1 siRNA-treated samples (*=P<0.05 
significant, **=P<0.01 highly significant, ***=P<0.001 very highly significant); (B) Whole 
cell extracts were prepared from U2OS cells in the same experiment, separated by SDS-
PAGE and immunoblotted to assess hnRNPUL-1 depletion by siRNA. An antibody against β-
actin was used as a loading control. 
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and 8 hours after treatment with IR (Figure 3.9A). The P-value at 24 h after IR reflects the 
highly significant difference between cells with reduced levels and those with endogenous 
levels of hnRNPUL-1 (Figure 3.9A). Figure 3.9B confirms the depletion of hnRNPUL-1 at 
the protein level by Western blotting. Taken together these data demonstrate that the depletion 
of hnRNPU-1 leads to an elevated G1/S checkpoint arrest compared to cells treated with 
control siRNA and may indicate that hnRNPUL-1 plays a role in p53-mediated cell cycle 
regulation, probably through its effect on p21 expression. 
3.2.6 The interaction site on hnRNPUL-1 for p53 encompasses the BBS domain 
The domain required on p53 for the interaction with hnRNPUL-1 has been shown to reside 
within the C-terminal region of p53 (Barral et al., 2005). However, the interaction site on 
hnRNPUL-1 required for this association has not been mapped with any precision. Given that 
hnRNPUL-1 and p53 have been found to interact before and after DNA damage and that 
hnRNPUL-1 appears to negatively regulate p53 transcriptional activity, the domains required 
for the interaction on hnRNPUL-1 were mapped using various fragments encompassing the 
open reading frame of hnRNPUL-1 (Figure 3.10A).The hnRNPUL-1 ‘splice variant’ 
commences at exon 2 and from this point it is identical to WT hnRNPUL-1 (Figure 3.10A) 
(Rusch, 2003). The hnRNPUL-1 fragments, together with full length hnRNPUL2, were in 
vitro translated, labelled with [
35
S] methionine and incubated with GST-p53 or GST alone in 
a pull-down assay (Figure 3.10B). No binding of the hnRNPUL-1 fragments to GST was 
seen, whereas p53 bound to full length hnRNPUL-1, and to the C-terminal and central regions 
of hnRNPUL-1 (Figure 3.10B). Interestingly, p53 was shown to bind to full-length 
hnRNPUL-2, which is structurally and functionally similar to hnRNPUL-1 but does not 
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possess a PP region at its C-terminus (Figure 3.10A). This is the first demonstration that 
hnRNPUL-2 binds to p53 and also indicates that the PP region is not required for this 
interaction (Figure 3.10B). Virtually no binding of p53 to the N-terminal region of 
hnRNPUL-1 was observed (Figure 3.10B). This is consistent with the minimal binding 
observed between GST-p53 and the N-terminal region of hnRNPUL-1 reported in Barral et 
al., (2005). The fragment corresponding to the splice variant protein was also found to 
interact strongly with p53 (Figure 3.10B). The splice variant does not contain part of the N-
terminal sequence of WT hnRNPUL-1 and the data is consistent with the fact that the N-
terminal region of hnRNPUL-1 is not required by p53 to bind to this protein (Figure 3.10A) 
(Barral et al., 2005). The deletion of the central BRD7-binding site (BBS) region of 
hnRNPUL-1 resulted a significantly decreased binding of p53 to hnRNPUL-1 (Figure 3.10B).  
To gain further insight into the nature of this interaction, hnRNPUL-1 deletion mutants with 
differing deletion of the BBS region were examined for their ability to bind to p53. Notably, 
the binding of p53 decreased with increasing deletion of the BBS region of hnRNPUL-1, 
indicating that it is necessary for the interaction between p53 and hnRNPUL-1 (Figure 
3.10B).  
To confirm that this region of hnRNPUL-1 does interact with p53, GST-fused p53 and GST 
alone were incubated with the RGG-BBS domain of hnRNPUL-1 that had been in vitro 
translated and labelled with [
35
S] methionine (Figure 3.11A). GST-fused p53 was also 
incubated with [
35
S] methionine-labelled hnRNPUL-1 and [
35
S] methionine-labelled 
hnRNPUL-2 as controls and again as a confirmation that p53 does associate with the full 
length proteins (Figure 3.11A). The pull-down assay showed strong binding between p53 and 
the region corresponding to the BBR-RGG domain of hnRNPUL-1 (Figure 3.11A). A  
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Figure 3.10 p53 requires the BBS domain of hnRNPUL-1 for binding 
(A) Schematic of hnRNPUL-1 and the different [
35
S] methionine-labelled fragments covering 
the open reading frame of hnRNPUL-1; (B) [
35
S] methionine-labelled fragments were in vitro 
translated and incubated with GST-p53 or GST alone as a control. Δ denotes deleted 
sequences; UL-1 and Ul-2 denote full-length hnRNPUL-1 and hnRNPUL-2 respectively; WT, 
Nt, Ct and M denote wildtype, N-terminal, C-terminal and middle fragments respectively. 
UL-1 ΔBBS2a and 2b are different DNA preparations of the same construct. Input represents 
5% of the radiolabeled protein or polypeptide used for the pull down assay. 
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Figure 3.11 p53 binds to the BBS region of hnRNPUL-1 
(A) GST pull-down using the indicated [
35
S] methionine-labelled hnRNPUL-1, hnRNPUL-2 
and RGG-BBS and GST-p53 or GST alone as a control; (B) Reciprocal pull-down using the 
indicated [
35
S] methionine-labelled p53 and GST-BBS-RGG or GST alone as a control. Input 
represents 5% of the radiolabeled protein or polypeptide used for the pull down assay. 
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reciprocal pull-down assay was performed, where GST-BBS-RGG and GST alone were 
incubated with [
35
S] methionine-labelled p53 (Figure 3.11B). This verified the association of 
the BBS-RGG domain of hnRNPUL-1 and p53 (Figure 3.11B). An interaction between the 
BBS-RGG domain and NBS1 was used as a control as reported by Polo et al. (2012).  
3.3 DISCUSSION 
p53 is a transcription factor that plays a major role in the DNA damage repair pathways and 
coordinates the cellular response to a range of genotoxic stresses. Many co-factors exist to 
regulate p53 activity during both normal stress-free conditions and following cellular stress, 
including those that influence p53-mediated cellular outcomes such as Hzf, which enhances 
p53 transactivation of cell cycle arrest genes, and ASPP1 and ASPP2 that promote p53 
binding to promoters of pro-apoptotic genes (Das et al., 2007, Samuels-Lev et al., 2001). In 
addition to its role in mRNA metabolism, the hnRNP family member, hnRNPUL-1, has been 
shown to be involved in regulating p53 transcriptional activity following over-expression 
(Barral et al., 2005). The data presented here confirm that hnRNPUL-1 functions as a 
transcriptional co-factor for p53 and is of particular importance in regulating p21 levels and, 
subsequently, of cell cycle arrest. 
Consistent with previous GST pull-down and co-immunoprecipitation assays, studies here 
confirm that hnRNPUL-1 and p53 interact (Figure 3.1). This interaction could be seen before 
and after damage with two types of genotoxic stress; IR and UV. This suggests that at least a 
certain proportion of the cellular hnRNPUL-1 and p53 exists in a protein complex and that 
this complex is present before and after DNA damage. Presumably the reduction in the 
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amount of binding protein co-immunoprecipitated in both cases is due to the marked increase 
in p53 following DNA damage and the consequent ‘dilution’ of the complex. 
Previous studies in which hnRNPUL-1 was over-expressed in human tumour cells had 
indicated that it could act as a repressor of p53 activity (Barral et al., 2005). To confirm and 
to expand on these observations, an alternative approach was adopted here based on the 
reduction of hnRNPUL-1 levels using siRNA. Initially, luciferase reporter assays were 
performed in cells depleted of hnRNPUL-1. The data established that p53 transcriptional 
activity was enhanced when hnRNPUL-1 was down-regulated using siRNA (Figure 3.2). The 
effect on the promoters of specific p53 transcriptional targets, p21 and MDM2, was also 
examined using luciferase assays and these results showed that p53-mediated transcription of 
these genes was greatly increased upon hnRNPUL-1 depletion (Figures 3.4A and 3.5A). The 
findings provide significant evidence that hnRNPUL-1 may be acting to negatively regulate 
the transcriptional activity of p53.  
A previous study has shown that hnRNPUL-1 interacts with p53 and requires C-terminal 
sequences of p53 to do so (Barral et al., 2005). The C-terminal region of p53 is known as the 
regulatory domain and is the site of many post-translational modifications (Appella and 
Anderson, 2001). Many modifications at the C-terminus affect other regulatory events such as 
co-factor recruitment and the mediation of promoter-specific activity (Kruse and Gu, 2009a). 
In particular, 6 C-terminal lysine sites present on p53 are subject to modification by 
phosphorylation, ubiquitylation, methylation, sumoylation, neddylation and acetylation 
(Brooks and Gu, 2003). It is conceivable that the binding of hnRNPUL-1 may mask some of 
the modification sites on p53, therefore, affecting the level of post-translational modification 
that occurs on this tumour suppressor. It has been reported that, by mutating these lysine 
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residues to arginine, p53-dependent gene transcription was impaired (Feng et al., 2005). 
Therefore, it is possible that masking of these sites at the C-terminus of p53 consequently 
affects its ability to transcriptionally activate target genes. The fact that hnRNPUL-1 and p53 
have been shown to interact provides further evidence for the inhibition of p53 transcriptional 
activation in this way. Interestingly, the increase in p53 transcriptional activity when 
hnRNPUL-1 levels are reduced occurs in the absence of DNA damage, therefore suggesting 
that hnRNPUL-1 could be functioning to repress p53 transcriptional activity before genotoxic 
stress. Most noticeably, knockdown of hnRNPUL-1 expression results in a marked increase in 
p21 levels even in the absence of cellular stress (Figure 3.7). 
There is evidence to suggest that p53 binds to DNA in unstressed cells and that it is even 
present at promoters of its target genes under normal homeostasis (Kaeser and Iggo, 2002). It 
is possible that hnRNPUL-1 and p53 may interact before assembly onto transcriptional 
promoters. This is supported by the observation that both proteins can be co-
immunoprecipitated from cells that have been treated to genotoxic stresses and those that 
have not (Figure 3.1). However, further research would be needed to examine whether 
hnRNPUL-1 is recruited to the promoters of p53 target genes and whether the depletion of 
hnRNPUL-1 affects p53 recruitment to these promoters. Such a finding would be determined 
using Chromatin Immunoprecipitation (ChIP) analysis. 
Using qRT-PCR, the effect of depletion of hnRNPUL-1 on a number of p53 target genes was 
assessed. Although p21 mRNA levels were appreciably increased, it is notable that Bax was 
not increased following hnRNPUL-1 depletion (Figure 3.6). Bax is a pro-apoptotic gene that 
is generally found to be upregulated in response to DNA damage in a p53-dependent manner. 
If hnRNPUL-1 is acting generally to negatively regulate p53-dependent transactivation it 
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would be expected that the levels of this gene would be increased following the down-
regulation of hnRNPUL-1. However, there is evidence to suggest that specific mechanisms 
exist that activate different subsets of p53 target genes after genotoxic stress (Kruse and Gu, 
2009a). For example, the activation of the subset of genes involved in apoptosis requires the 
recruitment of co-activators of p53 and modifications on p53 that are different to those 
required for the activation of the subset of genes involved in cell cycle regulation (Vousden 
and Prives, 2009). The acetylation of K120 in the DBD of p53 is indispensible for p53-
mediated transcription of its apoptotic genes; however, the transcription of non apoptotic 
targets remained unaffected when this site was mutated (Sykes et al., 2006). Indeed, no 
evidence of apoptosis was seen in any cells depleted of hnRNPUL1.  
Redundancy exists amongst the lysine residues that are acetylated to enable the activation of 
p21 since it takes the simultaneous mutation of 8 lysine sites within p53 to inhibit p21 
activation (Tang et al., 2008). In contrast, more specific modification of p53 is required for 
the activation of pro-apoptotic genes. This emphasises the fact that the requirements for the 
full activation of apoptotic genes are more stringent, which is unsurprising since the apoptotic 
response is irreversible (Kruse and Gu, 2009a). In this manner, the lack of increase in Bax 
mRNA levels following hnRNPUL-1 depletion could possibly be because hnRNPUL-1 does 
not affect the more specific modifications on p53 that are needed for pro-apoptotic gene 
activation. 
It is also possible that hnRNPUL-1 affects other co-factors that regulate p53 activity and alter 
their activity in a gene-specific manner. For example, a transcriptional target of p53, Hzf, 
binds to p53 after its induction and is preferentially recruited to promoters of cell cycle arrest 
genes (Das et al., 2007). The opposite could also occur; co-factors exist to cause the 
Chapter 3 
148 
 
activation of the expression of pro-apoptotic genes alongside the inhibition of cell cycle 
genes. Co-factors of p53 belonging to the latter category include ASPP1 and 2, which aid p53 
binding to promoters of apoptotic genes such as Bax, PUMA and NOXA (Samuels-Lev et al., 
2001). Therefore, hnRNPUL-1 may repress or activate particular co-factors of p53 and in this 
regard, hnRNPUL-1 may be acting to interfere with the recruitment of such proteins and thus 
affect preferential transactivation by p53. Further experiments will have to be conducted to 
determine whether hnRNPUL-1 affects the expression of other p53-regulated genes and to 
identify any patterns that emerge indicating the transcriptional activation of a subset of p53 
target genes. 
Promoters of cell cycle genes such as p21 possess high levels of bound RNA polymerase II 
before activation whereas lower levels exist at the promoters of pro-apoptotic targets 
(Espinosa et al., 2003). This phenomenon has been further supported by the examination of 
core promoter structures of p53 targets, which are required to direct the initiation of 
transcription (Morachis et al., 2010). It was found that, while the pro-apoptotic Fas promoter 
undergoes slow initiation component formation, the p21 core promoter rapidly assembles 
these initiation components (Morachis et al., 2010). Evidence points to the fact that promoters 
of cell cycle genes are highly responsive and it is more than likely that mechanisms exist to 
exercise some caution in activating these genes. It can be hypothesised that the inhibition of 
p53 transcriptional activity by hnRNPUL-1 is one factor contributing to repression of the 
activation of certain p53 target genes, in particular p21, and perhaps others involved in cell 
cycle regulation. 
A similar argument could apply to the effects on MDM2. Although loss of hnRNPUL-1 
results in hyperactivation of the p53-dependent DDR, the expression of MDM2 is reduced 
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compared to control cells (Figure 3.7). Taken at face value, this observation would suggest 
that, although hnRNPUL-1 functions to negatively regulate the p53 response, this does not 
apply to all known p53 target genes. However, MDM2 is known to be a negative regulator of 
p53 through its ability to ubiquitylate p53 and target it for proteolytic destruction by the 
proteasome (Haupt et al., 1997). Therefore, if the function of hnRNPUL-1 is to repress p53 
function, it would seem logical for hnRNPUL-1 to potentiate the expression of negative 
regulators, such as MDM2. The defective induction of MDM2 in cells devoid of hnRNPUL-1 
following exposure to DNA damaging agents would lend support to this proposition. 
Another possibility may be that since the phosphorylation of S15 of p53 remains unaffected 
by the depletion of hnRNPUL-1, this implies that hnRNPUL-1 does not affect the degradation 
of p53. It is known that phosphorylation at the N-terminal region of p53 causes the inhibition 
of the p53-MDM2 interaction (Kruse and Gu, 2009a). Therefore, if the absence of hnRNPUL-
1 results in unchanged levels of S15 phosphorylation of p53 the inhibition of the interaction 
between p53 and MDM2 would remain and MDM2 protein levels would be reduced. 
Phosphorylation of T18 of p53 is also known to be important in the regulation of the p53-
MDM2 interaction but unfortunately this has not been examined here (Schon et al., 2002). 
The discrepancy between the MDM2 in vitro luciferase data and the in vivo qRT-PCR and 
Western blot analysis may be explained by the fact that the luciferase assay is an artificial 
system, acting as a surrogate for measuring promoter activity. Therefore, this system may not 
reflect the true interactions that exist and may not fully recapitulate mRNA regulation in vivo. 
The mRNA levels and proteins levels of MDM2 following hnRNPUL-1 depletion depict a 
more accurate representation of what is actually happening in the cell in a more 
physiologically-relevant manner. In this regard, it is of interest that MDM2 levels at the 
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mRNA level are in agreement with those at the protein level in that they are decreased 
following hnRNPUL-1 depletion (Figures 3.6A and 3.7). 
The heightened p53-dependent DDR after hnRNPUL-1 depletion is again seen in the cell 
cycle distribution where, interestingly, cells depleted of hnRPUL-1 exhibit an elevated G1/S 
checkpoint arrest compared to cells treated with control siRNA (Figures 3.8 and 3.9A). This 
presumably reflects the ability of hnRNPUL-1-depleted cells to induce p21, which is the main 
mediator of p53-dependent G1 arrest in response to DNA damage (Deng et al., 1995). p21 
usually mediates G1 cell cycle arrest by inhibiting CDKs and by inhibiting the role of PCNA 
in DNA replication (Abbas and Dutta, 2009). It is possible that by negatively regulating the 
expression of p21 levels, hnRNPUL-1 causes a functional effect by negatively regulating cell 
cycle progression after DNA damage.   
The binding site on p53 for hnRNPUL-1 has been reported to be within the C-terminal 
domain of p53 (Barral et al., 2005). However, the precise binding site on hnRNPUL-1 that is 
required for this interaction had not been determined. To map the hnRNPUL-1 region that 
mediates the interaction with p53, various hnRNPUL-1 fragments and deletion mutants, 
including those with deletions in the BBS were generated (Kzhyshkowska et al., 2003, 
Kzhyshkowska et al., 2001, Polo et al., 2012) and used in GST pull-down assays. The BBS 
domain of hnRNPUL-1 was shown to be required for p53 binding to hnRNPUL-1(Figures 
3.10B and 3.11). Incidentally, this region of hnRNPUL-1 was recently found to be partially 
responsible for its interaction with NBS1 (Polo et al., 2012).  
BRD7 is a bromodomain-containing gene and has been implicated in transcriptional 
regulation  (Peng et al., 2006). This is not surprising since the bromodomain is found in 
proteins that are involved in transcriptional regulation and there is evidence to suggest that 
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mutations in bromodomain genes contribute to the development of cancer (Jeanmougin et al., 
1997). Significantly, BRD7 has recently been found to bind to p53 and that this interaction 
requires the C-terminal region of p53 (Drost et al., 2010). It is possible that the binding of 
BRD7 to p53 at the C-terminus of p53 may be inhibited when hnRNPUL-1 binds to the same 
region on p53. Since BRD7 has been found to function as a transcriptional co-factor of p53 
(Drost et al., 2010), the binding of hnRNPUL-1 to p53 may abrogate the ability of BRD7 to 
function in this manner. This will have to await future investigation. 
Interestingly, BRD7 was shown to be required to activate a subset of p53 target genes, namely 
cell cycle genes such as p21 (Drost et al., 2010). The results in that study are consistent with 
the findings here, which show that the depletion of hnRNPUL-1 results in the activation of the 
cell cycle inhibitor, p21, but does not seem to cause an increase in levels of the pro-apoptotic 
protein, Bax. Further to this, it is known that BRD7 is found at promoters of non-apoptotic 
targets of p53 and that it induces histone acetylation around the p53-binding site of the p21 
promoter (Drost et al., 2010). BRD7 is also able to interact with p300, a critical co-activator 
of p53 that is required for the acetylation of several p53 C-terminal lysine residues (Drost et 
al., 2010, Gu and Roeder, 1997).  In addition, there are also studies that support a role of 
BRD7 in BRCA1-dependent transcription such that BRD7 recruits BRCA1 to specific 
promoters (Harte et al., 2010). Taken together, it is conceivable that BRD7 may be acting to 
regulate the activation of p53, an action that may be inhibited by the binding of hnRNPUL-1 
to p53. In this manner it can be surmised that hnRNPUL-1 may be competing with BRD7 for 
the binding site on the C-terminal region of p53.  
It has been previously shown that BRD7 is a binding partner of hnRNPUL-1 and that 
disruption of the BRD7-hnRNPUL-1 complex increased the ability of hnRNPUL-1 to inhibit 
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basic transcription (Kzhyshkowska et al., 2003). Therefore, the fact that BRD7 competes for 
the same binding site on hnRNPUL-1 as p53 may indicate that the binding of p53 to 
hnRNPUL-1 displaces BRD7 and causes hnRNPUL-1 to act as a transcriptional co-repressor.  
This study has revealed an interaction between p53 and hnRNPUL-2 that has not been 
demonstrated previously. It would be interesting to examine the nature of this interaction in 
the future since a lack of reagents such as antibodies and hnRNPUL-2 constructs hindered 
further such investigations. 
Taken together, these findings confirm that hnRNPUL-1 is functioning to negatively regulate 
p53 transcriptional activity and may be acting at the transcriptional level. Given the ability of 
hnRNPUL-1 to bind to p53 and the fact that it can regulate p53 transcriptional activity, it can 
be hypothesised that hnRNPUL-1 plays a role in limiting the extent of p53 activity following 
DNA damage as well as shutting off the p53-dependent response once the damage has been 
repaired. It is also apparent that hnRNPUL-1 seems to be acting to regulate the p53-dependent 
transactivation of some genes, not others. Whether this relationship is dependent on 
interactions with, or the activity of, BRD7 is not clear at present. In summary, in the absence 
of hnRNPUL-1, the transcriptional activity of p53 significantly increases and these findings, 
observed in an artificial system, can also be reflected in vivo by an increase in cell cycle 
arrest. It can be speculated that hnRNPUL-1 is functioning as a co-repressor of p53 
transcriptional activity.   
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CHAPTER 4 CHARACTERISATION OF THE DNA 
DAMAGE RESPONSE INDUCED BY THE NOVEL 
CHEMOTHERAPEUTIC AGENT, ALCHEMIX 
4.1 INTRODUCTION 
The plethora of cellular pathways that detect DNA damage and replication stress to 
orchestrate repair processes and the resolution of DNA replication are collectively known as 
the DDR. The key proteins that mediate the DDR belong to the family of PIKKs – ATM, 
ATR and DNA-PK. ATM and DNA-PK primarily respond to DSBs, whereas ATR is 
activated mainly in response to ssDNA regions that are generated at stalled replication forks 
(Lovejoy and Cortez, 2009). These components of the DDR activate cellular responses to 
DNA damage to preserve the integrity of the genome. This is through the activation of cell 
cycle arrest and the repair of DNA lesions or through the promotion of apoptosis if the 
damage cannot be repaired (Khanna and Jackson, 2001). 
Anti-cancer drugs usually exert their cytotoxic action through their ability to generate DNA 
damage in tumour cells, such that they are forced to undergo cell death whilst normal cells are 
spared (Al-Ejeh et al., 2010). The DNA lesions that arise from the use of DNA damaging 
agents are diverse and, therefore, activate a variety of DDR pathways, which function to 
stimulate numerous downstream processes that include DNA repair pathways. Therefore, an 
understanding of the DDR pathways that become activated in response to a particular DNA 
damaging anti-cancer drug is of fundamental importance since specific abrogation of 
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components in these pathways may increase the effectiveness of the chemotherapeutic drug in 
question. 
Alkylating agents are some of the most commonly prescribed anti-cancer drugs and are often 
used in combination therapy. It is important that particular components of DNA repair 
pathways that recognise alkyl lesions are inhibited alongside treatment with an alkylating 
agent to allow the conversion of the damage into fatal replication lesions (Helleday et al., 
2008). Another class of chemotherapeutic drug of interest is the topoisomerase inhibitors, 
which can be classified into TOP1 or TOP2 inhibitors. The TOP2 inhibitors can be divided 
further into the following: TOP2 poisons or TOP2 catalytic inhibitors. TOP2 poisons, such as 
etoposide, doxorubicin and mitoxantrone, function by trapping the TOP2cc so that they reach 
lethal levels. DSBs are subsequently formed, which activate apoptosis. The catalytic 
inhibitors of TOP2 disrupt the formation of the TOP2cc by reducing the activity of TOP2 
(Larsen et al., 2003). Chromosome decatenation is consequently inhibited and cell death 
ensues through mitotic catastrophe (Giménez-Abián et al., 2000, Wang, 2002). 
A common challenge in the use of standard chemotherapeutic agents is the increasing 
prevalence of drug resistance, which can occur through a number of mechanisms. Mutations 
in known tumour suppressors such as ATM  and TP53 are often the primary cause of 
resistance in tumours after prolonged exposure to chemotherapeutic DNA damaging agents 
(Austen et al., 2007, Lowe et al., 1993). Interestingly, another resistance mechanism is the 
reinstatement of repair of drug-induced DNA damage due to acquired secondary mutations in 
components of the DDR that allow once defective components of the repair machinery to 
regain some function (Lord and Ashworth, 2012). For example, secondary mutations in 
BRCA2 result in a partially functional protein that leads to the resistance to PARP inhibitors 
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that would otherwise rely on inactive BRCA2 (Bryant et al., 2005, Edwards et al., 2008).  
Furthermore, the MMR pathway is actually required to mediate the toxicity of some anti-
cancer agents e.g. 6-thioguanine; therefore, defects in this repair pathway are often associated 
with an increased resistance to some chemotherapeutic drugs (Fink et al., 1998, Helleday et 
al., 2008). The over-expression of drug efflux transporters such as P-glycoprotein, poses 
another problem with chemotherapeutic resistance (Longley and Johnston, 2005). This is of 
particular concern since substrates of these efflux transporters are vast; therefore, the design 
and development of compounds that are not recognised by such pumps is of fundamental 
importance. 
In view of these resistance mechanisms, the use of single agents as the choice of anti-cancer 
therapy has been largely superseded by a range of combination therapies or by the use of 
agents that cause DNA damage through two or more independent mechanisms. This is in the 
hope that the tumour cell would be sensitised to the damaging effect of the drug whilst 
reducing the ability of the tumour cell to select for genetic events that allow its survival (Aziz 
et al., 2012). In addition, the response to multi-functional chemotherapeutic agents should be 
sufficiently lethal so as not to be affected by mutations in proteins that act downstream of 
damage. 
ALX belongs to the anthraquinone family of anti-cancer drugs. The anthraquinones have long 
been used as anti-cancer drugs and they act by specifically inhibiting TOP2 (Sparreboom et 
al., 2005). Anthraquinone-based drugs are centred on a tricyclic pharmacophore and several 
natural derivatives of the anthraquinones have been identified, although it was clear that these 
were too toxic to enter clinical trials (Lown, 1993). This prompted the use of these natural 
products as leads for the design of new drugs by attaching functional groups such as the 
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hydroxyethyl moiety to the tricyclic structure. Mitoxantrone and several other drugs emerged 
as clinically effective but since many are substrates for multi-drug resistance mechanisms, 
tumours rapidly develop a tolerance to these compounds (Pors et al., 2004). The generation of 
a hybrid class of agents consisting of both intercalating and alkylating capabilities has been 
undertaken: of these compounds, ALX demonstrated the most potent anti-tumour activity, 
most notably in a cisplatin-resistant cell line (A2780/cp70) and a doxorubicin-resistant 
tumour cell line (2780AD) (Pors et al., 2004, Pors et al., 2003). Incidentally, the latter cell 
line also contained elevated levels of the P-glycoprotein efflux pump, indicating that ALX is 
not a substrate of this drug transporter (Pors et al., 2003). ALX itself is a prototype of the 
non-symmetrical 1,4 disubstituted anthraquinone hybrid structure, specifically called a 
chloroaminoanthraquinone and, therefore, functions as both a TOP2 inhibitor as well as 
possessing alkylating abilities (Figure 4.1) (Pors et al., 2003). Interestingly, the symmetrical 
1,4-disubstituted anthraquinones containing alkylating groups on both side chains lose their 
effectiveness in drug-resistance cancer cells while their non-symmetrical counterparts such as 
ALX remain cytotoxic (Pors et al., 2003). In addition, recent studies have shown that the 
length of the alkylating side-chain of ALX (ethyl) is more effective than longer butyl and 
pentyl side-chains (Abdallah et al., 2012). Despite these promising findings, little is known 
about the mode of action of this novel agent.  
This study aims to: 
 Determine which DDR pathways become activated in response to ALX 
 Identify which of its two functions induce a greater DDR 
 Examine whether the inactivation of a number of key DDR components results in a 
reduced signalling response to ALX 
 Identify the mode of cell death that ALX initiates. 
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Figure 4.1 Schematic representation of the structure of Alchemix 
The alkylating moieties of ALX are highlighted in blue, including the bis-chloroethyl 
moieties. It is clear that ALX contains non-symmetrical side-chains. The intercalating or 
topoisomerase-inhibiting moiety of ALX is highlighted in grey. 
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4.2 RESULTS 
4.2.1 Treatment with ALX induces a DDR in multiple cancer cell lines 
Dose response experiments were conducted before any other experiments to determine the 
sensitivity of two different cancer cell lines, H1299 and U2OS, to serial dilutions of ALX and 
also to identify the dose of ALX that stimulated a cellular response. This preliminary analysis 
indicated that ALX was capable of inducing a DDR even at nano-molar concentrations after 
both 5 h and 24 h of treatment in H1299 and U2OS cells (Figures 4.2 and 4.3 respectively). 
The results also indicated that 50 nM ALX would be sufficient to induce a DDR. 
To ascertain whether this response could be recapitulated in cancer cell lines that differ in 
both their DNA repair and apoptotic capacities, U2OS (WT TP53), H1299 (TP53 null), DLD1 
(MSH6 mutant), and HCT116 (MLH1 and MRE11 mutant) cells were treated with ALX (50 
nM). Western blotting was used to examine the activation of the DDR using phospho-specific 
antibodies for DDR proteins. Interestingly, ALX induced a DDR in the p53 proficient U2OS 
cell line, the p53 proficient but MLH1 and MRE11 mutant HCT116 cell line, the TP53 and 
MSH6 mutant DLD1 cell line, and the TP53 null H1299 cell line, indicating that there is a 
widespread response to ALX regardless of the p53 status and despite the difference in their 
DNA repair and apoptotic capabilities (Figures 4.4, 4.5, 4.6 and 4.7 respectively). More 
robust phosphorylation of RPA2 was observed in U2OS cells in response to ALX compared 
to other cell lines where extremely low levels of phosphorylated RPA2 were detected (Figure 
4.4). The levels of phosphorylated DNA damage proteins after ALX treatment were lower in 
HCT116 cells in comparison to more robust phosphorylation observed in the other cell lines 
(Figure 4.5). These differences in the kinetics of the signalling response to ALX could be 
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Figure 4.2 Treatment with serial dilutions of ALX for 5 and 24h induces a DDR in 
H1299 cells 
(A) H1299 cells were treated to 0, 100 pM, 1 nM, 10 nM, 100 nM, 1 µM and 10 µM ALX 
and harvested after 5h and; (B) 24h.  Whole cell lysates were prepared, separated by SDS-
PAGE and immunoblotted with the indicated antibodies against DNA damage proteins. 
Antibodies against total proteins were used as loading controls.
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Figure 4.3 Treatment with serial dilutions of ALX for 5 and 24h induces a DDR in U2OS 
cells 
(A) U2OS cells were treated to 0, 100 pM, 1 nM, 10 nM, 100 nM, 1 µM and 10 µM ALX and 
harvested after 5h and; (B) 24h.  Whole cell lysates were prepared, separated by SDS-PAGE 
and immunoblotted with the indicated antibodies against DNA damage proteins. Antibodies 
against total proteins were used as loading controls. 
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Figure 4.4 ALX induces a DDR in the U2OS cancer cell line 
p53 proficient U2OS cells were treated to 50 nM ALX and harvested at the times indicated 
after treatment. Whole cell lysates were prepared, separated by SDS-PAGE and 
immunoblotted with the indicated antibodies against DNA damage proteins. Antibodies 
against total proteins were used as loading controls. 
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Figure 4.5 ALX induces a DDR in the HCT116 cancer cell line 
p53 proficient HCT116 cells that also express mutant MLH1 and mutant MRE11 were treated 
to 50 nM ALX and harvested at the times indicated after treatment. Whole cell lysates were 
prepared, separated by SDS-PAGE and immunoblotted with the indicated antibodies against 
DNA damage proteins. Antibodies against total proteins were used as loading controls. 
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Figure 4.6 ALX induces a DDR in the DLD1 cancer cell line 
DLD1 cells that express mutant p53 and mutant MSH6 were treated to 50 nM ALX and 
harvested at the times indicated after treatment. Whole cell lysates were prepared, separated 
by SDS-PAGE and immunoblotted with the indicated antibodies against DNA damage 
proteins. Antibodies against total proteins were used as loading controls. 
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Figure 4.7 ALX induces a DDR in the H1299 cancer cell line 
p53 null H1299 cells were treated to 50 nM ALX and harvested at the times indicated after 
treatment. Whole cell lysates were prepared, separated by SDS-PAGE and immunoblotted 
with the indicated antibodies against DNA damage proteins. Antibodies against total proteins 
were used as loading controls. 
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due to the differences in the genetic background of the cells.  
To ascertain whether ALX could induce DSBs, HeLa cells were treated with ALX and fixed 
at certain time points over a 24 h time period. DSB formation was measured using 
fluorescence microscopy coupled with antibodies recognising phosphorylated H2AX 
(γH2AX) and 53BP1. Although previous studies showed that γH2AX foci were a reliable 
marker for the quantification of DSBs, evidence now suggests that the numbers may not 
reflect true DSBs induced by different damaging agents (Bouquet et al., 2006, Sedelnikova et 
al., 2002). Therefore, 53BP1foci were used alongside γH2AX for an accurate measurement of 
DSB formation (Schultz et al., 2000). Although Western blot analysis had shown 
phosphorylation of H2AX relatively early in response to ALX (Figures 4.4-4.7), visible 
γH2AX/53BP1 foci were only detected at later time points of 8h-24 h (Figure 4.8A). This 
result indicates that DSBs are induced only after prolonged exposure to ALX. In addition, the 
level of damage after 24 h ALX treatment was assessed by microscopy and by looking at the 
different types of staining pattern. The results indicated that, after 24 h of ALX exposure, 
50% of cells contain DSBs, as shown by the cumulative percentage of cells showing types III 
and IV staining, again suggesting that it is only after the prolonged treatment times that ALX 
induces DNA DSBs (Figure 4.8B). Taken together, these data suggest that the anti-tumour 
activity of ALX is likely to be, in part, mediated by its ability to induce DNA damage. 
4.2.2 The activation of the DDR by ALX is ATM independent 
The onset of DNA damage triggers the activation of ‘sensors’ such as the PIKK family, which 
signal different types of DNA damage. To discern which pathway the cell utilises to induce  
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Figure 4.8 Treatment with ALX induces DSBs at later timepoints 
(A) HeLa cells were treated with 50 nM ALX and fixed at the times indicated after treatment. 
Cells were processed for immunofluoresence using antibodies recognising γH2AX and 
53BP1; (B) The level of damage in HeLa cells that had been fixed 24 h after ALX treatment 
was assessed by looking at different staining patterns:  type I represents no damage; type II 
depicts the increased retention of protein on the chromatin and not DSBs; types III and IV 
show foci that represents DSBs and type V represents DSBs that may have merged into one. 
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the observed DDR following ALX treatment, the effects of inhibiting key kinases was 
examined. Since ALX is a putative TOP2 inhibitor, it was conceivable that the signalling 
response after treatment with ALX was due to the activation of the ATM kinase pathway, 
which responds primarily to DSBs; this seemed likely due to the fact that ALX was shown to 
induce DSBs at later time points (Figure 4.8). To determine whether this was the case, H1299 
cells were pre-treated with the ATM inhibitor, KU-55933, before being treated with ALX. 
Western blotting was used to assess the level of phosphorylation of different DDR proteins 
over a time course of treatment with the drug in combination with the ATM inhibitor. 
Interestingly, the inhibition of ATM kinase did not affect the signalling response compared to 
cells that had not been treated with the ATM inhibitor (Figure 4.9). The combination of 
treatment with ionising radiation and the ATM inhibitor was used as a positive control (Figure 
4.9). 
This was repeated in different cell lines and using a greater range of time points to ascertain 
whether the observed response was cell-type specific. Figures 4.10A and 4.10B show that the 
response did not change in U2OS and HeLa cells respectively. The results indicate that the 
inhibition of ATM kinase does not affect the DDR after treatment with ALX and correlates 
with the very weak auto-phosphorylation of ATM observed in the four different cancer cell 
lines after ALX treatment (Figures 4.4-4.7). Taken together, this indicates that ATM is not 
strongly activated following treatment with this drug. HeLa cells were further treated with 
ALX and Western blotting was used to assess the levels of phosphorylation of ATM-specific 
substrates, KAP-1 and Chk2. ALX did not induce the activation of either protein as shown by 
the lack of phosphorylation (Figure 4.11). Therefore, despite the potential of ALX to generate 
DSBs (Figure 4.8), ATM does not appear to be activated and combining the ATM inhibitor 
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Figure 4.9 ALX acts independently of ATM kinase in an initial timecourse experiment 
H1299 cells were pre-treated with 10 µM ATM inhibitor, treated with 50 nM ALX after 1h 
and harvested at the times indicated. Whole cell lysates were prepared, separated by SDS-
PAGE and immunoblotted with the indicated antibodies against DNA damage proteins. 
Irradiated cells were used as controls alongside cells pre-treated with 10 µM ATM inhibitor 
and irradiated with 2 Gy. Antibodies against total proteins were used as loading controls. 
ATMi denotes ATM inhibitor. 
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Figure 4.10 ALX acts independently of ATM kinase 
(A) U2OS cells were pre-treated with 10 µM ATM inhibitor, treated with 50 nM ALX after 
1h and harvested at the times indicated. This was repeated in; (B) HeLa cells. Whole cell 
lysates were prepared, separated by SDS-PAGE and immunoblotted with the indicated 
antibodies against DNA damage proteins. Irradiated cells were used as controls alongside 
cells pre-treated with 10 µM ATM inhibitor and irradiated with 2 Gy. Antibodies against total 
proteins were used as loading controls. ATMi denotes ATM inhibitor. 
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Figure 4.11 ALX does not activate ATM-specific substrates 
HeLa cells were treated with 50 nM ALX and cells were harvested at the times indicated after 
treatment. Whole cell lysates were prepared, separated by SDS-PAGE and immunoblotted 
with antibodies recognising the phosphorylated forms of KAP-1 and Chk2. Antibodies against 
total proteins were used as loading controls. 
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with ALX does not affect the DDR. 
The MRN mediator complex senses DSBs in the cell and recruits ATM to these sites 
following damage (Lee and Paull, 2005). Any disruption to the MRN complex results in both 
ATM localisation and activation defects. Since ALX-induced phosphorylation was lower in 
the MRE11 mutant HCT116 cells compared to the other cell lines, the function of this 
component of the MRN complex was inhibited. Two methods were used to investigate the 
effect this would have on the response to ALX. Firstly, the MRE11 inhibitor, Mirin, was used 
to pre-treat cells before they were exposed to ALX. Mirin inhibits MRE11-associated 
exonuclease activity. The results indicate that, despite a slight decrease in both NBS1- and 
Chk1- phosphorylation and a concomitant increase in RPA2- and H2AX-phosphorylation, 
treatment with Mirin did not affect the signalling response to ALX (Figure 4.12A). 
Camptothecin-treated cells were used as a positive control (Figure 4.12A). 
Secondly, MRE11 protein levels were depleted in U2OS cells using MRE11 siRNA prior to 
treatment with ALX. The reduced levels of MRE11 were confirmed by Western blotting 
(Figure 4.12B). The levels of NBS1 were also reduced in cells depleted of MRE11; this is 
unsurprising since it is known that depletion of MRE11 affects levels of all three MRN 
components (Figure 4.12B) (Stewart et al., 1999). The results in Figure 4.12B show that the 
down-regulation of MRE11 protein levels did not affect the response to ALX and re-enforces 
the lack of involvement of the ATM-MRN pathway in the ALX-dependent DDR.  
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Figure 4.12 The MRN complex does not play a role in the cellular response to ALX 
(A) U2OS cells were pre-treated with 100 µM Mirin, treated with 50 nM ALX and harvested 
at the times indicated. Cells treated with 1 µM CPT were used as controls, alongside cells pre-
treated with 100 µM Mirin and treated with 1 µM camptothecin; (B) HeLa cells depleted of 
MRE11 using siRNA were treated as in (A). Whole cell lysates were prepared, separated by 
SDS-PAGE and immunoblotted with the indicated antibodies against DNA damage proteins. 
Antibodies against total proteins were used as loading controls. Experiments were performed 
twice to ensure reproducibility. CPT denotes camptothecin. Low exp and high exp denote low 
exposure and high exposure respectively. 
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4.2.3 Exposure to ALX induces a DDR that is mediated by ATR and, partly, by 
DNA-PK 
Both TOP2 inhibitors and alkylators can induce replication-associated DNA damage, which 
suggests that ATR may play a role in activating the damage-induced signalling pathways in 
response to ALX. To assess whether the ATR kinase pathway was involved in the response to 
ALX, DLD1-Seckel cells were treated with ALX. These cells contain a hypomorphic 
mutation at the ATR locus that, at the cellular level, significantly decreases ATR expression 
due to aberrant splicing of the ATR mRNA transcript (O'Driscoll et al., 2003). Cells that were 
engineered to re-express ATR were treated with ALX alongside the DLD1-Seckel cells. The 
phosphorylation response observed in cells with low levels of ATR was markedly different to 
that seen in the ATR complemented cell line, indicating that ALX is acting in an ATR-
dependent manner (Figure 4.13A). Reducing the level of ATR caused a dramatic reduction in 
the phosphorylation of a number of DDR proteins such as NBS1 and Chk1; this was rescued 
by the re-expression of ATR (Figure 4.13A). Interestingly, the phosphorylation of H2AX and 
RPA2 in DLD1-Seckel cells was highly elevated following ALX treatment compared to the 
complemented cells (Figure 4.13A). This observation may be due to an increase in cellular 
replication stress since ATR-deficient cells contain high levels of fragile site breakage where 
stalled forks collapse and DSBs accumulate (Cimprich and Cortez, 2008). Consistent with 
this, the observed enhanced H2AX response in the DLD1-Seckel cells is indicative of an 
increase in DSB formation (Figure 4.13A). 
The activation of Chk1, a checkpoint kinase regulated by ATR, after DNA damage is known 
to require the phosphorylation of sites within its C-terminal region, which includes the highly 
conserved serine 317 residue (S317). ATR is able to phosphorylate Chk1 at this site, which is 
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essential to the activation of downstream DNA damage signalling as well as to enhance 
efficiency of phosphorylation on neighbouring serine residues such as S345 (Zhao and 
Piwnica-Worms, 2001). Since ALX treatment induces an ATR-dependent cellular DDR, the 
DNA damage signalling function of Chk1 in response to ALX was examined using DLD1 
cells that have a point mutation in the Chk1 locus, which abrogates the S317 residue (S317A) 
(Wilsker et al., 2008). These cells and parental DLD1 cells were treated with ALX and 
Western blotting was used to assess the phosphorylation levels of DDR proteins. As expected, 
levels of S345 phosphorylated Chk1 were reduced in the Chk1 S317A mutant cells (Figure 
4.13B). Interestingly, cells harbouring the mutant Chk1 phosphorylation site appeared to 
exhibit a similar exacerbated signalling response after ALX treatment as the DLD1-Seckel 
cells (Figure 4.13B). The levels of phosphorylated RPA and H2AX were increased in 
Chk1S317A mutant cells compared to levels in the DLD1 parental cells after treatment with 
ALX (Figure 4.13B). These data indicate that mutations in the ATR-Chk1 pathway affect the 
cellular response to ALX induced DNA damage.  
Notably, when DLD1-Seckel cells were treated with ALX in combination with the ATM 
inhibitor, the induced replication stress was not alleviated (Figure 4.14). Although ATM 
signalling can occur at collapsed replication forks, the data suggest that ATM does not 
mediate the signalling response to ALX even in the absence of ATR.  
A level of redundancy does exist amongst PIKK signalling and, although it appears that ATM 
does not play a role in the DDR following treatment with ALX, it may be possible that DNA-
PK does. There is evidence that DNA-PK becomes activated in response to stalled replication 
forks that have generated DSBs upon Chk1 inhibition, implying that DNA-PK does not only 
function in NHEJ (McNeely et al., 2010). The effect on the levels of phosphorylation of 
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Figure 4.13 The ATR-Chk1 pathway is involved in the signalling response to ALX 
(A) DLD1 Seckel and ATR complemented cells were treated with 50 nM ALX and harvested 
at the times indicated; (B) DLD1 parental and Chk1S317A mutant cells were treated as in 
(A). Whole cell lysates were prepared, separated by SDS-PAGE and immunoblotted with the 
indicated antibodies against DNA damage proteins. Antibodies against total proteins were 
used as loading controls. Low exp and high exp denote low exposure and high exposure 
respectively. 
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Figure 4.14 ATM does not mediate the signalling response to ALX if ATR is depleted 
DLD1 Seckel cells were pre-treated with DMSO or 10 µM ATM inhibitor, then treated with 
50 nM ALX after 1h and harvested at the times indicated. Whole cell lysates were prepared, 
separated by SDS-PAGE and immunoblotted with the indicated antibodies against DNA 
damage proteins. Irradiated cells were used as controls alongside cells pre-treated with 10 µM 
ATM inhibitor and irradiated with 2 Gy. Antibodies against total proteins were used as 
loading controls. ATMi denotes ATM inhibitor. Low exp and high exp denote low exposure 
and high exposure respectively. 
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Figure 4.15 DNA-PK is involved in mediating the DDR in response to ALX 
(A) HeLa cells were treated to 50 nM ALX and cells were harvested at the times indicated; 
(B) DLD1-Seckel cells were pre-treated with 50 µM DNA-PK inhibitor, treated with 50 nM 
ALX after 1h and harvested at the times indicated. Whole cell lysates were prepared, 
separated by SDS-PAGE and immunoblotted with the indicated antibodies against DNA 
damage proteins. Antibodies against total proteins were used as loading controls. DNA-PKi 
denotes DNA-PK inhibitor. 
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DNA-PK after treatment with ALX was, therefore, assessed in HeLa cells treated with the 
drug over a 24 h time period. It was observed that there were increasing levels of 
phosphorylated DNA-PK with increasing time of exposure to ALX (Figure 4.15A). These 
results indicate that DNA-PK becomes activated in response to ALX treatment.  
To further address this, DLD1-Seckel cells were treated with ALX in the presence or absence 
of the DNA-PK inhibitor, DMNB. Western blot analysis showed a significant reduction in 
H2AX and RPA2 phosphorylation in DLD1-Seckel cells that had been pre-treated with 
DMNB, despite only partial inhibition of DNA-PK kinase activity upon treatment with this 
inhibitor (Figure 4.15B). In addition, levels of phosphorylated Chk1 and SMC1 were 
decreased in cells that had been treated with the DNA-PK inhibitor compared to cells that had 
not, giving rise to the suggestion that, in response to ALX, DNA-PK may be functioning to 
activate cell cycle checkpoints as well as in the response to replication-associated DSBs 
(Figure 4.15B). Together, these data suggest that the DDR, upon exposure to ALX, is 
primarily mediated by ATR and, to a lesser extent, DNA-PK. In contrast, ATM appears to 
play no significant role in the signalling response to this novel anthraquinone. 
4.2.4 ALX requires both TOP2α and TOP2β and its alkylating function to elicit a 
DDR 
Although ALX is a TOP2 inhibitor, it also contains an alkylating moiety, potentially capable 
of inducing DNA crosslinks and causing DNA base damage. To determine which function of 
ALX activates the observed DDR, HeLa cells were exposed to ALX or a derivative of ALX, 
ZP275, which lacks the alkyating side chain whilst retaining its ability to inhibit TOP2. 
Interestingly, both compounds elicited the phosphorylation of known PIKK downstream 
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targets, including SMC1, NBS1, Chk1, RPA2 and H2AX (Figure 4.16). However, the loss of 
the alkylating side chain severely attenuated this response, implying that both functions of 
ALX are required for its ability to activate the DDR (Figure 4.16). Interestingly, the 
phosphorylation of Chk1 was severely compromised in cells treated with ZP275, indicating 
that the alkylating ability of ALX is required for the ATR-dependent DDR in response to the 
drug (Figure 4.16). However, the fact that the signalling response is not completely abolished 
in response to ZP275 does indicate that both functions of ALX contribute to its ability to 
induce a DDR (Figure 4.16). 
It is known that alkylation damage is a potent inducer of the TLS damage tolerance pathway 
that functions to bypass bulky DNA lesions allowing the replication fork to progress. 
Activation of this pathway is primarily controlled by the mono-ubiquitylation of PCNA by the 
E3 ubiquitin ligase Rad18, which is potently induced by the treatment of cells with agents that 
induce replication-associated DNA damage, e.g. UV, H2O2 and alkylating agents. To 
determine whether the replication-associated DNA damage observed in cells treated with 
ALX coincided with activation of the TLS pathway, HeLa cells were treated with ALX, 
etoposide (a known TOP2 inhibitor) or UV. It was observed that, unlike UV, ALX or 
etoposide treatment of HeLa cells failed to induce the mono-ubiquitylation of PCNA (Figure 
4.17). This result indicates that the DNA alkylating ability of ALX does not conform to the 
mechanism that is typical to the class of alkylating agents as a whole. It is also possible that 
ALX might be functioning via its alkylating ability only at sites of DNA that contain bound 
TOP2, i.e. at regions of DNA where TOP2 has been inhibited.  
Since ALX, as an anthraquinone derivative, has previously been found to inhibit TOP2α, this 
suggests that DNA damage, particularly the DSBs, generated from ALX exposure, would  
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Figure 4.16 ALX requires a combination of its ability to inhibit TOP2 and its capacity to 
alkylate DNA to induce a DDR 
HeLa cells were treated to 50 nM ALX or 50 nM ZP275 (a derivative of ALX that lacks the 
alkylating side chain). Cells were harvested at the times indicated. Whole cell lysates were 
prepared, separated by SDS-PAGE and immunoblotted with the indicated antibodies against 
DNA damage proteins. Antibodies against total proteins were used as loading controls. Low 
exp and high exp denote low exposure and high exposure respectively. 
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Figure 4.17 ALX does not induce PCNA mono-ubiquitylation 
HeLa cells were treated with 50 nM ALX and harvested at the times indicated. Whole cell 
lysates were prepared, separated by SDS-PAGE and immunoblotted with the indicated 
antibodies against PCNA. UV-irradiated cells and etoposide-treated cells were used as 
controls after 8 h exposure to each respective damaging agent. mUb denotes mono-
ubiquitylation. Low exp and high exp denote low exposure and high exposure respectively. 
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depend on the presence of TOP2. To determine whether this was the case, HeLa cells were 
transfected with either TOP2α or TOP2β siRNA and treated with ALX over a 24 h time 
period. The DDR was subsequently determined using Western blotting. Surprisingly, the 
depletion of either TOP2α or TOP2β alone did not alleviate the cytotoxicity of ALX since 
many of the downstream targets in the DDR such as SMC1, NBS1, Chk1, RPA2 and H2AX 
were still phosphorylated (Figure 4.18A). This indicates that ALX does not solely depend on 
the presence of either TOP2α or TOP2β, but may be capable of inhibiting multiple class II-
type topoisomerase enzymes.  
To investigate the possibility of redundancy between the two isoforms of TOP2, HeLa cells 
were treated with siRNA to both TOP2α and TOP2β prior to exposure to ALX. Interestingly, 
the siRNA-mediated depletion of both topoisomerases resulted in decreased levels of 
phosphorylated RPA2 and H2AX, implying that TOP2α and TOP2β can both be targeted by 
ALX, not just TOP2α (Figure 4.18B). Despite this depletion of both TOP2α and TOP2β, the 
checkpoint response, as measured by Chk1 phosphorylation induced by ALX, was not 
abrogated, supporting a role for the alkylating function of ALX being important for ATR-
dependent cell cycle regulation (Figure 4.18B). 
Since etoposide is a known TOP2α inhibitor, it was used as a positive control to compare the 
response to ALX. The reduced response to etoposide in cells treated with TOP2α siRNA 
compared to those cells treated with control is expected since etoposide requires the presence 
of TOP2α to induce a DDR (Figure 4.19) (Baldwin and Osheroff, 2005). This is in contrast 
the response of these cells to ALX where the depletion of TOP2α did not alleviate the 
response to ALX (Figure 4.18A). The lack of a checkpoint signalling response observed in  
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Figure 4.18 The ALX-induced DDR requires both TOP2α and TOP2β but is not 
dependent on either enzyme 
(A) HeLa cells depleted of either TOP2α or TOP2β using siRNA were treated with 50 nM 
ALX; (B) HeLa cells depleted of both TOP2 enzymes simultaneously using siRNA were 
treated as in (A). Cells were harvested at the times indicated and whole cell lysates were 
prepared, separated by SDS-PAGE and immunoblotted with the indicated antibodies against 
DNA damage proteins. Antibodies against total proteins were used as loading controls. 
Experiments were performed twice to ensure reproducibility. 
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Figure 4.19 The DDR induced by etoposide solely requires TOP2α 
HeLa cells were depleted of TOP2α and treated with 1 μM etoposide. Cells were harvested at 
the times indicated and whole cell lysates were prepared, separated by SDS-PAGE and 
immunoblotted with the indicated antibodies against DNA damage proteins. Antibodies 
against total proteins were used as loading controls. IR- and UV-treated cells were used as 
controls after 1 h exposure to each respective damaging agent. 
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cells treated with etoposide further supports the idea that ALX uses its alkylating function to 
activate ATR. IR- and UV-treated cells were used as controls (Figure 4.19). 
Collectively, these data suggest that the DDR that is induced by ALX requires its ability to 
inhibit both isoforms of TOP2. Furthermore, the ALX-induced ATR-dependent checkpoint 
response appears to be reliant on the alkylating properties of this chemotherapeutic drug. 
4.2.5 ALX does not require the MMR pathway or the FA repair pathway 
Whilst it is clear that ALX activates the ATR-Chk1 replication stress pathway, the 
components of cellular repair pathways that are involved in the response to ALX are not 
known. The MMR pathway is known to recognise and remove a number of alkyl lesions and 
MSH2, in particular, is required for the activation of ATR following treatment with the 
methylating agent, MNNG (Wang and Qin, 2003). Since it has been shown that the alkylating 
ability of ALX is required for the activation of the ATR-dependent DDR, it is conceivable 
that elements of the MMR pathway are required for the response to ALX. To determine 
whether the MMR pathway becomes activated upon exposure to ALX, siRNA targeting 
MSH2 was transfected into HeLa cells that were then treated with ALX over a 24 h time 
period. Rather than alleviating the ATR-dependent DDR after ALX treatment, the depletion 
of MSH2 resulted in heightened activation of Chk1, thus indicating that MSH2 is not required 
for the activation of ATR in response to ALX (Figure 4.20). The levels of phosphorylated 
SMC1, RPA2 and H2AX were also increased in cells depleted of MSH2, which suggests that 
the signalling response to ALX is not recognised by components of the MMR pathway 
(Figure 4.20). This is important since tumour cells with deficiencies in the MMR pathway 
may prove to be sensitive to the cytotoxic effects of ALX. 
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The FA pathway is also involved in the repair of lesions that are encountered during DNA 
replication and may, therefore, become activated in response to ALX. The 2008 ovarian 
carcinoma cell line is deficient in the FA pathway due to methylation of the FANCF promoter 
region, and this is restored by the functional complementation with FANCF (Taniguchi et al., 
2003). The loss of the mono-ubiquitylation of FANCD2 in the FANCF deficient cells is a 
marker of function of this pathway and is, therefore, restored in the complemented cells since 
FANCF is a component of the E3 ubiquitin ligase that targets FANCD2 in the FA pathway 
(Taniguchi et al., 2003). These cells were treated with ALX over a 24 h time period and the 
activation of the DDR was determined using Western blotting. The deficiency in FANCF in 
the 2008 cell line was shown by the lack of FANCD2 ubiquitylation in these cells compared 
to the levels of ubiquitylated FANCD2 in the complemented cells (Figure 4.21). The lack of 
any difference in the signalling response to ALX between cells with and without FANCF 
showed that the FA pathway is dispensable for the ALX-induced DDR (Figure 4.21). This 
suggests that any perturbations within the FA pathway will not affect the response after ALX 
treatment and will, therefore, be unlikely to contribute to any resistance to ALX. It also 
suggests that ALX is unlikely to induce DNA crosslinks that are recognised by the FA 
pathway. 
4.2.6 Exposure to ALX leads to a G2/M checkpoint arrest, mitotic abnormalities 
and death by mitotic catastrophe 
TOP2 inhibitors and alkylating agents induce DNA damage that occurs during replication; 
therefore, it is likely that the progression of cells through S phase will be affected by such 
agents. Since ALX possesses both of these properties, and given the fact that that TOP2 is  
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Figure 4.20 ALX-induced alkylated damage is not recognised by the MMR pathway 
HeLa cells depleted of MSH2 using siRNA were treated with 50 nM ALX and harvested at 
the times indicated. Whole cell lysates were prepared, separated by SDS-PAGE and 
immunoblotted with the indicated antibodies against DNA damage proteins. Antibodies 
against total proteins were used as loading controls. Low exp and high exp denote low 
exposure and high exposure respectively. 
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Figure 4.21 ALX-induced alkylated damage is not recognised by the FA pathway 
2008+vector (FANCF deficient) and 2008+FANCF (FANCF complemented) cells were 
treated to 50 nM ALX and harvested at the times indicated. Whole cell lysates were prepared, 
separated by SDS-PAGE and immunoblotted with the indicated antibodies against DNA 
damage proteins. Antibodies against total proteins were used as loading controls. 
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also involved in chromosome segregation, the possibility that cells would be disrupted in  
both S phase and mitosis in response to ALX is likely.  
To investigate the effect of ALX on the cell cycle, flow cytometric analysis was performed in 
HeLa cells treated with ALX over a 24 h time period. The results indicate that treatment with 
ALX induced an S phase arrest of the cell cycle between 4 h and 8 h, which is consistent with 
the early activation of the ATR-mediated checkpoint response observed in Figures 4.4-4.7 
(Figure 4.22A). In addition, at the later time of 24 h, cells appeared to arrest in late S 
phase/G2-phase of the cell cycle, an observation that is consistent with the late induction of 
DSBs and the activation of a DNA-PK-mediated DDR upon exposure to ALX depicted in 
Figures 4.8 and 4.15 respectively (Figure 4.22A).  
To further support the fact that ALX-treated cells accumulate in late S/G2, HeLa cells that 
had been treated with ALX for 24 h were analysed by Western blotting using antibodies 
recognising specific markers of mitosis. These markers included phosphorylated histone H3 
(H3 S10-P), which is a marker of mitotic cells, and cyclin A and cyclin B1, which are 
normally degraded as cells progress through mitosis. H3 S10-P levels were greatly reduced in 
ALX-treated cells compared to cells that had not been treated with ALX, indicating that cells 
exposed to ALX for 24 h have undergone activation of a G2 checkpoint (Figure 4.22B). 
Consistent with this are the elevated levels of cyclin A and cyclin B1 in these cells, showing 
that cells have not progressed through mitosis (Figure 4.22B).  
Despite this, mitotic cells could still be observed by immunofluorescence microscopy after 
treatment with ALX for 24 h, indicating that some cells had bypassed the G2/M checkpoint 
observed in Figure 4.22A (Figure 4.23). Interestingly, these cells were found to contain 
mitotic abnormalities, including chromosome segregation and DNA decatenation defects such  
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Figure 4.22 ALX induces a cell cycle arrest in S phase and, after 24 h, induces a G2/M 
arrest 
(A) HeLa cells treated with 50 nM ALX were analysed by flow cytometry using PI dye to 
quantify DNA content during the cell cycle. The percentage of cells accumulating in sub G1, 
G1, S or G2/M is shown for DMSO- (0h) and ALX-treated samples at the times indicated. 
The FACS profiles shown are representatives from two independent experiments; (B) HeLa 
cells treated with 50 nM ALX were harvested after 24 h. Whole cell lysates were prepared, 
separated by SDS-PAGE and immunoblotted with the antibodies recognising cyclin A, cyclin 
B and H3 S10-P. The antibody against total histone H3 was used as a loading control. 
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Figure 4.23 A small number of cells bypass the ALX-induced G2/M checkpoint and 
contain mitotic abnormalities 
HeLa cells were treated with 50 nM ALX and fixed after 24 h treatment. Cells were washed 
and mounted in Vectashield containing DAPI before being visualised using a Nikon Eclipse 
E600 Microscope. A graphical representation of the mitotic abnormalities is depicted 
alongside the images. 
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as misaligned chromosomes, lagging chromosomes depicted by anaphase bridging and multi-
polar metaphase spindles (Figure 4.23). Together, these data indicate that, although cells 
accumulate in late S/G2 after treatment with ALX, some cells bypass this checkpoint and 
enter mitosis with unrepaired breaks and mitotic abnormalities. 
To establish whether the unrepaired DNA damage induced by ALX in cells entering mitosis 
contributed to cell death, HeLa cells were treated with two doses of ALX and harvested for 
FACS analysis every 24 h for 5 days. It was observed that both concentrations of ALX could 
induce a significant amount of cell death, as depicted by the increase in the sub G1 population 
of these cells compared to untreated cells (Figure 4.24). Cisplatin-treated cells were used as a 
control to induce cell death through the apoptotic pathway and these samples showed 
extremely high levels of cells that had accumulated in sub G1 (Figure 4.24).  
The sub G1 peak is not specific for apoptosis: it is an indicator of dead cells with less than a 
2n DNA content, which includes apoptotic cells, necrotic cells, cells that have undergone 
mitotic catastrophe and cells that have undergone autophagy. Therefore, to establish the mode 
of cell death that is induced by ALX treatment, HeLa cells were exposed to ALX and 
analysed by Western blotting using antibodies recognising specific markers of apoptosis. 
These markers included the reduction of procaspase 3 levels, signifying its 
cleavage/activation and consequent induction of apoptosis, reduced lamin B levels to 
represent the loss of nuclear membrane integrity during apoptosis, and the cleavage of PARP1 
that again, signifies apoptosis. Interestingly, the levels of procaspase 3 in cells treated with the 
two high concentrations of ALX were no different to the levels in untreated cells, implying 
that ALX-induced cell death is not associated with this marker of apoptosis (Figure 4.25A). In 
contrast, cisplatin-treated cells exhibited significantly reduced levels of procaspase 3,  
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Figure 4.24 Damaged mitotic cells from ALX treatment cause cell death in HeLa cells 
HeLa cells were treated with 150 nM and 500 nM ALX and harvested every 24 h for 5 days. 
Samples were analysed by flow cytometry using PI dye to quantify DNA content during the 
cell cycle. The percentage of cells accumulating in sub G1, G1, S or G2/M is shown for 
untreated and ALX-treated samples at the times indicated. Cisplatin-treated cells were used as 
controls.  
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Figure 4.25 The mode of cell death induced by ALX is not through apoptosis or 
autophagy 
(A) HeLa cells were treated with 150 nM and 500 nM ALX and harvested every 24 h for 5 
days. Whole cell lysates were prepared, separated by SDS-PAGE and immunoblotted with the 
antibodies recognising PARP1, procaspase 3 and lamin B. Cisplatin-treated cells were used as 
controls; (B) 293 cells stably expressing the autophagy GFP-LC3 fusion protein were treated 
with three doses of ALX and then serum-starved for 4 h. Cells were fixed and mounted on 
glass slides. GFP-LC3-labelled puncta were visualised on a Nikon Eclipse E600 Microscope. 
Media-replenished cells and serum-starved cells were used as controls. Standard deviations 
from three independent experiments are presented, with P-values depicting significant 
differences (*=P<0.05 significant, **=P<0.01 highly significant, ***=P<0.001 very highly 
significant).  
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Figure 4.26 Exposure to ALX leads to cell death primarily by mitotic catastrophe 
HeLa cells were treated with 150 nM ALX and fixed 72 h after treatment. Cells were 
processed for immunofluoresence using antibodies recognising γH2AX, lamin B and H3 S10-
P. (A) Visualisation of cells using a Nikon Eclipse E600 Microscope; (B) Graphical 
representation of the percentage of dead cells undergoing each mode of cell death. For 
quantification, a minimum of 500 cells were counted per experiment. pH3 denotes H3 S10-P. 
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signifying the induction of apoptosis (Figure 4.25A). In addition, the unchanged lamin B1 
levels in cells exposed to ALX signified no change to the nuclear membrane of these cells 
compared to the loss of nuclear membrane integrity in cisplatin-treated cells (Figure 4.25A). 
Notably, a small amount of PARP1 cleavage could be observed, more significantly at early 
times, following ALX treatment, implying that a small proportion of ALX-treated cells may 
be undergoing apoptosis (Figure 4.25A). However, at late times no major PARP1 cleavage 
product could be seen, as is the case with the cisplatin-treated cells (Figure 4.25A). 
The possibility that ALX may be inducing cell death through autophagy was investigated by 
using an autophagosomal marker LC3 (that had been fused to GFP) in cells treated with ALX. 
During autophagy, cytoplasmic constituents are sequestered into autophagosomes, of which 
LC3 is a membrane component. Treatment with ALX did not induce LC3 puncta in contrast 
to serum starvation, which is known to induce autophagy (Figure 4.25B). The lack of an 
increase in LC3 puncta in ALX-treated cells indicates that the mode of cell death after ALX 
treatment is not through autophagy (Figure 4.25B).  
Immunofluorescence microscopy was conducted on ALX-treated HeLa cells for further 
analysis of the mode of ALX-mediated cell death. Apoptotic cells were distinguished from 
cells undergoing mitotic catastrophe by the presence of a blebbed nuclear morphology, 
intense γH2AX staining and a lack of an intact nuclear membrane as depicted by reduced 
lamin B1 staining (Figure 4.26A). Cells undergoing mitotic catastrophe could be 
differentiated from those undergoing other forms of cell death by the presence of multiple 
micronuclei, an intact nuclear matrix and no H3 S10-P staining. The γH2AX staining in cells 
undergoing mitotic catastrophe is indicative of the large number of unrepaired DSBs (Figure 
4.26A).  Cells that were going through abortive mitosis exhibited fragmented chromosomes, a 
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loss of lamin B1 staining but retained H3 S10-P staining and γH2AX foci (Figure 4.26A). At 
the microscopic level, ALX-treated cells were found to primarily undergo cell death through 
mitotic catastrophe compared to cisplatin-treated cells that went through apoptosis (Figure 
4.26B).  
It can be seen that a small percentage of cells do undergo apoptosis after treatment with ALX 
(Figure 4.26B). This is consistent with the small amount of PARP1 cleavage depicted in 
Figure 4.25A. Recently, it has been found that cells that are subjected to a prolonged arrest in 
mitosis can undergo a p53-dependent apoptotic response (Orth et al., 2012). Consistent with 
this, ALX is able to induce the stabilisation of p53 in the p53-proficient U2OS cell line 
(Figure 4.27). The exposure to ALX in these cells also led to the up-regulation of 
transcriptional targets of p53, including MDM2 and p21, although the levels of these proteins 
were only increased at later times of between 8-24 h following ALX treatment (Figure 4.27). 
The activation of p53 at later times after exposure to ALX coincides with the formation of 
DSBs at later times during the ALX-induced DDR (Figure 4.8) and the cells that undergo 
mitotic abnormalities (Figure 4.23). 
To investigate whether ALX could induce cell death in other cell lines, p53 null H1299 cells 
and p53 WT U2OS cells were treated with varying doses of ALX and harvested every 24 h 
for FACS analysis over 4 or 5 days respectively. Similar to the response in HeLa cells, ALX 
induced a significant amount of cell death in both H1299 and U2OS cells as shown by the 
higher percentage of cells in sub G1 compared to untreated cells (Figures 4.28 and 4.29 
respectively). Cisplatin treatment was again used as a positive control. 
Together, the results indicate that, despite ALX treatment causing an arrest in late S and G2 
phases of the cell cycle, some cells do enter mitosis with abnormalities, although a small  
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Figure 4.27 ALX stabilises p53 and causes its transcriptional activation at later times  
U2OS cells were treated with 50 nM ALX and harvested at the times indicated. Whole cell 
lysates were prepared, separated by SDS-PAGE and immunoblotted with the indicated 
antibodies recognising p53, MDM2 and p21. An antibody against β-actin was used as a 
loading control. 
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Figure 4.28 Damaged mitotic cells from ALX treatment cause cell death in a p53 null 
cell line 
H1299 cells were treated with 150 nM and 500 nM ALX and harvested every 24 h for 4 days. 
Samples were analysed by flow cytometry using PI dye to quantify DNA content during the 
cell cycle. The percentage of cells accumulating in sub G1, G1, S or G2/M is shown for 
untreated and ALX-treated samples at the times indicated. Cisplatin-treated cells were used as 
controls. 
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Figure 4.29 Damaged mitotic cells from ALX treatment cause cell death in a p53 
proficient cell line 
U2OS cells were treated with 150 nM and 500 nM ALX and harvested every 24 h for 5 days. 
Samples were analysed by flow cytometry using PI dye to quantify DNA content during the 
cell cycle. The percentage of cells accumulating in sub G1, G1, S or G2/M is shown for 
untreated and ALX-treated samples at the times indicated. Cisplatin-treated cells were used as 
controls. 
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amount of apoptosis was detected. It is clear that the abnormal mitotic cells cause ALX-
induced death primarily through mitotic catastrophe.  
4.2.7 DNA damage following exposure to ALX is enhanced in cycling cells and can 
be exacerbated under conditions of replication stress 
Since ALX appears to induce a DDR that is primarily mediated by ATR and that the loss of 
cell viability due to ALX treatment is predominantly through mitotic catastrophe, it is 
possible that ALX may be acting preferentially in replicating cells. To address whether this 
was the case, hTERT-immortalised RPE1 cells that were cycling asynchronously or that had 
been synchronised and arrested in G0/G1 by serum starvation and contact inhibition, were 
treated with ALX over a 24 h timecourse. Western blotting was subsequently used to 
determine the DDR induced by ALX in these cells. The percentage of cells arrested in G1 in 
samples that had been synchronised compared to asynchronous cells was confirmed by flow 
cytometry (Figure 4.30A). The asynchronously-growing cells exhibited a significantly 
increased response to ALX compared to the cells that had been arrested in G0/G1 (Figure 
4.30B). This can be seen by the increase in levels of phosphorylated DNA-PKcs, SMC1, 
NBS1, Chk1 and H2AX (Figure 4.30B). In addition, the expression of the key regulatory 
effector molecule, Chk1, was significantly down-regulated in arrested cells (Figure 4.30B). 
Consistent with these results, cells that were arrested in G0/G1 displayed a lower signalling 
response to ALX compared to asynchronous cells (Table 4.1). The percentage of dead cells 
after treatment with ALX is greatly increased in the asynchronous, cycling cells compared to 
the percentage in the non-cycling, synchronous cells (Table 4.1). Together, these data 
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demonstrate that ALX induces a greater DDR in actively-replicating cells rather than those 
that have exited the cell cycle. 
Early stage tumours have been found to display markers suggestive of an enhanced DDR and 
heightened DNA replication stress (Bartkova et al., 2005). One of the causes of such 
constitutive stress in tumour cells is the elevated levels of certain oncogenes, including cyclin 
E, whose increased expression is a common occurrence in carcinomas and leads to genomic 
instability (Spruck et al., 1999). To further investigate the enhanced activity of ALX in 
replicating cells, the effect of the drug in cells undergoing replication stress was examined 
using U2OS-derived cells in which cyclin E could be over-expressed by the removal of 
tetracycline. To test whether increased replication stress could exacerbate the DDR-induced 
by ALX, cells with and without tetracycline were treated with ALX over a 24 h time period. 
Western blot analysis demonstrated that cells over-expressing cyclin E displayed amplified 
levels of phosphorylated RPA2 and H2AX and, to a lesser extent, increased the levels of 
phosphorylated Chk1 (Figure 4.31). This enhanced signalling response to ALX in cyclin E-
over-expressing cells shows that the anti-tumourigenic activity of ALX may indeed be more 
effective in cells that replicate faster compared to cells with a normal rate of proliferation 
(Figure 4.31).  
4.3 DISCUSSION 
Organisms have evolved a complex array of pathways, collectively known as the DDR, to 
preserve genomic integrity in response to DNA damage. These pathways can be exploited in 
cancer therapy since the majority of chemotherapeutic agents function by inducing irreparable 
DNA damage that forces the tumour cell to enter damage-dependent apoptosis. High levels of  
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Figure 4.30 Non-cycling cells display a reduced signalling response to ALX 
hTERT immortalised RPE1 cells were either arrested in G0/G1 by serum starvation or left to 
cycle asynchronously. (A) Samples were analysed by flow cytometry using PI dye to quantify 
DNA content during the cell cycle. The percentage of cells accumulating in sub G1, G1, S or 
G2/M is shown for synchronous and asynchronous cells; (B) Both cell types were treated with 
50 nM ALX and harvested at the times indicated. Whole cell lysates were prepared, separated 
by SDS-PAGE and immunoblotted with the indicated antibodies against DNA damage 
proteins. Antibodies against total proteins were used as loading controls. 
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 Synchronous (non-cycling) cells in sub G1 (%) 
 24 h 48 h 72 h 96 h 120 h 
Untreated 0.99 1.30 4.43 1.64 1.28 
150 nM ALX 1.33 1.00 2.61 2.22 0.99 
500 nM ALX 1.50 4.77 5.66 5.01 2.24 
10 µg/mL cisplatin 6.88 23.99 77.81 80.91 51.85 
 Asynchronous (cycling) cells in sub G1 (%) 
 24 h 48 h 72 h 96 h 120 h 
Untreated 1.3 3 14.5 7.2 6.9 
150 nM ALX 8.8 20.6 37.3 63 65.8 
500 nM ALX 31.5 42.7 30.9 50 73.9 
10 µg/mL cisplatin 18.4 49.9 87.1 94.1 93.9 
 
Table 4.1 ALX causes a higher percentage of cell death in actively-cycling cells 
hTERT immortalised RPE1 cells were either arrested in G0/G1 by serum starvation or left to 
cycle asynchronously. Cells were treated with 150 nM and 500 nM ALX and harvested every 
24 h for 5 days. Samples were analysed by flow cytometry using PI dye to quantify DNA 
content during the cell cycle. The percentage of cells accumulating in sub G1 is shown for 
untreated and ALX-treated samples at the times indicated. 
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Figure 4.31 ALX exacerbates the DDR in cells with a high rate of replication 
U2OS cells with either normal or greatly elevated levels of cyclin E were treated with 50 nM 
ALX and harvested at the times indicated. Whole cell lysates were prepared, separated by 
SDS-PAGE and immunoblotted with the indicated antibodies against DNA damage proteins. 
Antibodies against total proteins were used as loading controls. 
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DNA damage in S phase can result in stalled replication forks or replication fork collapse, 
leading to replication-associated DSB formation. Since cancer cells have a higher rate of 
replication than normal cells, many anti-cancer drugs act by inducing DNA lesions during or 
following DNA replication (Helleday et al., 2008). 
Drug resistance remains a common problem in cancer therapy. To combat this, numerous 
strategies have been adopted, including the development of derivatives of TOP2 inhibitors. 
This has resulted in the generation of a hybrid class of compounds that also possess alkylating 
capabilities, of which ALX was proven to be most effective (Figure 4.1) (Pors et al., 2003). 
4.3.1 The DDR in response to ALX 
Although ALX has been shown to possess anti-tumour activity, an understanding of the DDR 
pathways that are activated in response to it remains limited. Preliminary dose-response and 
timecourse experiments were performed, which established that ALX was capable of inducing 
a DDR at nanomolar concentrations and in a variety of cancer cell lines that possessed 
different genetic backgrounds (Figures 4.2-4.7).  
It was also observed that longer exposure to ALX generated DSBs; therefore, further 
characterisation of ALX was required to determine which DDR pathways were activated in 
response to it (Figure 4.8). Interestingly, the abrogation of ATM or components of the ATM-
dependent pathway did not inhibit the ability of ALX to induce a DDR in these cells, despite 
the fact that ATM primarily responds to DSBs (Figures 4.9-4.12).  It has become increasingly 
apparent that the functional state of ATM (often in combination with the state of p53) in 
individual patient tumours has a huge impact on identifying those patients who are most likely 
to respond to a particular chemotherapeutic agent (Jiang et al., 2009). The fact that ATM is 
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not required in the ALX-induced DDR indicates that a cytotoxic response can potentially be 
initiated in tumour cells that possess inactive ATM, which would otherwise often be 
associated with resistance to treatment.  
The lack of involvement of the ATM pathway indicates that the signalling response to ALX 
requires the presence of another PIKK; therefore, the effect of reducing the levels of ATR and 
components of the ATR pathway on the response to ALX was investigated. The data 
established a requirement of ATR and Chk1 to mediate the activation of the ALX-induced 
cell cycle checkpoint since the loss of this DDR pathway exacerbated the formation of DSBs 
(Figure 4.13). Notably, the abrogation of Chk1 has been of particular interest in order to 
sensitise cancer cells to a number of anti-cancer agents, including mitomycin C and cisplatin 
(Akinaga et al., 1993, Bunch and Eastman, 1996). It has also been found that the depletion of 
ATR renders cancer cells extremely sensitive to alkylating agents, a finding that is consistent 
with the results observed in this study since ALX possesses alkylating capabilities. The 
increased generation of DNA damage in cells with reduced ATR levels treated with ALX 
highlights the therapeutic potential of ALX in combination with inhibitors of the ATR 
pathway to potentiate its effects (Figure 4.13) (Wilsker and Bunz, 2007).  
The enhanced H2AX response after ALX treatment in DLD1-Seckel cells could be due to the 
fact that ATR-deficient cells contain an increased level of genomic instability from high 
levels of replication fork stalling, their subsequent collapse and the accumulation of DSBs 
(Cimprich and Cortez, 2008). Therefore, it is likely that another PIKK is activated in response 
to ALX and that this kinase can function in a redundant manner to ATR. Consistent with this 
suggestion, the pre-treatment of the DLD1-Seckel cells with a DNA-PK inhibitor reduced the 
levels of phosphorylated DDR proteins, indicating that ALX treatment induces a DNA-PKcs-
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dependent cellular response that can function as well as ATR (Figure 4.15B). This is 
consistent with the observations that that DNA-PK can phosphorylate a subset of DDR 
proteins involved in the chromatin remodelling response, such as H2AX (Mukherjee et al., 
2006, Stiff et al., 2004, Tomimatsu et al., 2009). Since it was also observed that levels of 
phosphorylated Chk1 and SMC1 were reduced following both ATR depletion and DNA-PK 
inhibition, it would be interesting to determine whether DNA-PK plays a role in the 
phosphorylation of other DDR proteins in response to ALX and to ascertain whether DNA-
PK is actually involved in the cell cycle response to ALX (Figure 4.15B). In addition, since 
the efficiency of DNA-PK inhibition was only moderate, the use of siRNA to deplete the 
levels of DNA-PK would be a better approach to study this effect on the response to ALX. 
4.3.2 The mode of action of ALX 
4.3.2.1 ALX and topoisomerase 
It appears that the alkylating moiety of ALX does elicit a DSB response, since the signalling 
response is greatly reduced when the alkylating side-chain is removed (Figure 4.16). 
However, as the DNA damage induced by ALX also requires the presence of TOP2, it is 
possible that the alkylating damage after treatment with ALX is limited to regions where 
TOP2 is inhibited (Figure 4.18B). This is consistent with the lack of PCNA mono-
ubiquitylation after ALX treatment, indicating that the base damaging activity of ALX may be 
restricted to TOP2-bound replication forks (Figure 4.17).  This is an attractive hypothesis 
since it implies the specific targeting of base damage to certain regions of DNA rather than it 
being indiscriminate as with other commonly used alkylating agents. Region-specific DNA 
damage is a concept that has already been developed to localise drug-induced damage to 
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critical nucleotide sequences; for example, drugs like bizelesin, target AT-rich fragile sites 
that are unstable regions found in leukaemias and lymphomas (Woynarowski, 2002, 
Woynarowski et al., 2001).  
As noted above, the response induced by ALX does require the presence of TOP2 (Figure 
4.18B). However, in contrast to previously published data showing that ALX acts specifically 
to inhibit the alpha isoform, the depletion of TOP2α did not alleviate the cytotoxicity of ALX 
to the same extent as etoposide (Figures 4.18 and 4.19). Interestingly, it required the 
combined depletion of both TOP2 isoforms to reduce the phosphorylation of H2AX after 
ALX treatment, indicating that ALX functions by inhibiting both TOP2α and TOP2β (Figure 
4.18B). Mutations in TOP2 enzymes have been linked to resistance to many anti-cancer drugs 
and can be categorised into 3 groups: those that decrease the affinity of the drug for the 
enzyme, mutations that change the DNA-binding affinity of the enzyme and mutations in the 
active site residues (Dingemans et al., 1998, Vassetzky et al., 1995). Therefore, if both 
TOP2α and TOP2β were mutated or depleted in cancer cells, resistance to ALX might, 
conceivably, develop. However, it is notable that the combined depletion of both isoforms 
does not lead to decreased phosphorylation of Chk1 in response to ALX, indicating that the 
ATR-mediated checkpoint response remains unaffected (Figure 4.18B).  
The results also highlight the fact that it may be the alkylating function of ALX that is 
responsible for the continued checkpoint response in the absence of TOP2 expression since it 
has already been shown that the alkylating side-chain is importance for the ability of ALX to 
induce a DDR (Figure 4.16). This is of particular interest since it reduces the possibility of 
developing resistance to ALX if the cellular levels of both topoisomerases were to be 
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depleted. This is, therefore, another example of potential drug resistance that would not seem 
to affect the DNA response induced by ALX. Notably, the use of some catalytic inhibitors of 
TOP2 often potentiates the cytotoxicity of chemotherapeutic compounds like alkylating 
agents  (Larsen et al., 2003). The mechanism by which this occurs remains controversial, 
although there have been reports that TOP2 is involved in DNA repair, therefore, the reduced 
activity of TOP2 results in increased sensitivity to alkylating agents (Tan et al., 1987). 
Another possibility is that some catalytic inhibitors of TOP2 also inhibit drug efflux pumps 
through their ability to block the ATP binding site, thus enabling cytotoxic agents to remain at 
their target sites for longer (Larsen et al., 2003). In this regard, it is possible that the inhibition 
of TOP2 by ALX may be rendering the cells sensitive to the alkylating effect of this agent. 
4.3.2.2 ALX and the MMR and FA pathways 
MSH2 is an important component of the MMR pathway, which mediates the toxicity of a 
number of chemotherapeutic agents (Fink et al., 1998). Not only has the loss of MMR 
pathway in tumours been linked to resistance to alkylating agents and platinum-based 
compounds, it has also been reported to result in resistance to TOP2 inhibitors such as 
etoposide and doxorubicin (Fedier et al., 2001, Fink et al., 1998). Notably, the specific loss of 
MSH2 was shown to result in resistance to the TOP2 poisons (Fedier et al., 2001). Contrary 
to these findings, the loss of MSH2 in this study actually exacerbates the signalling response 
to ALX, indicating that the abrogation of the MMR pathway in tumours will not affect the 
activity of ALX and that it evades this particular resistance mechanism (Figure 4.20).  
There is also the possibility that tumours that harbour deficiencies in this repair process may 
be hypersensitive to the cytotoxic effects of ALX. This is consistent with the capacity of ALX 
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to induce a DDR in cells known to be deficient in another component of the MMR pathway, 
MLH1 (Pors et al., 2003).  
Interestingly, catalytic inhibitors of TOP2 exhibit toxicity by inhibiting the activity of the 
enzyme and do not rely on MMR-mediated apoptosis to potentiate their effects since the 
mode of death caused by these inhibitors is through mitotic catastrophe. The fact that ALX 
does not specifically inhibit TOP2α and does not mirror the activity of etoposide means that 
there is a possibility that ALX is acting in a similar manner to catalytic inhibitors of TOP2 
and not mimicking the activity of TOP2 poisons  (Figures 4.18 and 4.19). Another reason why 
MMR deficiency does not affect ALX activity might also be due to the types of alkyl lesions 
it generates since these will determine the repair pathway that is activated. For example, the 
DNA adducts resulting from treatment with the nitrogen mustard, melphalan, do not seem to 
be recognised by the MMR pathway (Fink et al., 1998). In addition, ALX may induce a 
number of different alkyl lesions; therefore, if one type is repaired, others could remain 
cytotoxic, regardless of the MMR status of the tumour cell.  
FANCF is one of the components of the E3 ubiquitin ligase complex that ubiquitylates 
FANCD2 in the FA pathway. The FA pathway is the repair pathway that is responsible for 
recognising and removing lesions encountered during replication such as DNA ICLs. These 
are lesions induced by platinum-based chemotherapeutics like cisplatin and some bifunctional 
alkylating agents (Fu et al., 2012, Kee and D'Andrea, 2010). Indeed, tumours with an intact or 
restored FA pathway display drug-induced ICL resistance (Taniguchi et al., 2003). Since the 
FA pathway appears to be dispensable for the ALX-induced DDR (Figure 4.21), this suggests 
that ALX does not generate DNA ICLs, which is surprising considering it contains two 
functional alkylating moieties (Figure 4.1). It is also unexpected since ALX contains 
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chloroethyl moieties that render it able to modify N
7 
and O
6
 of guanine bases to generate 
chloroethyl adducts; O
6
Cl-ethylG adducts can undergo rearrangement to result in G-C ICLs 
(Fu et al., 2012). However, earlier work demonstrates that ALX, although it does possess a 
bis-alkylating function, does not covalently cross-link DNA, which is consistent with the 
results shown here (Pors et al., 2004). 
Similar to alkylating agents like the nitrogen mustards, ALX is likely to target N
7
 of guanine 
to form bulky N-monoadducts in addition to its potential to form O
6
Cl-ethylG adducts. It 
would be interesting to determine whether the abrogation of components of other repair 
pathways would affect the DNA damage generated by ALX as this would give a better 
indication of the lesions that ALX induces. It is clear that ALX contains properties that 
circumvent both MMR and FA deficiency. 
4.3.3 Mechanism of ALX-induced cell death 
The mechanism by which ALX induces cell death appears complicated. This is perhaps not 
surprising considering that ALX has the ability to induce a number of cytotoxic DNA lesions, 
including alkyl lesions, stalled replication forks and DNA DSBs as discussed above. 
The primary mode by which ALX appears to induce cell death is through mitotic catastrophe.  
The exact mechanism of mitotic catastrophe is not fully understood; however, it mostly likely 
represents a mechanism to remove cells with severe chromosomal abnormalities (Roninson et 
al., 2001). It has been suggested that mitotic catastrophe can be caused by cells that enter 
mitosis with extensive levels of unrepaired DNA damage. Whilst it is clear that ALX induces 
a robust G2/M checkpoint, the presence of aberrant mitotic cells with unrepaired DNA 
damage suggests that the cells can bypass this blockade in the cell cycle (Figures 4.22 and 
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4.23). Since it is known that the progression of cells from G2 to M phase of the cell cycle is 
driven by the activation of the CDK1/cyclin B1 complex, the high levels of cyclin B1 in cells 
treated with ALX after 24 h may be the underlying driving force behind this premature entry 
in mitosis (Figure 4.22B). Indeed, it has been found that aberrant mitotic entry is often 
associated with the over-expression and premature entry of CDK1/cyclin B1 into the nucleus  
(Jin et al., 1998).  
There is a likelihood that the transient G2/M arrest could be caused by the low level of 
expression of p53 in the HeLa cells used in the aforementioned experiment since cells with 
deficient p53 are able to initiate a G2/M checkpoint but are not able to sustain it (Bunz et al., 
1998). However, a similar transient G2/M arrest can also be observed in both p53-null and 
p53-proficient cell lines that had been treated with ALX over the same period of time (Figures 
2.28 and 2.29). These results indicate that the p53 status does not affect the transient nature of 
the observed G2/M checkpoint arrest and this is consistent with the assumption that p53 is not 
required for the onset of mitotic catastrophe (Roninson et al., 2001), and nor for any of the 
effects of ALX seen in this study. 
The occurrence of mitotic catastrophe in cells exposed to ALX for long periods of time could 
also be explained by the prolonged growth arrest of these cells. There are studies that show 
that p21-induced growth arrest results in the inhibition of a number of mitotic proteins, 
thereby causing abnormal chromosome segregation and abnormal mitosis (Chang et al., 
2000). The G2/M checkpoint arrest that was observed in ALX-treated cells could result in the 
inhibition of the transcription of genes that are required for correct mitotic function; therefore, 
when some cells bypass the checkpoint and enter mitosis, they will be forced to undergo 
abnormal mitosis. Notably, DNA-PK has been implicated in mitotic catastrophe from 
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observations that its inhibition results in prolonged G2/M arrest and aberrant spindle 
formation, eventually accumulating in mitotic catastrophe (Shang et al., 2010b). Since ALX-
induced damage partially depends on DNA-PK, it would be interesting to determine whether 
the response is increased following DNA-PK depletion and longer exposure to ALX. 
It was observed that ALX could induce a low level of apoptosis, associated with partial 
PARP1 cleavage in the HeLa cell line expressing low levels of p53, although procaspase 3 
and lamin B1 levels remained unchanged in these samples compared to those treated with 
cisplatin (Figure 4.25A). Several studies have found that mitotic catastrophe is often 
accompanied by the release of pro-apoptotic proteins as well as other molecular events that 
define apoptosis (Castedo et al., 2004a, Castedo et al., 2004b). In addition, the mode of cell 
death can often depend on the anti-cancer agent itself and the dose that is used; in this way, 
one form of cell death could occur before the second is initiated. This is clearly demonstrated 
when cells treated with the anthracycline antibiotic, doxorubicin, exhibit apoptotic 
morphology at earlier times of treatment before eventually dying through mitotic catastrophe  
(Eom et al., 2005). 
Although ALX induces its stabilisation, p53 only appears to be transcriptionally competent at 
the later time of exposure to ALX (Figure 4.27). This coincides with the formation of DSBs at 
later treatment times as well as the onset of aberrant mitosis (Figures 4.8 and 4.23). Therefore, 
it is conceivable that ALX will induce cell death through mitotic catastrophe and/or apoptosis 
depending on the presence of an intact p53 pathway.  
TOP2 is critically involved in removing catenated sister chromatids during chromosome 
segregation and in removing DNA supercoils during replication. The catalytic inhibitors of 
TOP2 exert their cytotoxicty by inhibiting the activity of the enzyme, which inevitably results 
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in abnormal mitosis and mitotic catastrophe (Giménez-Abián et al., 2000). Since ALX is a 
known TOP2 inhibitor, it is possible that it displays similarities with the non-DNA-damaging 
catalytic TOP2 inhibitors rather than the TOP2 poisons. In this regard, it is likely that cells 
that enter mitosis following ALX treatment fail to undergo proper chromosome decatenation 
after DNA replication.   
Despite a poor understanding of the mechanistic details of mitotic catastrophe, it is becoming 
preferable, from a clinical point of view, that chemotherapeutic drugs are designed to induce 
modes of death other than apoptosis since many tumour cells are refractory to the induction of 
apoptosis caused by many of these agents. Indeed, the primary target of anti-microtubular 
agents, such as Vinca alkaloids and the taxanes, is the mitotic spindle, which results in the 
disruption of mitosis and the induction of mitotic catastrophe (Roninson et al., 2001). 
Interestingly, mitotic catastrophe was found to be the predominant mechanism of cell death in 
different cell lines treated with one of the taxanes, Docetaxel (Morse et al., 2005). More 
importantly, the exposure of some cancer cells to ICRF-193, a compound belonging to the 
catalytic TOP2 inhibitors, causes cellular effects that are similar to those observed from 
exposure to agents that interfere with the mitotic spindle (Larsen et al., 2003). In addition, 
incomplete chromatid decatentation was shown to occur after treatment with certain catalytic 
TOP2 inhibitors; some were also demonstrated to activate the catenation checkpoint, although 
a number of different agents were able to overcome this checkpoint (Larsen et al., 2003).  
4.3.4 Conclusions 
The activation of an ATR-dependent checkpoint in response to ALX results in the 
accumulation of cells in S phase, which is indicative of ALX interfering with DNA 
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replication (Figure 4.22A). The response to ALX then appears to culminate in a G2/M 
checkpoint arrest, which is consistent with the fact that if cells are damaged in S phase they 
exit this stage of the cell cycle and undergo arrest at the G2/M checkpoint (Bartek et al., 
2004). 
Observations throughout this study suggest that the primary DDR following exposure to ALX 
requires ATR and that the loss of cell viability after treatment is predominantly mediated 
through mitotic catastrophe. Thus, it is clear that the ability of ALX to induce a DDR is cell 
cycle dependent. Consistent with this notion, non-cycling cells displayed a severely 
attenuated DDR after ALX treatment as well as lower percentage cells in sub G1 compared to 
cycling cells (Figure 4.30B and Table 4.1). In addition to this specificity for cycling cells, 
ALX was also found to induce an enhanced signalling DDR in cells undergoing replicative 
stress (Figure 4.31). A sustained proliferative capacity is one hallmark of cancer cells and it is 
becoming increasingly apparent that early stage tumours harbour elevated levels of DNA 
damage (Bartkova et al., 2005, Gorgoulis et al., 2005, Hanahan and Weinberg, 2000). 
Therefore, it appears that ALX exacerbates the DDR in tumour cells that are characterised by 
dysregulated DNA replication and high levels of replication stress. This is further 
demonstrated by the earlier findings that ALX treatment resulted in a greatly heightened 
H2AX response in cells undergoing replicative stress due to the depletion of ATR (Figure 
4.13A). Tumours that display dysregulated DNA replication and high levels of replication 
stress may, therefore, be more sensitive to treatment with ALX. 
The response to chemotherapeutic agents does not rely on a single pathway to mediate its 
effects; rather, it is the combined outcome of many different signalling pathways, be they 
defective or normal, which determine the fate of the tumour cell. The status of key signalling 
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pathways are, therefore, vital to the potential of the drug in question and may lead to 
resistance, exacerbated side effects or  ineffectual treatment.  
As an example of a DNA-directed alkylating agent, ALX is a ‘combination’ on its own, 
requiring TOP2α and TOP2β, as well as its ability to alkylate DNA. Furthermore, it is 
possible that ALX-induced alkylating damage is initiated at regions where TOP2 binds to 
DNA. Functionally, ALX seems to cause irreparable S phase damage that is cytotoxic as the 
cells progress into mitosis; tumour cells that are undergoing replication stress are therefore 
likely to be particularly sensitive to ALX-mediated cytotoxicity.  It is capable of inducing a 
response in tumour cells independently of a number of components that are often considered 
necessary for the action of chemotherapeutic agents, including ATM, p53, proteins involved 
in the MMR and FA pathways and the apoptotic pathway.  
This attribute of ALX also reduces the requirement for combination therapy. Drug-induced 
DNA damage along with repair pathway inhibitors has been successful and many such 
combinations are in development. However, it is often a concern that the increase in the 
number of drugs given to an individual, could lead to elevated side effects. The fact that the 
response to ALX is unaffected by components of the repair pathways observed in this study 
means that inhibitors of these pathways are not needed, although other pathways will require 
investigation. There is, therefore, a potential for ALX to be used as a novel anti-cancer agent 
in resistant secondary tumours that have acquired mutations. 
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CHAPTER 5 FINAL DISCUSSION AND FUTURE WORK 
5.1 FINAL DISCUSSION 
5.1.1 The DDR and cancer 
The DDR comprises a series of pathways that function together to maintain genomic integrity 
(Ciccia and Elledge, 2010). This involves numerous signal transduction pathways that sense 
and repair DNA damage, as well as those that determine the fate of the cell. The abrogation of 
proteins involved in the DDR leads to the loss of genomic stability, which is a characteristic 
of cancer cells (Hanahan and Weinberg, 2011). Conversely, defects in components of the 
DDR have been exploited through the use of chemotherapeutic agents, which induce DNA 
damage in tumour cells (Aziz et al., 2012). However, tumour cells exhibit differing 
sensitivities to DNA damaging anti-cancer agents primarily due to selective alterations in 
pathways regulating cell cycle checkpoints, DNA repair and apoptosis. The underlying 
genetic defects of a tumour cell can be the cause of resistance to many existing anti-cancer 
treatments. 
In this thesis an attempt has been made to address these two aspects of cancer biology: firstly, 
looking at certain properties of the p53 tumour suppressor and one of the mechanisms by 
which its transcriptional activity can be regulated and, secondly, characterizing, in detail, the 
mode of action of a novel chemotherapeutic agent, ALX. 
5.1.2 A role for hnRNPUL-1 as a p53 co-repressor 
Previous findings have implicated hnRNPUL-1 in the regulation of transcription, although the 
exact mechanism by which this occurs was unknown (Barral et al., 2005, Kzhyshkowska et 
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al., 2003). Data presented in this study confirm a role for hnRNPUL-1 in the transcriptional 
regulation of p53, one of the most extensively studied and important component of the DDR. 
Data in Chapter 3 corroborate previous reports that hnRNPUL-1 can interact with p53 and 
inhibit its transcriptional activity, indicating that hnRNPUL-1 functions as a p53 co-repressor 
(Figures 3.1-3.5). The ability of p53 to function as a transcriptional regulator is essential to its 
role as a tumour suppressor since the majority of tumour-derived mutations in p53 reside 
within its DBD and these render it incapable of binding and activating target promoters (Kato 
et al., 2003). 
Findings within Chapter 3 show that, from the p53-activated genes examined in this study, the 
mRNA and protein levels of p21 were significantly increased compared to other p53 target 
genes such as MDM2 and Bax following hnRNPUL-1 depletion (Figures 3.6A and 3.7). 
Interestingly, the p21 promoter requires BRD7 for efficient transcriptional activation, whereas 
pro-apoptotic genes do not (Drost et al., 2010). BRD7 knockdown also resulted in the 
reduction of p300 and acetylated p53 bound to the p21 promoter  (Drost et al., 2010). 
Previous studies have confirmed that both hnRNPUL-1 and BRD7 interact with each other 
and with the C-terminal region of p53 (Barral et al., 2005, Drost et al., 2010). Therefore, it is 
conceivable that, through direct competitive binding, hnRNPUL-1 inhibits the interaction 
between p53 and its co-activator, BRD7, to specifically inhibit a subset of p53 target genes. 
The findings here and by Drost et al. (2010) are not the only examples of specificity conferred 
by BRD7: another has been described by Harte et al. (2010), where BRD7 recruits BRCA1 to 
specific promoters of BRCA1 targets (Drost et al., 2010, Harte et al., 2010). It would be 
interesting to examine, using ChIP analysis, whether hnRNPUL-1 affects the p53-dependent 
recruitment of BRD7 to a specific subset of p53 target promoters. 
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The ability of p53 co-factors to determine the ability of p53 to transactivate different target 
genes that affect p53-mediated cellular outcome is apparent in many proteins  (Beckerman 
and Prives, 2010). The negative regulator of p53, APAK, binds to a region on the pro-
apoptotic gene p53AIP1 that overlaps with the p53 responsive element (p53RE) that is, in 
turn, responsible for the ability of p53 to transactivate this gene  (Yuan et al., 2012). 
Similarly, ZBTB2 utilises a similar DNA-binding competition mechanism to selectively block 
the p53-dependent transactivation of cell cycle arrest genes  (Jeon et al., 2009). Data 
presented in Chapter 3 provide evidence that hnRNPUL-1 may also function as a co-factor 
that regulates selective target gene activation by p53, specifically repressing a growth 
inhibitory gene. ChIP analysis would need to be conducted to determine whether hnRNPUL-1 
binds to p53-binding sites of specific promoters and whether this binding subsequently 
represses p53-dependent transactivation of a subset of genes.  
Results in Chapter 3 also show that p53 binds to the BBS region on hnRNPUL-1 (Figures 
3.10B and 3.11). Since the deletion of this region increases the ability of hnRNPUL-1 to 
repress basic transcription, it is possible that the binding of p53 to this site on hnRNPUL-1 
inhibits the binding between the latter protein and BRD7 (Kzhyshkowska et al., 2003). This 
would, subsequently, enable hnRNPUL-1 to function as a repressor of transcription as is 
depicted in this study. 
It is also possible that hnRNPUL-1 may be functioning to inhibit p53 transcriptional activity 
by recruiting additional co-repressors or by inhibiting elements of the transcriptional 
machinery. The latter is supported by evidence that identifies the interaction between 
hnRNPUL-1 and TATA-binding protein (TBP), a transcription factor that is a component of 
the transcriptional machinery (Barral, 2004). Since TBP recruits RNA polymerase II and a 
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host of other transcription factors to the transcription start site, it is possible that the binding 
of hnRNPUL-1 to TBP inhibits the initiation of transcription (Rhee and Pugh, 2012). 
Previous data has identified the interaction between hnRNPUL-1 and other proteins that are 
involved in transcriptional regulation, including CBP, Elf-1 and pRB (Barral, 2004). 
Incidentally, hnRNPUL-1 was also shown to interact with PLZF, which, in turn binds to p53 
(Barral, 2004). Although the biological consequences were not investigated, the interaction of 
hnRNPUL-1 with these proteins may affect the transcriptional regulation of p53. 
5.1.3 A role for hnRNPUL-1 in disease progression 
There is evidence that other members of the hnRNP family are involved in disease 
progression (Carpenter et al., 2006). Recent work has shown that patients containing a 
deletion in the chromosomal region that encompasses the hnRNPU gene display 
developmental abnormalities, seizures and low muscle tone (Caliebe et al., 2010). Notably, 
this is the hnRNP member with which hnRNPUL-1 shares the most sequence homology. 
Mutations in hnRNPUL-1 itself have been associated with early-onset myocardial infarction 
(Shiffman et al., 2006).  
It has been shown that some hnRNP proteins are involved in the onset of tumourigenesis; for 
example, transgenic mice overexpressing hnRNPD were found to develop sarcomas (Gouble 
et al., 2002). In addition, the levels of hnRNPA2 and B1 have been proposed to be markers of 
cancer, particularly lung cancer, and have also been linked to cell proliferation (Fielding et 
al., 1999, He et al., 2005b). Data presented in Chapter 3 demonstrate that hnRNPUL-1 
represses p53 transcriptional activity and inhibits p21 transactivation (Figure 3.4). It is 
possible that the inhibition of p53 by hnRNPUL-1 is sufficient to aid cellular proliferation. 
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This is further supported by the cellular response elicited after DNA damage in which there is 
an increase in cells arrested in G1 following hnRNPUL-1 depletion (Figures 3.8 and 3.9A). 
Therefore, the repression of p53 by hnRNPUL-1 may facilitate the propagation of damaged 
cells due to checkpoint loss. The repression of genes required for growth inhibition is a 
characteristic of oncogenes; therefore, if hnRNPUL-1 contains growth-promoting effects 
through its inhibition of p53, it may have oncogenic potential. To date, however, there have 
been no reports of over-expression of hnRNPUL-1 in tumour cell lines, although as 
endogenous levels are already high, definitive conclusions are difficult to draw.  
BRD7 was identified as a tumour suppressor gene required for p53-dependent oncogene-
induced senescence (OIS) (Drost et al., 2010). It is conceivable that the ability of BRD7 to act 
as a p53 co-factor is inhibited by hnRNPUL-1, which would lead to a loss of p53-dependent 
OIS and the subsequent onset of oncogene-induced transformation. Indeed, low levels of 
BRD7 expression were reported in nasopharyngeal carcinoma tumours as well as in a subset 
of breast tumours harbouring WT p53 (Drost et al., 2010, Liu et al., 2008). 
5.1.4 A role for ALX in the treatment of apoptotic-resistant tumours 
While the mutation or loss of p53 is a major contributing factor to the onset of genomic 
instability, p53-deficient tumours are particularly refractory to chemotherapeutic treatment. 
TP53 is mutated in nearly 30% of B-cell chronic lymphocytic leukaemia (CLL) chemo-
resistant tumours, despite being mutated in only 5-10% of cases at the time of diagnosis 
(Cordone et al., 1998, el Rouby et al., 1993). However, from the data presented in Chapter 4, 
ALX, a substituted anthraquinone with intercalating and alkylating properties, has been found 
Chapter 5 
225 
 
to be unaffected by p53 status and, since p53 does not appear to mediate its toxicity, ALX has 
the potential to treat tumours independently of p53 (Figures 4.7 and 4.28). 
Similarly, ALX-induced DNA damage was found to occur irrespective of ATM status 
(Figures 4.9-4.12). ATM is strongly implicated in p53 activation and the abrogation of ATM 
can result in defective p53 activity since mutations in ATM have been found to be an 
alternative mechanism by which p53 function is disabled in CLL (Pettitt et al., 2001). Patients 
with dysfunctional ATM have also been shown to have shorter survival times and those CLL 
patients with a loss of ATM function respond poorly to chemotherapy (Austen et al., 2007, 
Starostik et al., 1998). The ATM-p53 pathway is critical for the induction of apoptosis after 
DNA damage.  
A number of chemo-resistant tumours with mutations in ATM and p53 frequently display 
defective apoptotic pathways. Therefore, there is a need for novel approaches to kill cancer 
cells that possess mutations in ATM or p53 and where drug resistance is present. The 
observation that ALX does not induce cell death mainly through apoptosis reduces the 
likelihood of drug-induced resistance (Figure 4.25A). The culmination in cell death by 
checkpoint slippage-induced mitotic catastrophe means that ALX has the potential to cause 
death in apoptosis-resistant cancer cells and reduces the clonogenic survival of any apoptosis-
resistant cells (Figure 4.26). This is of particular importance since repeated exposure of many 
tumours to anti-cancer drugs can result in the selection of chemo-resistant cancer cells that 
subsequently possess enhanced tumourigenic and metastatic potential and means that the use 
of chemotherapeutics can often be counterproductive. For example, repeated exposure of 
melanoma cells to dacarbazine, a non-classical alkylating agent, results in a more aggressive 
phenotype (Lev et al., 2004). 
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5.1.5 A role for ALX in the treatment of genetically-different tumour types 
One of the challenges that face chemotherapeutic intervention is the targeting of specific 
therapies to genetically-distinct types of tumours. As mentioned before in 4.3.1, the reduced 
expression of ATM is often associated with resistance to chemotherapeutic agents; however, 
the altered level of ATM and its downstream components do not affect the signalling response 
elicited after treatment with ALX, confirming a lack of involvement of the ATM pathway in 
mediating its effects (Figures 4.9-4.12). In contrast, the loss of ATR potentiates the effects of 
ALX (Figure 4.13A). However, loss of ATR is particular rare in human tumours, although it 
has been reported in a very limited number of cases  (Tanaka et al., 2012). 
 As demonstrated in this thesis, ALX-induced DNA damage was not attenuated by defects in 
MSH2; indeed, its effects were exacerbated (Figure 4.20). Colorectal tumours are almost 
always associated with defects in the MMR pathway and mutations in MSH2, MLH1, MSH6 
and PMS2 are linked to a familial form of colorectal cancer, hereditary non-polyposis 
colorectal cancer (Chapelle, 2004). The genetic defects in the MMR pathway are not confined 
solely to colorectal cancers: MSI linked to MMR abnormalities has also been found in 
sporadic leukaemias and bladder cancers (Gu et al., 2002a, Gu et al., 2002b). Conversely, 
defects in MMR components can lead to the resistance to many chemotherapeutic agents, 
because of an inability of the cells to detect drug-induced adducts or because MMR mediates 
the toxicity of some anti-cancer drugs  (Pors and Patterson, 2005). 
Although they initially respond well to treatment, patients with ovarian cancer frequently 
relapse and, very often, die. The restoration of FA genes in ovarian tumour cells leads to 
resistance to chemotherapeutic drugs, such as cisplatin (Taniguchi et al., 2003). From data 
presented here, ALX-induced damage in the 2008 ovarian carcinoma cell line is unaffected by 
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defects in the FA pathways (specifically the loss of FANCF in this cell line), which reduces 
the chances that this type of tumour will become refractory to ALX treatment (Figure 4.21). 
This is important since in early tumour progression and in expanding tumour cells, FANCF is 
inactive, so cells remain sensitive to cisplatin; whereas in some cells, demethylation of 
FANCF leads to the restoration of the repair pathways and subsequently to chemo-resistance 
(Taniguchi et al., 2003). Therefore, if ALX-induced lesions are not recognised by the FA 
pathway to begin with, ALX has the potential to be used to treat tumours like ovarian tumours 
without the fear of drug resistance occurring in this manner. 
TOP2-targeting drugs often have limited effectiveness due to mutations in TOP2 itself that 
lead to the reduced or altered expression of this enzyme (Dingemans et al., 1998, Vassetzky et 
al., 1995). This is a particular problem since many TOP2 inhibitors are widely used as 
chemotherapeutic agents for the treatment of solid tumours such as breast and lung cancers as 
well as haematological malignancies. Data in Chapter 4 show that the reduced expression 
levels of both isoforms of TOP2 did not alter the checkpoint response to ALX, suggesting that 
this particular resistance mechanism may not reduce the ability of ALX to exert its anti-cancer 
activity (Figure 4.18). This is also supported by the observation that ALX can utilise its 
alkylating ability to initiate a DDR and does not rely on one function alone (Figure 4.16). 
If high enough, the dose of a particular chemotherapeutic agent could overwhelm the repair 
capacity of the cancer cell in question. However, higher therapeutic doses could potentially 
lead to more serious side-effects. If the damage induced by ALX is not recognised by specific 
repair pathways a reduced dose of the drug may be sufficiently effective. 
It is important to note that, because cancer cells are heterogeneous, different mechanisms of 
drug resistance can occur. Although the restoration or abrogation of DNA repair pathways is 
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one mechanism, other modes of drug resistance include increased drug efflux and the 
impaired ability of the cell to undergo apoptosis (Longley and Johnston, 2005). Previous 
findings have shown that ALX is not a substrate for P-glycoprotein and data here has 
established that ALX is not affected by the ATM or TP53 status and does not cause cell death 
by apoptosis. Since this study has also shown that ALX is unaffected by defects in notable 
repair pathways that are often implicated in chemo-resistance, there is great scope to develop 
ALX further, potentially to treat resistant tumours. 
5.2 FUTURE WORK 
5.2.1 Mechanisms behind the co-repressor function of hnRNPUL-1 
Since data in Chapter 3 show that hnRNPUL-1 and p53 interact and that hnRNPUL-1 
negatively regulates p53, it is possible that the interaction between the two inhibits the 
recruitment of p53 to its target gene promoters. To determine whether hnRNPUL-1 is itself 
recruited to promoters of p53-responsive genes, ChIP analysis would have to be conducted. If 
it does not directly bind to these promoter regions, a similar technique would need to be 
utilised to establish whether the depletion of hnRNPUL-1 relieves any inhibition of p53 being 
recruited. Once the ChIP assay is optimised, it will be possible to examine the effect of 
hnRNPUL-1 on the ability of p53 to bind to the promoter elements of its growth arrest genes 
compared to its pro-apoptotic targets. This would give a better understanding of any 
specificity that hnRNPUL-1 has in conferring the ability of p53 to transactivate its target 
genes. 
It is also possible that hnRNPUL-1 functions in an indirect manner by repressing p53 co-
activators. BRD7 is a p53 co-activator and has also been implicated in  the ability  of 
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hnRNPUL-1 to regulate transcription (Drost et al., 2010, Kzhyshkowska et al., 2003). Since 
BRD7 is required to activate a subset of p53-dependent target genes, not just p21, it would be 
interesting to determine whether hnRNPUL-1 affects the expression levels of these other 
genes in a p53-dependent manner (Drost et al., 2010).  
To establish whether hnRNPUL-1 associates with BRD7, co-immunoprecipitation 
experiments will need to be conducted. A co-immunoprecipitation between p53 and BRD7 
could be performed, in the presence and absence of hnRNPUL-1, to ascertain whether the 
interaction between p53 and BRD7 is enhanced in cells depleted of hnRNPUL-1.  
Although the binding of hnRNPUL-1 to CBP has been identified, any interaction between 
another acetyltransferase, p300, will also need to be determined by using co-
immunoprecipitation assays (Barral, 2004). These enzymes function as p53 co-activators by 
acetylating p53 itself as well as surrounding histones (Gu and Roeder, 1997, Lill et al., 1997). 
Initial luciferase reporter assays have already been optimised to measure p300/CBP activity 
after the down-regulation of hnRNPUL-1. Preliminary findings show that the depletion of 
hnRNPUL-1 results in an increase in the activity of p300/CBP, although the transfection 
efficiency appeared to be poor. Further assays will need to be performed, possibly using a 
different cell line that possesses higher transfection efficiency. 
It would be interesting to determine the consequence of hnRNPUL-1 depletion on other p53 
responses, since the effects on the cell cycle have been examined in this study. Initial Western 
blot analysis has been conducted to look at the effects of the depletion of hnRNPUL-1 on 
known apoptotic proteins after DNA damage; however, no difference in the levels of these 
proteins could be discerned in samples treated with hnRNPUL-1 siRNA compared to those 
treated with control siRNA. Further doses of DNA damaging agents will need to be 
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examined, as well other means of determining the apoptotic response using, for example, the 
Annexin V assay. However, it is possible that hnRNPUL-1 does not inhibit the expression of 
apoptotic genes, and will, therefore, not affect the p53-dependent apoptotic response. 
Data in Chapter 3 also show an increase in the mRNA levels of the repair protein, DDB2, 
after the down-regulation of hnRNPUL-1. The effect of hnRNPUL-1 on other p53-dependent 
repair genes will be significant, especially in light of recent advances implicating hnRNPUL-
1 in DNA-end resection and the promotion of DSB repair by HR (Polo et al., 2012).  
5.2.2 The effect of the abrogation of other repair pathways on ALX-induced 
damage 
BER and NER are important major pathways that act to repair damage induced by alkylating 
agents; however, these pathways have not been investigated in this study. Abdallah et al. 
(2012) recently used the DRAG assay to determine the growth inhibitory effects of ALX in 
Chinese hamster ovary (CHO) cells with defects in NER genes (Abdallah et al., 2012). For 
the purpose of completeness in this study, it would be beneficial to obtain cells derived from 
XP patients, such as XP12RO, that contain genetic defects in NER. Exposure of these cells to 
ALX and the subsequent effect on the levels of DDR proteins would need to be conducted. 
The effect of the abrogation of components in the BER and direct reversal pathways will also 
need to be investigated.  
If a specific repair pathway is disabled in some way, other repair pathways can compensate, 
thereby enabling tumour cells to survive (Al-Ejeh et al., 2010). Alkyl lesions can be repaired 
by a number of pathways, including compensating pathways such as HR, NHEJ and TLS (Fu 
et al., 2012). Although the disruption of major repair systems does not appear to affect ALX-
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mediated cytotoxicity, the effect of abrogating components of secondary repair pathways will 
need to be investigated. In this manner, the effect of combined defects of two repair pathways 
on ALX-induced DNA damage would be particularly interesting.  
5.2.3 The use of mouse models to determine the chemotherapeutic potential of ALX 
Studies in Chapter 4 highlight the importance of genetic heterogeneity in influencing the 
response to anti-cancer therapy. Human-derived cancer cell lines have been used throughout 
this study; however, mouse tumour xenograft systems provide a more physiologically relevant 
study of the response to particular drugs. The non-obese diabetic/severe combined 
immunodeficient (NOD/SCID) xenograft mouse model is one of the most successful models 
in which to study haematological malignancies such as B cell chronic lymphocytic leukaemia 
(B-CLL) and acute lymphoblastic leukaemia (ALL) (Macor et al., 2008); our preliminary 
studies have made use of this (Appendix 6.1 and 6.2). 
The results in Chapter 4 have provided evidence that ALX is capable of inducing a response 
regardless of ATM or TP53 gene status. Therefore, the use of B cell chronic lymphocytic 
leukaemia (B-CLL) as a model tumour system will be of the utmost importance since this 
type of cancer often displays resistance to conventional treatment due to mutations in  ATM or 
TP53. Preliminary findings have indicated that the administration of ALX to NOD/SCID 
mice engrafted with the TP53 mutant MEC-1 cell line resulted in a reduction in the relative 
tumour volume compared to the vehicle-treated mice (Figure 6.1A). The reduction of the 
solid tumour after treatment with ALX in these mice can also be observed (Figure 6.1B). 
Further experiments using the ATM mutant mantle cell lymphoma cell line, Granta, also need 
to be conducted and this will be completed in the near future. 
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The engraftment of primary leukaemic cells in NOD/SCID mice will be an ideal model to 
recapitulate primary disease and to subsequently study the effects of ALX. A mouse xenograft 
model system with patient T-ALL cells has been established (Appendix 6.2). Preliminary data 
in these mice have shown that the administration of ALX caused a reduction in tumour 
volume as assessed by the shrinking of the spleen compared to the larger spleen weight of the 
vehicle-treated mice (Figure 6.2). 
Thus, we have shown that it is feasible to examine the efficacy of ALX in the treatment of 
human leukaemias using this mouse model. In future we will use it to examine the effects of 
ALX derivatives as well as cell lines and tumours with differing combinations of mutations. 
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CHAPTER 6 APPENDIX 
6.1 APPENDIX 1 – MEC-1 XENOGRAFT MOUSE MODEL  
MEC cells cultured were harvested and resuspended at a density of 5x10
7 
cells/ml.  
NOD/SCID mice (aged 5-9 weeks; Biomedical Services Unit) were injected subcutaneously 
with 5 x 10
6 
MEC cells. At week 6, all mice had solid tumours and were randomised into two 
groups: treatment and vehicle. A stratified randomisation was conducted to achieve similar 
average tumour volumes of 250mm
3
 in each group. On the day of randomisation, animals 
received either 8mg/kg ALX or 0.1% DMSO in water via intraperitoneal injection. Animals 
were weighed and tumours measured every other day over a period of 8 days. On day 8, 
animals were culled because tumour volumes were >1200mm
3
.  Tumour volumes were 
measured manually using a calliper. 
6.2 APPENDIX 2 – PRIMARY ALL XENOGRAFT MOUSE MODEL  
Primary T-ALL cells were resuspended at a density of 1 x10
7 
cells/ml in PBS.  100µl of the 
cell suspension was injected into the 4-8 week old sub-lethally irradiated NOD/SCID mice. 
Tumour cell engraftment was confirmed by FACS analysis of human anti-CD45 (cell surface 
marker to confirm that the cells that engrafted were human), mouse anti-CD45 and human 
anti-CD3 (T-cell marker to confirm the engraftment of a T-ALL cell line) (all eBioscience). 
At week five following infusion of cells, at least 1% of cells in the peripheral blood of mice 
were human CD45-positive. Mice were then randomised into two groups: treatment and 
vehicle and treated as before by intraperitoneal injection. Mice were culled at day 8 and 
tumour load in the spleen was assessed by FACS analysis of human CD45-positive cells. 
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Figure 6.1 ALX impedes the growth of p53 mutant cells in vivo in a MEC-1 mouse 
xenograft model 
(A) The effect of ALX treatment on subcutaneous tumour volume generated by MEC-1 
engraftment compared with vehicle alone over a period of 8 days; (B) Subcutaneous tumour 
size in mice treated with ALX compared to vehicle alone after 8 days of treatment. Each 
group contained n=4. 
(Experiments performed and figures provided by Tracey Perry). 
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Figure 6.2 ALX reduces the tumour volume in a primary ALL xenograft mouse model. 
NOD/SCID mice were engrafted with primary ALL cells. (A) After 8 days of either ALX- or 
vehicle-treatment, spleens from these mice were removed and weighed; (B) The percentage of 
human CD45-positive cells in the spleen of mice engrafted with ALL cells after treatment 
with ALX or vehicle alone. Standard deviations from three individual experiments are 
presented. Each group contained n=4. 
(Experiments performed and figures provided by Tracey Perry). 
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